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1 Executive summary 
 
This report presents the findings of a systematic review commissioned by the NICE 
Centre for Public Health to support the development of updated guidance on 
tuberculosis. The review questions are: 
 
 What case management strategies and interventions are effective and cost 
effective in increasing the uptake of, or adherence to, treatment for people 
with active or latent TB? 
 What is known from studies of case management interventions about the 
barriers to uptake and adherence to treatment for active or latent TB? 
 
We searched a range of database sources from 1993 to 2013. We included outcome 
evaluations, cost-effectiveness studies or studies reporting views about an 
intervention, where the intervention involved a case manager working with individual 
patients (including directly observed therapy), in order to increase uptake of or 
adherence to treatment. Quality assessment and data extraction were carried out 
using standardised forms from the NICE methods manual. Data were synthesized 
narratively. 
 
Thirty studies were included in the review (13 effectiveness studies, 16 cost-
effectiveness studies, and two views studies, with one study in two categories). 
Seven studies were rated high quality (++), eight medium (+) and fifteen low (–). 
 
The findings of the studies are summarised in the evidence statements below. 
 
Evidence statement 1: effectiveness of case management and DOT for patients 
with active TB on treatment adherence and completion 
 
There is weak evidence from one (–) US study1 that a videophone DOT intervention 
achieves similar rates of adherence to TB treatment as standard DOT (95% against 
97.5%). 
 
There is weak evidence from one (–) South Korean study2 that a service-level 
intervention involving intensified supervision of staff to improve case management 
practice achieves improved rates of follow-up X-rays (intervention 90.8% against 
control 80.2%, significance NR), sputum smear and culture tests (97.6% against 
70.2%, significance NR), drug collection rates (87.9% against 77.1%, p<0.01), delays 
in drug collection of 7 days or more (4.7% against 12.2%, p<0.01), treatment 
completion rates (78.8% against 65.2%, p<0.01), and treatment success (75.2% 
against 45.8%, p<0.01). 
 
There is strong evidence from one (++) Australian study3 that family-based DOT 
does not lead to higher adherence (RR 1.04 (0.88–1.23)) than standard treatment 
with self-administered therapy. There was a non-statistically-significant trend towards 





The evidence is directly applicable to people in the UK. This is because there are no 
obvious differences in the population, context or setting of the studies compared to 
the UK context.  
 
1 DeMaio et al., 2001 (–) 
2 Jin et al., 1993 (–) 
3 MacIntyre et al., 2003 (++) 
 
Evidence statement 2: effectiveness of case management and DOT for drug 
users on treatment uptake, adherence and completion 
 
There is weak evidence from one US study (–)1 that a policy of directly observed 
preventive therapy (DOPT) showed a non-statistically-significant trend towards lower 
rates of TB among drug users compared to self-administered preventive therapy 
(one-group RR 0.4 (0.04-4.8)). 
 
There is conflicting evidence from two (++) US studies2,3 as to whether DOPT leads 
to higher adherence rates than SAT among drug users. There is strong evidence 
from one (++) US study3 that DOPT does not lead to higher completion rates, or 
adherence rates, than usual care with SAT among drug users (completion 80% 
against 79%; adherence 82% against 90% (for 80% adherence), 80% against 77% 
(for 90% adherence)). However, DOPT did lead to higher adherence rates than usual 
care for 100% adherence (77% against 10%, p<0.001), and to higher adherence 
rates than a peer support intervention (80% against 51% (for 90% adherence), p < 
0.001; 77% against 6% (for 100% adherence), p<0.001). 
 
There is strong evidence from one (++) US study2 that DOPT combined with 
methadone treatment leads to higher rates of TB treatment completion among 
heroin-dependent injecting drug users than usual care with SAT (77.1% against 
13.1%, p < 0.0001). However, an additional case management component with 
counselling and service access did not increase the effectiveness of the basic 
intervention (59.5% completion). 
 
There is strong evidence from one (++) US study4 that either outreach DOPT with 
incentives or on-site DOPT with incentives improve adherence among drug users 
more than outreach DOPT alone, but outreach DOPT with incentives is not 
significantly different from on-site DOPT with incentives (OR for outreach DOPT with 
incentive vs outreach DOPT alone 29.7 (56.5–134.5); OR for on-site DOPT with 
incentive vs outreach DOPT alone 39.7 (58.7–134.5)). 
 
There is strong evidence from one (++) Estonian study5 that an intervention involving 
incentives, scheduling visits and reminders, and providing transport, increases 





The evidence is partially applicable to people in the UK who use drugs. This is 
because the populations of drug users in the studies, or the services available to 
them, may differ from those in the UK. 
 
1 Graham et al., 1996 (–) 
2 Batki et al., 2002 (++) 
3 Chaisson et al., 2001 (++)) 
4 Malotte et al., 2001 (++) 
5 Rüütel et al., 2011 (++) 
 
Evidence statement 3: effectiveness of DOT for people with latent TB infection 
on treatment completion 
 
There is medium evidence from one (+) study conducted in multiple countries (not 
the UK)1 that DOT leads to higher treatment completion rates and lower risk of active 
TB than self-administered therapy (completion 82.1% against 69.0%, p < 0.001; risk 
of active TB adjusted hazard ratio 0.38 (0.15-0.99), p = 0.05). However, the regimens 




The evidence is directly applicable to people in the UK. This is because there are no 
obvious differences in the population, context or setting of the studies compared to 
the UK context.  
 
1 Sterling et al., 2011 (+) 
 
Evidence statement 4: effectiveness of case management and observed drug 
collection for migrants or new entrants on treatment uptake and completion 
 
There is weak evidence from one (–) US study1 that cultural case management, 
including culturally tailored education and support by trained peers, leads to higher 
uptake of treatment (88% against 73%, p<0.001) and completion of treatment (82% 
against 37%, p<0.001) for LTBI among refugee populations. 
 
There is weak evidence from one (–) Italian study2 that requiring immigrants to attend 
clinic sites to collect drugs for LTBI treatment leads to lower rates of treatment 




The evidence is partially applicable to immigrants to the UK. This is because the 
populations of migrants in the studies, or the policies in place around immigration, 
may differ from those in the UK.  
 
1 Goldberg et al., 2004 (–) 
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2 Matteelli et al., 2000 (–) 
 
Evidence statement 5: effectiveness of DOT for people with HIV on treatment 
completion 
 
There is medium evidence from one (+) US study1 that DOT leads to higher rates of 
treatment completion than SAT for LTBI treatment among people with HIV (93% 




The evidence is directly applicable to people in the UK. Despite differences in the 
broader healthcare context in the USA, there are are no obvious differences in the 
population, context or setting of the study compared to the UK context.  
 
1 Narita et al., 2002 (+) 
 
Evidence statement 6: effectiveness of education and tracking for homeless 
people on treatment completion 
 
There is strong evidence from one (++) US study1 that an education programme and 
active tracking of defaulters, with DOT and incentives, leads to higher rates of 
completion of LTBI treatment among homeless people than DOT and incentives 




The evidence is partly applicable to people in the UK. This is because the population 
of homeless people in the study, or the services available to them, may differ from 
those in the UK. 
 
1 Nyamathi et al., 2006 (++) 
 
Evidence statement 7: cost-effectiveness of DOT, increased outpatient care, 
and Find and Treat for patients with active TB 
 
There is medium evidence from five (3 + and 2 –) cost-effectiveness studies1-5  that 
directly observed therapy for active TB incurs lower net costs than self-administered 
therapy, when the cost savings resulting from reduced treatment failure are taken 
into account. Relative net cost savings from DOT in these studies1,4-5 range from 
US$1,788 to US$16,370 per patient treated (with other studies reporting a relative 
cost per death averted of US$1,2342, and a relative cost per patient cured of 
US$2,7833).  
 
However, there is weak evidence from one (–) cost-effectiveness study6 that DOT is 
more costly than SAT for patients at low risk of default (incremental cost of US$919 
per patient treated, US$40,260 per patient cured). There is also moderate evidence 
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from one (+) study that a policy of universal DOT is more costly than a policy of 
partial DOT (incremental cost of US$24,064 per patient cured).3  
 
There is medium evidence from one (+) cost-effectiveness study7 that a Find and 
Treat service which combines mobile screening for high-risk populations with 
enhanced case management support has an incremental cost-effectiveness 
compared to usual care of £6,400 per QALY (£18,000 per QALY for mobile 
screening and £4,100 per QALY for enhanced case management). 
 
There is weak evidence from one (–) cost-effectiveness study that a policy of 
increased outpatient care for TB is less costly than usual care (cost savings of 
US$10,804 for smear-positive patients, US$9,028 for smear-negative per patient 
cured), although the addition of DOT and incentives makes little difference to this. 
 
There is weak evidence from one (–) cost-effectiveness study9 that remote DOT via 
videophone has an incremental cost-effectiveness of Aus$1.32 per day of 
observation, compared to in-person DOT. 
 
1 Burman et al., 1997 (+) 
2 Moore et al., 1996 (+) 
3 Palmer et al., 1998 (+) 
4 Weis et al., 1999 (–) 
5 Wilton et al., 2001 (–) 
6 Snyder and Chin, 1999a (–) 
7 Jit et al., 2011 (+) 
8 Migliori et al., 1999 (–) 
9 Wade et al., 2012 (–) 
 
Evidence statement 8: Cost-effectiveness of screening and DOT for drug users 
 
There is weak evidence from three (1 +1 and 2 –2,3) cost-effectiveness studies that 
programmes for drug users which include screening and directly observed 
prophylactic therapy have lower relative net costs than no intervention, with net cost 
savings ranging from US$3,724 to US$30,770 per case averted, or from US$1,380 to 
US$3,590 per person treated1-3. 
 
1 Snyder et al., 1999b (+) 
2 Perlman et al, 2001 (–)  
3 Gourevitch et al., 1998 (–) 
 
Evidence statement 9: Cost-effectiveness of DOT for people with latent TB 
infection 
 
There is weak evidence from one (–) cost-effectiveness study1 that weekly isoniazid 
and rifapentine under DOT is cost saving compared to no intervention, while twice-
weekly isoniazid under DOT has an incremental cost-effectiveness ratio of $7,879 
per QALY compared to no intervention. 
 9 
 
1 Holland et al., 2009 (–) 
 
Evidence statement 10: Cost-effectiveness of screening, LTBI treatment and 
DOPT for new entrants 
 
There is good evidence from one (++) study1 that a screening and LTBI treatment 
programme for new entrants to the USA is cost saving compared to no intervention, 
and that reminders by phone, post or home visiting are also cost saving. However, 
this study finds the incremental cost of DOPT compared to the combination of all 
these interventions to be over US$100,000 per QALY.  
 
1 Porco et al., 2006 (++) 
 
Evidence statement 11: Cost-effectiveness of DOPT for neonates exposed to 
TB 
 
There is weak evidence from one (–) cost-effectiveness study1 that directly observed 
preventive therapy has an incremental cost-effectiveness of US$21,710,000 per 
death prevented compared to no intervention, substantially greater than parent-
administered therapy. 
 
1 Berkowitz et al., 2006 (–) 
 
Evidence statement 12: Qualitative evidence on interventions to promote 
adherence to treatment for TB or LTBI 
 
There is weak evidence from one (–) UK study1 that a link worker for marginalized 
people with TB or LTBI is viewed positively by staff in other agencies. Participants 
report that the link worker increases understanding of TB among workers in different 
services, facilitates service users’ access to different services and provides practical 
and emotional support.  
  
There is medium evidence from one (+) Australian study2 that a videophone DOT 
service is viewed positively by staff and patients. The privacy and convenience of the 
videophone DOT service were especially valued.  
 
1 Craig et al., 2008 (–) 






Sub-optimal uptake of, and adherence to, tuberculosis treatment for people with 
active or latent TB can lead to increased morbidity and mortality, increased 
infectiousness, and the emergence of drug resistance. 
 
A range of strategies may be employed to promote uptake of and/or adherence to 
treatment. This review focuses on case management approaches, including directly 
observed therapy. A separate review is also being conducted on education and 
support strategies.  
 
Case management can be defined as any approach in which a named case manager 
co-ordinates care and management for a patient with suspected or confirmed TB. 
Enhanced case management (ECM) involves the case manager working alongside a 
multidisciplinary team to co-ordinate clinical and psychosocial care. Existing UK 
guidance (Story and Cocksedge, 2012) recommends ECM for all patients with 
clinically or socially complex needs. As well as specialist clinical care, ECM should 
also include outreach and advocacy work to address patients’ other needs (e.g. 
housing, substance misuse, welfare) within a flexible and responsive model of care. 
 
Case management may include directly observed therapy (DOT), in which a trained 
health professional provides medication and observes the person swallowing every 
dose. Previous NICE public health guidance (PH37) recommends DOT for the 
following groups: 
 all hard-to-reach children aged under 16; 
 those who do not, or have previously not, adhered to treatment; 
 those previously treated for TB; 
 those with a history of homelessness, drug or alcohol misuse; 
 those who are currently, or have been previously, in prison; 
 those with a major psychiatric, memory or cognitive disorder; 
 those in denial of the TB diagnosis; 
 those who have multi-drug resistant TB; and 
 those too ill to administer treatment.  
 
Guidance from the Royal College of Nursing (Story and Cocksedge, 2012) 
recommends DOT for a similar range of populations, including in addition all children 
aged under 16 and those who request DOT. However, in previous NICE clinical 
guidance (CG117), DOT is recommended only for homeless people and those with a 







This review was conducted according to the methods guidance set out in the current 
(third) edition of Methods for the Development of NICE Public Health Guidance 
(National Institute for Health and Care Excellence, 2012). 
3.1 Review questions 
 
The review questions are: 
 What case management strategies and interventions are effective and cost 
effective in increasing the uptake of, or adherence to, treatment for people 
with active or latent TB? 
 What is known from studies of case management interventions about the 
barriers to uptake and adherence to treatment for active or latent TB? 
3.2 Searching 
3.2.1 Database searches 
 
The search strategy was designed through consultations with the CPH team and the 
Guideline Development Group. The following database sources were searched in 
October 2013 and searches were limited from 1993 to the most recent records (with 
the exception of the Conference Proceedings Citation Indexes, which were run from 
2011 to the present).  
 ASSIA 
 British Nursing Index 
 CINAHL 
 Cochrane Database of Systematic Reviews 
 Cochrane Health Technology Assessment database 
 Conference Proceedings Citation Index-Science 
 Conference Proceedings Citation Index-Social Science & Humanities  
 Database of Abstracts of Reviews of Effectiveness  
 Embase 




 Medline In Process 
 NHS Economic Evaluation Database 
 OpenGrey 
 Science Citation Index Expanded 
 Social Policy and Practice 
 Social Sciences Citation Index 
 Sociological Abstracts 
 
The search strategy took the following form: 
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(TB) AND (terms for uptake / adherence outcomes) AND (terms for case 
management interventions) 
 
A filter was used to exclude studies on animals. No language restriction was placed 
on the searches, although non-English language studies were subsequently 
excluded during the screening process. The full database search records can be 
found in Appendix A. 
 
3.2.2 Other searches 
 
The following websites were also searched: 
 British Infection Association via http://www.britishinfection.org/drupal/  
 British Thoracic Society via http://www.brit-thoracic.org.uk/  
 Campbell Collaboration via http://www.campbellcollaboration.org/  
 Chartered Institute of Environmental Health via http://www.cieh.org/  
 Cochrane Infectious Diseases Group Specialized Register via 
http://cidg.cochrane.org/specialized-register  
 Department of Health, Social Services and Public Safety of Northern 
Ireland via http://www.dhsspsni.gov.uk/  
 Health Protection Scotland via http://www.hps.scot.nhs.uk/  
 Health Quality Improvement Partnership via http://www.hqip.org.uk/   
 Infection Prevention Society via http://www.ips.uk.net/   
 Local Government Association via http://www.local.gov.uk   
 McMaster University Health Evidence via http://www.healthevidence.org/   
 National Guideline Clearinghouse http://www.guideline.gov/  
 NICE via http://www.nice.org.uk/  
 Public Health England via 
https://www.gov.uk/government/organisations/public-health-england  
 Public Health Observatory via http://www.apho.org.uk/  
 Stop TB UK via http://www.stoptbuk.org/  
 Target Tuberculosis via http://www.targettb.org.uk    
 TB Alert via http://www.tbalert.org  
 
Google was searched using a simplified version of the search string, and the 
advanced search options to limit to PDFs or word document files. The first 100 
search results were scanned for relevance. We searched PubMed using a time-
limited search to identify any new items. We conducted backwards citation searching 
(one generation) for all items included on full text. We conducted forwards citation 
searching for all items included on full text, using Web of Science and Google 
Scholar for forward citation chasing.  Finally, we searched BL Ethos 





EPPI-Reviewer 4 software was used to manage data. The following inclusion criteria 
were applied: 
1) Does the study measure uptake of, or adherence to, tuberculosis treatment as an 
outcome, or concern an intervention aiming to increase uptake or adherence?  
2) Does the study present primary data regarding an intervention, either concerning 
outcomes or processes?  
3) Was the study conducted in a country which is a current OECD member?1 
4) Does the intervention include case management (CM), defined as an intervention 
where a designated case manager works with an individual patient? (Purely 
educational or informational interventions were excluded. Interventions 
delivered by non-professionals without specific training in CM were excluded. 
Directly observed therapy, with or without other CM components, was 
included.)  
5) Is the study report written in English? 
6) Was the study either : 
(i) a prospective outcome evaluation (retrospective studies with no cost-effectiveness 
component were excluded, although studies with a prospective intervention 
group and a retrospective comparison were included); 
(ii) a cost-effectiveness study (either modelling or economic evaluation); or  
(iii) a qualitative study which reported views about an intervention? (Studies about 
views of TB in general, or about ongoing practice in TB treatment or TB 
services, were excluded.) 
 
An initial random sample of 10% of titles and abstracts was screened by two 
reviewers independently and differences arising were resolved by discussion. 
Agreement at this stage was 98.7%, with Cohen’s kappa κ=0.81. This was deemed 
to be adequate agreement, and subsequent titles and abstracts were screened by a 
single reviewer. The full text of all references which met criteria, or where it was 
unclear if they met the criteria, was retrieved and re-screened to the same criteria by 
two reviewers independently and differences were resolved by discussion. 
Agreement on the full-text screening was 96.1% with κ=0.92.  
 
3.4 Quality assessment, data extraction and synthesis 
 
Review quality was assessed, and data extracted, using the tools in the third edition 
of the CPH methods manual (National Institute for Health and Clinical Excellence, 
2012). Quality assessment and data extraction were conducted by one reviewer and 
comprehensively checked by a second reviewer. Data were synthesized narratively. 
  
                                               
1 These are: Australia, Austria, Belgium, Canada, Chile, Czech Republic, Denmark, Estonia, 
Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Israel, Italy, Japan, Korea, 
Luxembourg, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Slovak 
Republic, Slovenia, Spain, Sweden, Switzerland, Turkey, UK, USA. 
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4 Results 
4.1 Flow of literature through the review 
The searches returned a total of 3,796 unique records. After screening, 30 records 
were included in the review (13 effectiveness studies, 16 cost-effectiveness studies, 
and two views studies, with one study in two categories). Figure 1 shows the flow of 
literature through the review. 
 
Unique records identified through 
database searching  
(n=3,796) 
Additional records identified through 
other sources  
(n=0) 
Abstracts screened  
(n=3,796) 
Abstracts excluded  
(n=3,591) 
Full-text articles assessed 
for eligibility  
(n=187) 
Full-text articles excluded  
(n=156) 
1. Not adherence / uptake (n=5) 
2. No primary intervention data 
(n=46) 
3. Not a high-income country (n=8) 
4. Not case management (n=31) 
5. Not English language (n=1) 
6. Not prospective outcome eval’n, 
economic study, or views study  of 
intervention (n=44) 
7. Systematic review (n=21) 
 
 






Linked reports  
(n=1) 
Figure 1. Flow of literature through the review 
 15 
 
4.2 Results of quality assessment 
4.2.1 Effectiveness studies 
 
The results of quality assessment for the effectiveness studies are shown in Table 1. Six studies were rated high quality (++), two medium (+) 
and five low (–). 
 








Population Method of allocation to intervention/comparison Outcomes Analysis 
Sum-
mary 
Reference 1.1 1.2 1.3 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 
2. 
10 
3.1 3.2 3.3 3.4 3.5 3.6 4.1 4.2 4.3 4.4 4.5 4.6 5.1 5.2 
Batki et 
al., 2002 




RCT + + – ++ ++ ++ + + NR NR + + + + ++ + + ++ + ++ ++ NR ++ ++ ++ ++ + 
DeMaio et 
al., 2001  




BA ++ + – NA ++ NA NA + NA NA + + + + + + + + ++ NA NA NR ++ ++ ++ – – 
Graham et 
al., 1996 
BA + + – NA – NA NA + NA NA + + + + + + ++ + ++ NA NA NR ++ + ++ – – 
Jin et al., 
1993 








RCT + + ++ ++ ++ ++ ++ + NR NR + + + ++ ++ ++ ++ ++ ++ ++ + NR ++ ++ ++ ++ + 
Matteelli et 
al., 2000 
RCT + – NR + – NR + + NR NR – + – – – + – ++ + ++ – + – – – – – 
Narita et 
al., 2002 




RCT ++ + ++ ++ ++ NR + – ++ ++ + – + + + ++ ++ ++ ++ ++ ++ + ++ + ++ ++ + 
Rüütel et 
al. 2011 
RCT ++ – – + + NR NR + NR NR ++ + + + ++ +  + ++ + ++ ++ NR ++ ++ ++ ++ + 
Sterling et 
al., 2011 
RCT – – – + + NR ++ + NR – ++ NR + + + + ++ ++ ++ ++ ++ ++ ++ + ++ + – 
 
Key to questions: 
1.1 Is the source population or source area well described? 
1.2 Is the eligible population or area representative of the source population or area? 
1.3 Do the selected participants or areas represent the eligible population or area? 
2.1 Allocation to intervention (or comparison). How was selection bias minimised? 
2.2 Were interventions (and comparisons) well described and appropriate?  
2.3 Was the allocation concealed?  
2.4 Were participants and/or investigators blind to exposure and comparison?  
2.5 Was the exposure to the intervention and comparison adequate?  
2.6 Was contamination acceptably low?  
2.7 Were other interventions similar in both groups?  
2.8 Were all participants accounted for at study conclusion?  
2.9 Did the setting reflect usual UK practice?  
2.10 Did the intervention or control comparison reflect usual UK practice?  
3.1 Were outcome measures reliable?  
3.2 Were all outcome measurements complete?  
3.3 Were all important outcomes assessed?  
3.4 Were outcomes relevant?  
3.5 Were there similar follow-up times in exposure and comparison groups?  
3.6 Was follow-up time meaningful?  
4.1 Were exposure and comparison groups similar at baseline? If not, were these adjusted?  
4.2 Was Intention to Treat (ITT) analysis conducted?  
4.3 Was the study sufficiently powered to detect an intervention effect (if one exists)?  
4.4 Were the estimates of effect size given or calculable?  
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4.5 Were the analytical methods appropriate?  
4.6 Was the precision of intervention effects given or calculable? Were they meaningful?  
5.1 Are the study results internally valid? (i.e. unbiased)  
5.2 Are the study results generalisable to the source population? (i.e. externally valid) 
 
Key to sections 1-4: 
++ The study has been designed/conducted in such a way as to minimise the risk of bias 
+ Either the answer to the checklist question is not clear from the way the study is reported, or the study may not have addressed all potential sources of bias  
– Significant sources of bias may persist 
NR The study fails to report this particular question  
NA Not applicable given the study design 
 
Key to section 5: 
++ All or most of the checklist criteria have been fulfilled; where they have not been, the conclusions are very unlikely to alter 
+ Some of the checklist criteria have been fulfilled, where they have not, or not adequately described, the conclusions are unlikely to alter 




4.2.2 Cost-effectiveness studies 
 
The results of quality assessment for the effectiveness studies are shown in Table 2. One study was rated as ‘not applicable’ on section 1 of 
the tool, and in line with the guidance on the tool, was not data-extracted or further considered in the review. One study was rated as having 
‘minor limitations’ (++), five as having ‘potentially serious limitations’ (+) and nine as having ‘very serious limitations’ (–). 
 













Berkowitz et al., 
2006 
+ ++ + ++ + – – + Partly applicable + – + + – + – – + + NR 
Very serious 
limitations 
Burman et al., 
1997 
NR ++ + ++ + – – + Partly applicable + – + + + + + + + + NR 
Potentially serious 
limitations 
Chaulk et al., 2000 NR NR + NR NR – – – Not applicable             
Gourevitch et al., 
1998 
++ ++ + + + – – + Partly applicable + + + + – + – + – + NR 
Very serious 
limitations 
Holland et al., 
2009 
+ + + + + – ++ + Partly applicable + – + + – ++ – – ++ + ++ 
Very serious 
limitations 
Jit et al., 2011 ++ ++ ++ ++ ++ – ++ ++ Directly applicable + + + + + + + + ++ ++ ++ 
Potentially serious 
limitations 
Migliori et al., 
1999 
+ ++ + ++ – – – + Partly applicable – – – – – + + – – – NR 
Very serious 
limitations 
Moore et al., 1996 + ++ + ++ + – – ++ Partly applicable + – + – + + + + + + NR 
Potentially serious 
limitations 
Palmer et al., ++ + + ++ + – – + Partly applicable + + + + + + + + + + NR Potentially serious 
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1998 limitations 
Perlman et al., 
2001 
++ + + – + – – + Partly applicable + + – + – + + – ++ – NR 
Very serious 
limitations 
Porco et al., 2006 ++ + + ++ ++ – ++ + Directly applicable ++ + ++ + + ++ + + ++ ++ NR Minor limitations 
Synder & Chin, 
1999a  
+ ++ + ++ + – – + Partly applicable + – – + + + – – ++ + NR 
Very serious 
limitations 
Snyder et al., 
1999b 
++ ++ + ++ + – – + Partly applicable + + + + – + + + + + NR 
Potentially serious 
limitations 
Wade et al., 2012 ++ ++ + + – – – + Partly applicable – – – + + – + + ++ ++ ++ 
Very serious 
limitations 
Weis et al., 1999 ++ ++ + + + – – + Partly applicable – – – + + + + ++ – – NR 
Very serious 
limitations 




Key to questions: 
 
1.1 Is the study population appropriate for the topic being evaluated? 
1.2 Are the interventions appropriate for the topic being evaluated? 
1.3 Is the system in which the study was conducted sufficiently similar to the current UK context? 
1.4 Was/were the perspective(s) clearly stated and what were they? 
1.5 Are all direct health effects on individuals included, and are all other effects included where they are material? 
1.6 Are all future costs and outcomes discounted appropriately? 
1.7 Is the value of health effects expressed in terms of quality-adjusted life years (QALYs)? 
1.8 Are costs and outcomes from other sectors fully and appropriately measured and valued? 
2.1 Does the model structure adequately reflect the nature of the topic under evaluation? 
2.2 Is the time horizon sufficiently long to reflect all important differences in costs and outcomes? 
2.3 Are all important and relevant outcomes included? 
2.4 Are the estimates of baseline outcomes from the best available source? 
2.5 Are the estimates of relative 'treatment' effects from the best available source? 
2.6 Are all important and relevant costs included? 
2.7 Are the estimates of resource use from the best available source? 
2.8 Are the unit costs of resources from the best available source? 
2.9 Is an appropriate incremental analysis presented or can it be calculated from the data? 
2.10 Are all important parameters whose values are uncertain subjected to appropriate sensitivity analysis? 
2.11 Is there any potential conflict of interest? 
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4.2.3 Views studies 
The results of quality assessment for the views studies are shown in Table 3.  One study was rated medium quality (+) and one low (–). 
 
Table 3. Quality assessment of the views studies (N=2) 
Reference 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Overall 
Craig et al., 2008 Y Y ? ? N N N ? N ? N Y Y Y – 
Wade et al., 2012 Y Y Y Y N Y Y Y N Y N Y Y Y + 
 
Key to questions: 
1. Is a qualitative approach appropriate? 
2. Is the study clear in what it seeks to do? 
3. How defensible/rigorous is the research design/methodology? 
4. How well was the data collection carried out? 
5. Is the role of the researcher clearly described? 
6. Is the context clearly described? 
7. Were the methods reliable? 
8. Is the data analysis sufficiently rigorous? 
9. Is the data 'rich'? 
10. Is the analysis reliable? 
11. Are the findings convincing? 
12. Are the findings relevant to the aims of the study? 
13. Conclusions 
14. How clear and coherent is the reporting of ethics? 
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4.3 Findings: effectiveness 
This section presents the findings for the review of effectiveness. Table 4 
summarizes the overall characteristics of the studies. 
 
Table 4.  Summary of the effectiveness studies (N=13) 






Batki et al., 
2002 
RCT ++ USA Drug users 
DOPT, methadone, 
counselling / DOPT, 
methadone / usual 
care 
Completion Effective 
Active TB No difference 
Chaisson 
et al., 2001 
RCT ++ USA Drug users 
DOPT / peer support 
/ usual care 
Adherence No difference 
Completion No difference 
DeMaio et 
al., 2001  




Standard DOT / 
videophone DOT 
Adherence No difference 
Goldberg 
et al., 2004 
BA – USA Refugees Case management 
Uptake Effective 
Completion Effective  
Graham et 
al., 1996 
BA – USA Drug users DOPT TB Effective 
Jin et al., 
1993 























Family-based DOT / 
usual care 
Adherence No difference 
Completion No difference 
Malotte et 
al., 2001 
RCT ++ USA Drug users 
Outreach DOPT, 
incentive / outreach 












RCT – Italy Immigrants 
Supervised drug 









DOT Completion Effective 
Nyamathi 
et al., 2006 





of defaulters, DOT, 






RCT ++ Estonia Drug users 
Active referral, 





Sterling et RCT + Multi. People with DOT / SAT Completion Effective 
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al., 2011 LTBI TB Effective 
Death No difference 
 
In this section the findings are characterized by the main population group included 
in the studies, namely: 
 Patients with active TB (N=3 studies) 
 Drug users (N=5) 
 People with latent TB infection (general) (N=1) 
 Migrants or new entrants (N=2) 
 Patients with HIV (N=1) 
 Homeless people (N=1) 
 
In terms of the interventions evaluated, the majority of the studies focus exclusively 
on DOT alone, or DOT with incentives (N=8: Chaisson et al., 2001 (++); Graham et 
al., 1996 (–); MacIntyre et al., 2003 (++); Malotte et al., 2001 (++); Matteelli et al., 
2000 (–); Narita et al., 2002 (+); Sterling et al., 2011 (+)). One study evaluates 
intensified supervision for clinical staff (Jin et al., 1993 (–)). Only three (Batki et al., 
2002 (++); Goldberg et al., 2004 (–); Nyamathi et al., 2006 (++); Rüütel et al., 2011 
(++)) evaluate an intervention which incorporates other elements of case 
management; moreover, of these, one focuses mainly on reminders (Rüütel et al., 
2011 (++)) and one on education and tracking of defaulters (Nyamathi et al., 2006 
(++)), with only two investigating an approach which unambiguously fits the definition 
of ECM in current practice (Batki et al., 2002 (++); Goldberg et al., 2004 (–)).  
 
4.3.1 Patients with active TB (N=3) 
 
DeMaio and colleagues (2001 (–)) evaluated a telemedicine intervention for the 
delivery of directly observed therapy for TB by videophone in the USA. The study 
was very small (sample size N=6) and there was limited description of the methods, 
context or intervention. The study appears to have compared the same group of 
patients who received ‘standard’ DOT (presumably in person) at one time, and DOT 
using videophones installed in their homes at some other time. No information was 
provided on the sample, other than that patients with a history of injecting drug use 
were excluded. The study outcome was treatment adherence, defined as a 
completed DOT session.  
 
The study found that patients were adherent to videophone DOT in 95% of cases, 
and standard DOT in 97.5% of cases. The authors argued that videophone DOT 
used much less staff time than standard DOT (3 minutes per visit as against 1 hour), 
but no data were provided to justify this claim. 
 
Jin and colleagues (1993 (–)) evaluated a service-level intervention to improve TB 
treatment services in South Korea. The study used a cluster-randomised trial design, 
with only post-test outcome data reported, although there was limited detail provided 
on study methods. The settings were health centres in urban and rural areas. The 
intervention focused on clinical staff rather than on patients, and consisted of 
intensified supervision of staff by centre directors, and regular sessions for 
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discussions of the achievements of each member of staff, in order to improve their 
case management practice. (However, it is unclear what is meant by the latter – the 
focus of the study is entirely on the intervention with staff.) The comparison group 
were instructed to deliver services as normal, including regular supervision but not 
the intensified supervision received by the intervention group. The study outcomes 
were the number of follow-up patient examinations (X-ray and sputum smear and 
culture) performed, rates of drug collection and delays in drug collection, treatment 
completion, and treatment success defined by bacteriological conversion. (Given the 
nature of the outcomes, we have assumed that the population included consisted of 
those with active TB, but this is not explicitly stated.) 
 
The study found positive effects of the intervention on all these outcomes. The 
intervention group performed more follow-up X-rays (intervention 90.8% against 
control 80.2%, significance NR) and sputum smear and culture tests (97.6% against 
70.2%, significance NR); drug collection rates were higher in the intervention group 
(87.9% against 77.1%, p<0.01) and delays in drug collection of 7 days or more were 
lower (4.7% against 12.2%, p<0.01); treatment completion rates were higher (78.8% 
against 65.2%, p<0.01), as were treatment success rates (75.2% against 45.8%, 
p<0.01). 
 
MacIntyre and colleagues (2003 (++)) evaluated a family-based DOT intervention in 
new TB patients in Australia. The study used a quasi-randomised trial design, with 
alternating allocation of patients to intervention and control groups. The setting was 
urban healthcare clinics. The population was mostly foreign-born (89.6%) and spoke 
a first language other than English (81.5%); 26% were employed and 30% students. 
Patients with MDR-TB or HIV were excluded from the study. Patients in the 
intervention group were asked to nominate a family member; both the nominated 
family member and the patient received education, and the family member was 
trained to observe the patient’s daily treatment. Patients in the comparison group 
received usual care, including some element of education, but did not receive DOT 
as standard. The study outcomes were adherence, measured by urine testing of 
isoniazid levels and by electronic pill bottles, and treatment non-completion, 
measured by clinic attendance and drug collection rates. 
 
The study found that only 58% of the intervention group actually received the 
intervention as planned, either due to refusal or due to not having a suitable family 
member. There was no significant difference between the groups in compliance as 
measured by urine testing, on either an intention-to-treat analysis (RR 1.04 (0.88–
1.23)) or a per-protocol analysis (RR 0.96 (0.75–1.23)). However, a trend analysis of 
urinary isoniazid levels (intention-to-treat) showed significantly higher levels in the 
intervention group (p<0.05). Electronic pill bottle data were not analysed by treatment 
group, but showed higher levels of non-compliance (mean 13% of doses missed) 
than the urinary isoniazid outcome. Rates of treatment non-completion were lower in 
the intervention group (3.4% against 9.3%), but not significantly so (RR 2.7 (0.66–
14.2)).  
 
Evidence statement 1: effectiveness of case management and DOT for patients 
with active TB on treatment adherence and completion 
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There is weak evidence from one (–) US study1 that a videophone DOT intervention 
achieves similar rates of adherence to TB treatment as standard DOT (95% against 
97.5%). 
 
There is weak evidence from one (–) South Korean study2 that a service-level 
intervention involving intensified supervision of staff to improve case management 
practice achieves improved rates of follow-up X-rays (intervention 90.8% against 
control 80.2%, significance NR), sputum smear and culture tests (97.6% against 
70.2%, significance NR), drug collection rates (87.9% against 77.1%, p<0.01), delays 
in drug collection of 7 days or more (4.7% against 12.2%, p<0.01), treatment 
completion rates (78.8% against 65.2%, p<0.01), and treatment success (75.2% 
against 45.8%, p<0.01). 
 
There is strong evidence from one (++) Australian study3 that family-based DOT 
does not lead to higher adherence (RR 1.04 (0.88–1.23)) than standard treatment 
with self-administered therapy. There was a non-statistically-significant trend in this 




The evidence is directly applicable to people in the UK. This is because there are no 
obvious differences in the population, context or setting of the studies compared to 
the UK context.  
 
1 DeMaio et al., 2001 (–) 
2 Jin et al., 1993 (–) 
3 MacIntyre et al., 2003 (++) 
4.3.2 Drug users (N=5) 
 
Batki and colleagues (2002 (++)) evaluated an intervention for drug users 
implemented in a methadone clinic in the USA. The study used a randomised trial 
design. The population consisted of heroin-dependent injecting drug users with latent 
TB infection (excluding those who were pregnant, HIV-positive, or had evidence of 
liver disease). The intervention was a multi-component programme combining 
directly observed preventive therapy (limited details were provided on the DOPT 
component), methadone treatment, counselling twice monthly, and access to medical 
and social work services as necessary. A second ‘minimal’ intervention group 
received DOPT and methadone, but no other services. The comparison group 
received usual care, consisting of self-administered treatment for LTBI, and no 
methadone treatment (although participants in the intervention group could access 
methadone treatment elsewhere, and several did). The outcomes measured were 
treatment completion (defined as ≥80% of doses taken as measured by clinic 
records), duration of retention in therapy, and active TB. 
 
The study found that more people completed therapy in the full intervention group 
(59.5% (43.6-75.3)) and in the minimal intervention group (77.1% (61.3-91.0)) than in 
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the comparison group (13.1% (3-23.7)); the difference between both intervention 
groups and the comparison group was significant (p<0.0001), but there was no 
significant difference between the two intervention groups. This was also the case for 
the retention outcome (mean duration of treatment in full intervention group 5.0 
months (4.5–5.5), minimal group 5.7 months (5.4–6.0), comparison group 1.6 months 
(0.9–2.25) (p<0.0001)). There was one case of active TB in the minimal treatment 
group and one in the comparison group; neither of these had completed treatment.  
 
Chaisson and colleagues (2001 (++)) evaluated two different interventions to improve 
adherence to preventive treatment among drug users. The study used a randomised 
controlled trial design. The setting was a public TB clinic in Baltimore, USA. One 
intervention consisted of directly observed preventive therapy, administered by a 
nurse, and the other of a peer support intervention in which participants attended 
monthly meetings with a trained peer counsellor and support group meetings, and 
self-administered therapy. The comparison group received usual care including self-
administered therapy. The outcomes measured were treatment completion, 
adherence (at 100%, 90% and 80% levels) measured by observation for the DOPT 
group and self-report for the other groups, and validated by electronic pill bottles and 
urine testing for the non-DOPT groups. 
 
The study found that in the DOPT group, 80% of patients completed therapy 
compared to 78% of the peer support group and 79% for the usual-care group (NS). 
In the DOPT group, 77% of patients took all doses as compared to 6% of the peer 
support group and 10% of the usual-care group (p<0.001 for the DOPT vs peer and 
DOPT vs usual-care comparisons, NS for peer vs usual care); 80% of DOPT patients 
took at least 90% of doses, as compared to 51% of the peer support group and 77% 
of the usual-care group (p<0.001 for DOPT vs peer, NS for DOPT vs usual care, 
significance NR for peer vs usual care); and 82% of DOPT patients took at least 80% 
of doses, as compared to 71% of the peer support group and 90% of the usual-care 
group (NS). By self-report, the number of doses missed was 17% in the peer group 
and 11% in the usual care group (NS); however, the number of doses taken as 
measured by urine testing was found to be 47% in the peer group and 55% in the 
usual-care group (NS); and by electronic pill bottle monitoring, 59% in the peer group 
and 49% in the usual-care group (p<0.001). 
 
Graham and colleagues (1996 (–)) conducted a study of trends in TB and M. avium 
incidence among drug users in Baltimore, USA, which can also be interpreted as 
evidence of the effectiveness of DOT. The study used a one-group design. However, 
the timing of the intervention with respect to the outcomes is somewhat unclear: at 
some point the policy in place changed from self-administered chemoprophylaxis to 
DOPT, but it is unclear when this took place. The outcomes are incidence (cases per 
1000 person-years) of TB and M. avium. However, full outcome data were not 
reported in the study, only risk ratios. 
 
The study found that in years 4 to 5 of the study, presumably after DOPT was 
implemented, there was a non-significantly lower risk of TB compared to baseline 
(RR 0.4 (0.04-4.8)) but a significantly higher risk of M. avium (RR 7.3 (2.2-24.3)).  
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Malotte and colleagues (2001 (++)) compared the effectiveness of three different 
interventions to improve adherence to treatment for latent TB in people who injected 
drugs or used crack cocaine, in California. The study used a randomised controlled 
trial design. The setting was a ‘storefront’ facility conducting risk-reduction 
programmes for drug users. There were three groups in the study: condition 1 
received DOT conducted by an outreach worker at a location chosen by the 
participant and a monetary incentive of US$5 per visit; condition 2 received the same 
DOT intervention as condition 1, but without the incentive; and condition 3 received 
DOT at the study site, with the US$5 incentive. The outcomes measured were 
treatment completion and the percentage of medications taken on time. 
 
The study found that both the incentive conditions (1 and 3) led to significantly 
(p<0.001) higher rates of treatment completion than outreach DOT without an 
incentive (condition 2) (c1 52.8%; c2 3.6%; c3 60%; OR for c1 vs c2 29.7 (56.5–
134.5), for c3 vs c2 39.7 (58.7–134.5)), as well as significantly (p<0.001) higher rates 
of medication taken on time (c1 72%, c2 12%, c3 69%). However, conditions 1 and 3 
were not significantly different.  
 
Rüütel and colleagues (2011 (++)) conducted an intervention among injecting drug 
users which, unlike the other interventions in this section, was mostly intended to 
increase uptake rather than adherence. The study used a randomised trial design. 
The setting was a methadone maintenance clinic in Estonia, and the participants 
were injecting drug users who had been tested for TB. Although described as ‘active 
case management’, the intervention was relatively minimal: study personnel 
scheduled visits to TB services for participants and reminded them to attend, and 
provided transportation if necessary. There was also an incentive (€6.40 in vouchers) 
for participants who returned for test reading. The outcome measured was 
attendance at the TB clinic. 
 
The study found that a significantly higher (p=0.004) percentage of participants 
attended the clinic in the intervention group (57.1%) than in the control group 
(30.4%).  
 
Evidence statement 2: effectiveness of case management and DOT for drug 
users on treatment uptake, adherence and completion 
 
There is weak evidence from one US study (–)1 that a policy of directly observed 
preventive therapy (DOPT) showed a non-statistically-significant trend towards lower 
rates of TB among drug users compared to self-administered preventive therapy 
(one-group RR 0.4 (0.04-4.8)). 
 
There is conflicting evidence from two (++) US studies2,3 as to whether DOPT leads 
to higher adherence rates than SAT among drug users. There is strong evidence 
from one (++) US study3 that DOPT does not lead to higher completion rates, or 
adherence rates, than usual care with SAT among drug users (completion 80% 
against 79%; adherence 82% against 90% (for 80% adherence), 80% against 77% 
(for 90% adherence)). However, DOPT did lead to higher adherence rates than usual 
care for 100% adherence (77% against 10%, p<0.001), and to higher adherence 
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rates than a peer support intervention (80% against 51% (for 90% adherence), p < 
0.001; 77% against 6% (for 100% adherence), p<0.001). 
 
There is strong evidence from one (++) US study2 that DOPT combined with 
methadone treatment leads to higher rates of TB treatment completion among 
heroin-dependent injecting drug users than usual care with SAT (77.1% against 
13.1%, p < 0.0001). However, an additional case management component with 
counselling and service access did not increase the effectiveness of the basic 
intervention (59.5% completion). 
 
There is strong evidence from one (++) US study4 that either outreach DOPT with 
incentives or on-site DOPT with incentives improve adherence among drug users 
more than outreach DOPT alone, but outreach DOPT with incentives is not 
significantly different from on-site DOPT with incentives (OR for outreach DOPT with 
incentive vs outreach DOPT alone 29.7 (56.5–134.5); OR for on-site DOPT with 
incentive vs outreach DOPT alone 39.7 (58.7–134.5)). 
 
There is strong evidence from one (++) Estonian study5 that an intervention involving 
incentives, scheduling visits and reminders, and providing transport, increases 




The evidence is partially applicable to people in the UK who use drugs. This is 
because the populations of drug users in the studies, or the services available to 
them, may differ from those in the UK. 
 
1 Graham et al., 1996 (–) 
2 Batki et al., 2002 (++) 
3 Chaisson et al., 2001 (++)) 
4 Malotte et al., 2001 (++) 
5 Rüütel et al., 2011 (++) 
 
4.3.3 People with latent TB infection (N=1)  
 
One study (Sterling et al., 2011 (+)) examines different regimens for people with 
latent TB infection. The study was carried out in several countries (USA, Canada, 
Brazil, and Spain) and compared combination therapy (isoniazid and rifapentine once 
weekly) under DOT with self-administered therapy (daily isoniazid). However, no 
details were reported on the context or delivery of DOT. The study used a 
randomised trial design with a large sample size (N=7,731). The relevant outcomes 
measured were treatment completion, TB incidence and death. 
 
The study found that treatment completion rates were significantly higher in the DOT 
group than the SAT group (DOT 82.1%, SAT 69.0%, p<0.001). Incidence of TB was 
not significantly lower in the unadjusted analysis, but was significantly lower in the 
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intervention group after adjustment for baseline risk factors (adjusted hazard ratio 
0.38 (0.15-0.99), p = 0.05). Risk of death did not differ significantly between groups. 
 
Evidence statement 3: effectiveness of DOT for people with latent TB infection 
on treatment completion 
 
There is medium evidence from one (+) study conducted in multiple countries (not 
the UK)1 that DOT leads to higher treatment completion rates and lower risk of active 
TB than self-administered therapy (completion 82.1% against 69.0%, p<0.001; risk of 
active TB adjusted hazard ratio 0.38 (0.15-0.99), p=0.05). However, the regimens 




The evidence is directly applicable to people in the UK. This is because there are no 
obvious differences in the population, context or setting of the studies compared to 
the UK context.  
 
1 Sterling et al., 2011 (+) 
4.3.4 Migrants or new entrants (N=2) 
 
Two effectiveness studies focused on migrants or new entrants. Goldberg and 
colleagues (2004 (–)) investigated a case management programme for refugees 
arriving in Washington state, USA. The intervention used a one-group design 
comparing outcomes after the intervention to retrospective pre-test data. The 
intervention was a ‘cultural case management’ programme, focusing in particular on 
people from Somalia, the former Soviet states, and the former Yugoslavia (although 
people of some other national origins are also reported to have been included). 
Three case managers were recruited, one each from each of these groups, and were 
given training in TB by the staff of the refugee screening programme. The case 
management programme itself (which was delivered to 80% of the intervention 
participants) included home readings of TSTs, culturally tailored education, and 
referrals to other services such as housing and social services. Case managers also 
attempted to build trusting and supportive relationships with participants. The 
outcomes measured were treatment uptake (i.e. whether participants started 
treatment) and treatment completion. 
 
The study found that intervention participants had significantly higher uptake of 
treatment than the retrospective pre-test group (88% against 73%, p<0.001), as well 
as of treatment completion (82% against 37%, p<0.001). Subgroup analysis found 
that among participants from the former Yugoslavia and former Soviet Union there 
was a significant effect on both outcomes, while those from Somalia had higher 
completion rates but not higher uptake rates. 
 
Matteelli and colleagues (2000 (–)) evaluated the impact of different treatment 
regimens for immigrants undergoing TB screening and LTBI treatment in Italy. The 
study used a randomised trial design. The study compared three groups: one 
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received ‘supervised’ treatment on a twice-weekly regimen, one unsupervised 
treatment on a twice-weekly regimen, and one unsupervised treatment on a daily 
regimen. However, very little information was provided on what constituted 
‘supervision’ in this study: the authors report that participants had to report twice 
weekly to the clinical service sites to collect drugs, but there does not appear to have 
been any observation or other support. The outcomes measured were treatment 
completion and time to dropout. 
 
The study found that the supervised treatment group had significantly lower rates of 
treatment completion than either of the unsupervised groups (7.3% against 26% or 
41%, p=0.006 and p=0.001 respectively), as well as a significantly shorter mean time 
to dropout (3.8 weeks against 6 weeks or 6.2 weeks, p=0.003). 
 
Evidence statement 4: effectiveness of case management and observed drug 
collection for migrants or new entrants on treatment uptake and completion 
 
There is weak evidence from one (–) US study1 that cultural case management, 
including culturally tailored education and support by trained peers, leads to higher 
uptake of treatment (88% against 73%, p<0.001) and completion of treatment (82% 
against 37%, p<0.001) for LTBI among refugee populations. 
 
There is weak evidence from one (–) Italian study2 that requiring immigrants to attend 
clinic sites to collect drugs for LTBI treatment leads to lower rates of treatment 




The evidence is partially applicable to immigrants to the UK. This is because the 
populations of migrants in the studies, or the policies in place around immigration, 
may differ from those in the UK.  
 
1 Goldberg et al., 2004 (–) 
2 Matteelli et al., 2000 (–) 
4.3.5 Patients with HIV (N=1) 
 
One study (Narita et al., 2002 (+)) focused on treatment of latent TB infection for HIV-
infected patients. The study used a one-group design with retrospective pre-test 
data. The setting was community HIV clinics in Florida, USA. While the main focus of 
the study is on the change from isoniazid treatment to a regimen of rifamycin/ 
pyrazinamide, there was also a change from self-administered therapy to DOT, and 
hence the study meets criteria for inclusion in this review; however, very few details 
of DOT were reported, other than that treatment was observed by clinic staff. The 
outcome measured was treatment completion.  
 
The study found significantly higher rates of treatment completion after the change of 
regimen (93% against 61%, p < 0.001). 
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Evidence statement 5: effectiveness of DOT for people with HIV on treatment 
completion 
 
There is medium evidence from one (+) US study1 that DOT leads to higher rates of 
treatment completion than SAT for LTBI treatment among people with HIV (93% 




The evidence is directly applicable to people in the UK. Despite differences in the 
broader healthcare context in the USA, there are are no obvious differences in the 
population, context or setting of the study compared to the UK context.  
 
1 Narita et al., 2002 (+) 
4.3.6 Homeless people (N=1) 
 
One study (Nyamathi et al., 2006 (++)) focused on a case management intervention 
for homeless people with latent TB infection. The study used a randomised trial 
design. The setting was homeless emergency and recovery shelters in Los Angeles, 
USA. The intervention was delivered by a nurse and a trained outreach worker. The 
main component was an educational programme consisted of eight culturally tailored 
small-group sessions focusing on TB and HIV, self-esteem, communication skills, 
and problem-solving skills; they were also provided with information about services. 
Participants who missed a DOT dose were actively tracked and reintegrated into the 
programme where possible. Control participants received a single brief education 
session. Participants in both groups were required to report to the study clinic twice 
weekly for DOT, and received a $5 incentive for each visit, but control participants 
were not actively tracked. The outcomes were knowledge about TB and treatment 
completion. 
 
The study found that the intervention led to significantly better knowledge about TB 
(intervention 3.8±3.5, control 2.0±4.2, p<0.01). It also led to higher rates of treatment 
completion (intervention 61.5%, control 39.3%, p<0.01; a logistic regression model 
controlling for confounders produced an OR of 3.01 (2.15-4.20) in favour of the 
intervention group, p<0.001). Subgroup analyses indicated somewhat higher effect 
sizes among women (RR 1.94 (1.26-2.98)) than men (RR 1.46 (1.21-1.77)) and 
among people of white or Hispanic ethnicity (RR 2.32 (1.32-4.06)) than those of 
African-American ethnicity (RR 1.45 (1.22-1.74)), but all these subgroups showed a 
significant effect of the programme. 
 
Evidence statement 6: effectiveness of education and tracking for homeless 
people on treatment completion 
 
There is strong evidence from one (++) US study1 that an education programme and 
active tracking of defaulters, with DOT and incentives, leads to higher rates of 
completion of LTBI treatment among homeless people than DOT and incentives 





The evidence is partly applicable to people in the UK. This is because the population 
of homeless people in the study, or the services available to them, may differ from 
those in the UK. 
 
1 Nyamathi et al., 2006 (++) 
 
4.4 Findings: cost-effectiveness 
 
This section presents the findings for the review of cost-effectiveness. Table 5 
summarizes the overall characteristics of the studies. One study (Chaulk et al., 2000) 
was found at QA stage not to be applicable; in line with the methods guide, this study 
was not data-extracted or considered further in the analysis. 
 
Table 5. Characteristics of the cost-effectiveness studies (N=15) 




Neonates exposed to 
TB 
DOPT / parent-administered 
therapy 




+ Patients with active TB DOT / SAT Net cost savings 
Gourevitch 
et al., 1998 
– Drug users DOPT / SAT Net cost savings 
Holland et 
al., 2009 
– People with LTBI 
Four drug prophylaxis 
regimens, two DOT and two 
SAT 
Net cost savings; 
cost per QALY 
Jit et al., 
2011 
+ 
Patients with active TB 
from high-risk groups 
Mobile screening and 
enhanced case management 
including DOT / usual care 
Cost per QALY 
Migliori et 
al., 1999 
– Patients with active TB 
Changes to hospital policy; 
DOT; additional staffing; 
incentives 
Cost per cure 
Moore et al., 
1996 
+ Patients with active TB 
DOT / conventional SAT / 
fixed-dose SAT 
Cost per relapse 




+ Patients with active TB 
Universal DOT / partial DOT / 
SAT 
Cost per cure 
Perlman et 
al., 2001 
– Drug users Screening; DOPT; enablers 
Cost per case 
averted; net cost 
savings 
Porco et al., 
2006 
++ Immigrants 
Screening; active recruitment 
of immigrants; DOPT 




Patients with active TB 
at low risk of default 
DOT / SAT Cost per cure 
Snyder  et 
al., 1999b 
+ Drug users Screening; DOPT; enablers Net cost savings 
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Wade et al., 
2012 
– Patients with active TB 





Weis et al., 
1999 
– Patients with active TB DOT / SAT Net cost savings 
Wilton et al., 
2001 
– Patients with MDR-TB DOT / ‘conventional therapy’ Net cost savings 
 
The findings below are categorized by population or setting type, in the following 
categories: 
 
 Patients with active TB (N=9 studies) 
 Drug users (N=3) 
 People with latent TB infection (N=1) 
 Migrants or new entrants (N=1) 
 Neonates (N=1) 
 
As with the effectiveness evidence, the focus of the majority of the cost-effectiveness 
studies (N=13) is DOT (with, in some cases, incentives and enablers); only two could 
be said to incorporate elements of ECM (Jit et al., 2011 (+); Porco et al., 2006 (++)).   
 
The majority of the studies quantify cost-effectiveness in terms of net cost savings, 
i.e. the (healthcare) costs of the intervention compared to the healthcare costs of the 
cases of TB and drug-resistance averted by the intervention. Relatively few studies 
attempt to value health outcomes. We return to this point in the discussion below. 
 
4.4.1 Patients with active TB (N=9 studies) 
 
Burman and colleagues (1997 (+)) present a decision-analytic model to assess the 
cost-effectiveness of directly observed therapy in patients with active TB, compared 
to self-administered therapy. The cost data indicate that DOT was considered to be 
administered by nurses in a clinic setting or by home visits, although limited 
information was presented. The model considered the perspective of the programme 
as well as a broader healthcare system perspective, with a time horizon up to 2 years 
for some outcomes. Data were drawn from the records of a TB clinic in Denver, USA, 
as well as from the literature, with most data reflecting a USA setting. Adherence or 
compliance data were not considered in the model as such, and the treatment effect 
of DOT was drawn from a single retrospective one-group study measuring its 
impacts on failure and drug resistance. Findings were presented in the form of net 
costs, i.e. the costs of the programme less the treatment costs saved by reduced 
treatment failure and drug resistance. 
 
This study found that DOT was cost saving relative to SAT, with net cost savings of 
US$909 per patient treated from a programme perspective (DOT net costs 
US$1,405, SAT $2,314), US$7,744 from a healthcare perspective (DOT net costs 
$2,785, SAT $10,529), and US$8,168 from a perspective which also takes into 
account the losses of patients’ time resulting both from DOT and from the 
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consequences of treatment failure and drug resistance (DOT net cost $3,999, SAT 
$12,167). Sensitivity analyses indicated that DOT retained this advantage across a 
range of assumptions about cost and drug efficacy; in particular, the relative failure 
rates would have to change substantially (a five-fold increase in DOT or a six-fold 
decrease in SAT) to overturn the advantage of DOT. 
 
Jit and colleagues (2011 (+)) report a cost-effectiveness analysis of the Find and 
Treat service. This service combined a mobile radiography unit, which visits sites 
such as drug treatment services and homeless shelters, with an enhanced case 
management service in which staff members accompany clients to visits and 
appointments. There was also a broader awareness-raising component, again 
targeted at high-risk groups, and delivered by peer workers. (Thus, the mobile 
screening unit and the awareness-raising aimed to increase uptake of services, while 
the enhanced case management aimed to promote adherence to treatment among 
patients with active TB; we have categorised the study as a whole under the latter.) 
The Find and Treat service was compared to outcomes for patients who presented to 
usual TB services. The study used a discrete age cohort model to estimate the cost-
effectiveness of the service, with data drawn from programme records and from the 
literature – including data on the effect of the intervention on treatment completion 
rates – over a time horizon of 5 years. Findings were presented in the form of cost 
per QALY (unlike the majority of the studies in this review, the healthcare costs of 
averted treatment failures were not taken into account in calculating the benefits of 
the intervention).  
 
The study found that the incremental cost-effectiveness of the Find and Treat service 
was £6,400 per QALY. Separate analysis of the two components of the service found 
that the cost-effectiveness of the mobile screening service was £18,000 per QALY, 
and that of the enhanced case management programme £4,100 per QALY. 
Sensitivity analyses indicated that these ICERs would rise slightly under less 
favourable assumptions, with the most unfavourable combination of assumptions 
giving a cost-effectiveness of £10,000 per QALY for the service as a whole, £26,000 
per QALY for mobile screening, and £6,800 per QALY for enhanced case 
management.  
 
Migliori and colleagues (1999 (–)) report a cost-comparison study looking at the 
effects of different policies for management of patients with TB in Italy. Their main 
analysis compared two scenarios: scenario 1, based on current practice in Italy, and 
scenario 2, with a greater use of outpatient treatment. These scenarios were then 
considered in conjunction with DOT (limited information was provided on the delivery 
or setting of the DOT component), additional staffing, and/or food incentives for 
patients. The study appeared to use a healthcare perspective (the authors report 
also using a social perspective which included productivity loss, but this is not 
reported in any detail). Limited information was provided on the sources of the data, 
and in particular, the effectiveness data appeared to be assumed rather than derived 
from studies; the outcomes included in the model were also somewhat unclear. 
Findings were presented in the form of cost per cure; however, no incremental 
analysis of the data was presented in the report, limiting its value with respect to the 
DOT and incentive interventions.  
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The study findings for cost per cure (US$, smear-positive / smear-negative) in the 
base case scenario, using Italian population data on treatment success, are shown in 
Table 6. 
 
Table 6. Findings from Migliori et al., 1999 (–), cost per cure (1997 prices), US$ 
 Scenario 1 (current 
practice) 
Scenario 2 (more 
outpatient care) 
Alone 16,494 / 11,230 5,690 / 2,202 
With DOT 16,703 / 11,438 5,946 / 2,448 
With DOT + additional 
staff 
17,105 / 11,838 6,437 / 2,920 
With DOT + incentives 17,576 / 12,308 7,014 / 3,474 
With DOT + additional 
staff + incentives 
17,978 / 12,708 7,505 / 3,946 
 
Sensitivity analyses on treatment success rates indicated that the cost per cure could 
vary from US$25,503 to US$14,181 for scenario 1 alone, and from $8,799 to $4,893 
for scenario 2 alone, as treatment success varied between 50% and 90% for smear-
positive patients; similar ranges were seen for smear-negative patients and for the 
other forms of the scenarios.  
 
Moore and colleagues (1996 (+)) present a cost-effectiveness analysis of directly 
observed therapy for patients with TB. DOT was compared both to conventional self-
administered therapy, and to fixed-dose combination therapy (also self-
administered). In this study DOT was considered to be delivered by a registered 
nurse case worker and licenced practical nurse outreach worker, with each patient 
visiting the clinic once and then receiving 50 outreach visits. They used a decision-
analytic model, with a healthcare perspective, with some outcomes considered up to 
2 years. The data were generally drawn from the literature, and from clinic records; 
treatment effect data were based on several studies, most from the USA. Findings 
were presented in the form of costs per relapse averted and per life saved. 
 
This study found that the cost per relapse averted was US$17,305 for conventional 
SAT, $15,446 for fixed-dose SAT, and $14,378 for DOT. The cost per life saved was 
$15,200 for conventional SAT, $14,068 for fixed-dose SAT, and $13,966 for DOT. 
Sensitivity analyses found that the relative cost-effectiveness of the three options 
was not sensitive to changes in the costs of managing TB. However, the results were 
more sensitive to changes in costs, with DOT and fixed-dose SAT of comparable 
cost-effectiveness if the direct cost of DOT increases by $100; sensitivity analyses 
showed the marginal cost per life saved of DOT ranging between $0 and 
approximately $1,350, and the marginal cost per relapse averted between $0 and 
approximately $450, as the cost of DOT ranges from $13,600 to $15,000. They were 
also sensitive to relatively small increases in the probability of incomplete DOT 
leading to relapse, with the marginal cost per life saved of DOT ranging between $0 
and approximately $43 as the probability of relapse ranges between 0.27 and 0.30. 
They were also sensitive to variation in the probability of relapse with resistant TB for 
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fixed-dose combination therapy, with the marginal cost per life saved of DOT ranging 
between approximately $170 and $0 as this probability ranges between 0.001 and 
0.0016. 
 
Palmer and colleagues (1998 (+)) present a cost-effectiveness analysis of directly 
observed therapy, considering a scenario in which DOT is delivered to all patients, 
one in which it is delivered to only 15% of patients and the remainder have self-
adminstered therapy, and one in which there is no DOT and all patients have SAT. 
Limited information is presented on the delivery or context of DOT, although it 
appears to be assumed that a health professional conducts the observations. The 
study used a decision-analytic model with data drawn from clinic records and from 
the literature, most from the USA, including data on treatment completion. The model 
was analysed from a healthcare perspective, with a horizon of 10 years. The findings 
were reported as cost per case cured. 
 
The study found that the direct costs per cure were US$16,846 for the partial DOT 
strategy (15% of patients), $20,106 for the no DOT strategy, and $17,323 for 
universal (100%) DOT. The incremental cost-effectiveness of universal DOT 
compared to partial DOT was $24,064 per cure. Sensitivity analyses indicated that 
these results were not sensitive to changes in default rate, infection rate or hospital 
stay; however, they were somewhat sensitive to changes in outpatient costs, where a 
20% decrease gave an incremental cost-effectiveness of $18,184 per cure, and a 
20% increase $29,944.  
 
Snyder and Chin (1999a (–)) focused specifically on people with active TB who are at 
low risk of default, to inform the decision to move from a policy where DOT is 
targeted at high-risk patients to a universal DOT policy. They defined low-risk 
patients as those with no history of homelessness, injecting drug use or 
imprisonment, and without HIV infection or drug-resistant TB. These patients 
currently receive SAT, and the analysis considered the effect of providing DOT for 
this population, including incentives (value US$25 per week); however, no 
information was provided on the provider or setting of DOT. The model used a 
healthcare perspective, with some outcomes considered up to a 2-year horizon. Cost 
data were drawn from Medi-Cal reimbursement rates, while data on DOT 
effectiveness and baseline probabilities were drawn from the previous study by 
Moore et al. (1996 (+)), described above; data on SAT, including treatment default 
rates, were drawn from clinical record data from California. The findings were 
presented in the form of cost per patient treated and per patient cured.  
 
The study found that for this population, the direct costs of DOT per patient treated 
would be US$1,332 greater than SAT, and the net incremental cost of DOT including 
cost savings from treatment of relapses would be US$919 per patient treated; the net 
incremental cost per patient cured would be $40,260. Sensitivity analyses indicated 
that this result was sensitive to large changes in the default rate on SAT, with DOT 
becoming net-cost-saving at a SAT default rate of 32.2% (base case 1.7%), or in the 
relapse rate after completing SAT; however, it was not very sensitive to substantial 
changes in the effectiveness of DOT in preventing default.  
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Wade and colleagues (2012 (–)) investigate a telehealth programme for delivering 
DOT for active TB in South Australia. In this programme broadband connections and 
videophones were installed in patients’ homes, and nurses observed patients 
remotely. The evaluation compared this intervention to the previous model where 
nurses visited patients’ homes. (In fact some patients included in the telehealth arm 
were considered unsuitable for the videophone intervention, and continued to receive 
in-person DOT.) The study focused on establishing the cost per successful 
observation of each way of delivering DOT, and did not attempt to model the effects 
of this, for example on treatment completion or health state outcomes. The data 
populating the model come from the evaluation of the programme, which used a 
retrospective cohort design. The findings are presented in terms of cost per 
successful day of observation. 
 
The study found that the telehealth intervention cost Aus$2,654 per care episode and 
in-person DOT Aus$2,589; incorporating the difference in successful days of 
observation per episode, the incremental cost-effectiveness of the telehealth 
intervention was Aus$1.32 per day of observation. Sensitivity analyses indicated that 
the telehealth intervention would be dominant (net-cost-saving) with increased 
numbers of patients using the service, or with increased travel time for the in-person 
DOT service, but would have a higher ICER with a higher percentage of non-
compliant patients or lower staff salaries. 
 
Weis and colleagues (1999 (–)) conducted a retrospective economic evaluation of 
the implementation of DOT in Tarrant County, Texas. In the earlier phase of data 
collection almost all patients received SAT, with treatment only observed if patients 
relapsed or acquired drug resistance. In the later phase almost all patients received 
DOT.  The study used clinical record data on adherence and treatment failure to 
compare the cost-effectiveness of the two policies. The findings were reported in the 
form of the cost per patient treated, taking into account the costs of hospitalization 
resulting from treatment failures in each group. 
 
The study found that DOT was substantially less costly once the reduction in 
treatment failure was taken into account, with total costs per patient treated of 
US$11,260 as against US$27,630 in the SAT group. (However, there were also 
differences in the regimen received, with greater use of intermittent therapy in the 
DOT group, such that the direct costs of medication and laboratory services were 
actually greater in the SAT group, even without taking further outcomes into 
account.) 
 
Wilton and colleagues (2001 (–)) report a Monte Carlo model comparing DOT and 
‘conventional therapy’ in the USA and South Africa (only the USA analysis is 
considered here, in line with our review inclusion criteria). Very little information was 
provided about the delivery or setting of DOT, and none about what ‘conventional 
therapy’ means, although it appears to be SAT. Data, including data on default rates, 
were drawn from the literature and from previous cost-effectiveness studies, 
including Moore et al.’s discussed above (Moore et al., 1996 (+)); for treatment effect 
data Moore et al. (1996 (+)) and another modelling study were cited, rather than 
research data, but the latter studies appear to have been populated with empirical 
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data. The analysis used a healthcare perspective, but the time horizon is unclear. 
The findings were presented in terms of net costs. 
 
The study found that the total mean net cost of DOT was US$18,932, and of 
‘conventional therapy’ US$20,720. Sensitivity analyses indicated that DOT remained 
more cost-effective when a different and more costly protocol for second-line 
treatment was included.  
 
Evidence statement 7: cost-effectiveness of DOT, increased outpatient care, 
and Find and Treat for patients with active TB 
 
There is medium evidence from five (3 + and 2 –) cost-effectiveness studies1-5  that 
directly observed therapy for active TB incurs lower net costs than self-administered 
therapy, when the cost savings resulting from reduced treatment failure are taken 
into account. Relative net cost savings from DOT in these studies1,4-5 range from 
US$1,788 to US$16,370 per patient treated (with other studies reporting a relative 
cost per death averted of US$1,2342, and a relative cost per patient cured of 
US$2,7833).  
 
However, there is weak evidence from one (–) cost-effectiveness study6 that DOT is 
more costly than SAT for patients at low risk of default (incremental cost of US$919 
per patient treated, US$40,260 per patient cured). There is also moderate evidence 
from one (+) study that a policy of universal DOT is more costly than a policy of 
partial DOT (incremental cost of US$24,064 per patient cured).3  
 
There is medium evidence from one (+) cost-effectiveness study7 that a Find and 
Treat service which combines mobile screening for high-risk populations with 
enhanced case management support has an incremental cost-effectiveness 
compared to usual care of £6,400 per QALY (£18,000 per QALY for mobile 
screening and £4,100 per QALY for enhanced case management). 
 
There is weak evidence from one (–) cost-effectiveness study that a policy of 
increased outpatient care for TB is less costly than usual care (cost savings of 
US$10,804 for smear-positive patients, US$9,028 for smear-negative per patient 
cured), although the addition of DOT and incentives makes little difference to this. 
 
There is weak evidence from one (–) cost-effectiveness study9 that remote DOT via 
videophone has an incremental cost-effectiveness of Aus$1.32 per day of 
observation, compared to in-person DOT. 
 
1 Burman et al., 1997 (+) 
2 Moore et al., 1996 (+) 
3 Palmer et al., 1998 (+) 
4 Weis et al., 1999 (–) 
5 Wilton et al., 2001 (–) 
6 Snyder and Chin, 1999a (–) 
7 Jit et al., 2011 (+) 
8 Migliori et al., 1999 (–) 
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9 Wade et al., 2012 (–) 
 
4.4.2 Drug users (N=3) 
 
Three cost-effectiveness studies evaluated directly observed prophylactic therapy for 
drug users. 
 
Gourevitch and colleagues (1998 (–)) conducted a cost-effectiveness evaluation of a 
screening and DOPT programme integrated into a methadone maintenance 
treatment programme in New York City. All clients of the programme were screened 
at entry and annually for TB by a nurse, and those prescribed chemoprophylaxis 
were eligible for voluntary DOPT. The model used a programme perspective with a 
time horizon of 5 years. Most data were drawn from the programme evaluation, with 
the comparison outcomes (SAT) based on a hypothetical cohort. However, the 
effectiveness of DOPT appears to have been based purely on assumptions, and no 
data are cited for this. Adherence or compliance outcomes do not appear to have 
been considered in the model. The findings were presented in the form of net cost 
savings, including the costs saved by preventing future cases of TB. 
 
The study found that net cost savings per person treated by SAT ranged from 
US$1,289 to $3,418 depending on INH efficacy, and under DOPT from $1,380 to 
$3,590 depending on INH efficacy and DOPT effectiveness. Sensitivity analyses 
indicated that the programme was cost-saving even under less favourable 
assumptions (lower population risk). (It should also be noted that the analysis shows 
that the cost savings per person treated under SAT are actually greater than the 
additional savings produced by introducing DOPT, although both are cost-saving.) 
 
Perlman and colleagues (2001 (–)) similarly evaluated a screening and DOPT 
programme for drug users, also in New York City; this programme was based in a 
needle exchange service. All clients of the service were offered TB screening, with a 
US$15 incentive for returning to collect the results. Patients prescribed 
chemoprophylaxis were offered DOPT twice-weekly at the service site, and given 
transportation tokens to the value of US$5. The model used a healthcare perspective 
with a horizon of 5 years. Data were drawn from the programme evaluation and from 
the literature, but treatment effect appears to have based on Gourevitch et al. (1998 
(–)), which as discussed above, does not itself appear to have been based on 
empirical data. The findings were presented in the form of cost per case prevented 
and net cost savings. 
 
The study found that the costs of the intervention were US$14,213 to $18,951 per 
case averted, depending on isoniazid efficacy, and the total net cost savings for the 
programme as a whole were US$46,226 to US$123,081 ($15,407 to $30,770 per 
case averted). Further analyses indicated that if adherence were hypothetically 
increased to 100%, the cost would be $10,211 to $23,339 per case averted, and the 
total net cost savings for the programme $93,416 to $414,856 ($13,345 to $25,928 
per case averted). 
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Snyder and colleagues (1999b (+)) also presents an economic evaluation of a 
screening and DOPT programme in a methadone maintenance clinic, this one in San 
Francisco. Clinic clients were offered screening, and those recommended for 
chemoprophylaxis were educated by clinic staff about the benefits of treatment. A 
community health worker accompanied them to clinic visits, and transport or tokens 
and food were provided. A clinic nurse then supported them in developing an 
adherence plan and observed treatment, and community health workers looked for 
clients who missed treatment. The model reported in the study used a healthcare 
perspective with a time horizon of 10 years. Data were mostly drawn from the 
programme evaluation, which used a retrospective cohort design; however, 
treatment effect data appear to have been based on a study conducted in Eastern 
Europe in the 1970s, and the applicability of these results may be limited. The 
findings were presented in terms of net cost savings per case averted. 
 
The study found that the programme achieved a net cost saving of US$3,724 per TB 
case prevented. Sensitivity analyses indicated that this finding was sensitive to 
changes in the rates of treatment completion, with net costs ranging from a cost of 
$12,677 to a cost saving of $6,674 per case prevented across large changes in the 
completion rate. 
 
Evidence statement 8: Cost-effectiveness of screening and DOT for drug users 
 
There is weak evidence from three (1 +1 and 2 –2,3) cost-effectiveness studies that 
programmes for drug users which include screening and directly observed 
prophylactic therapy have lower relative net costs than no intervention, with net cost 
savings ranging from US$3,724 to US$30,770 per case averted, or from US$1,380 to 
US$3,590 per person treated1-3. 
 
1 Snyder et al., 1999b (+) 
2 Perlman et al, 2001 (–)  
3 Gourevitch et al., 1998 (–) 
 
4.4.3 People with latent TB infection (N=1) 
 
Holland and colleagues (2009 (–)) conducted a cost-effectiveness study of four 
regimens for the treatment of latent TB infection (based hypothetically on contacts of 
TB cases). While the main focus of the study was on drug efficacy, two of the 
regimens included DOT and two were self-administered, so it meets the criteria for 
this review: the 9H regimen (daily isoniazid) and the 4R regimen (daily rifampin) were 
self-administered, while the 9H-DOT (twice-weekly isoniazid) and the 3HP (weekly 
isoniazid and rifapentine) regimens were directly observed. DOT appears to have 
been considered to be delivered by an outreach worker in patients’ homes. The 
model used was a Markov model with some outcomes considered up to a horizon of 
9 months, comparing each of the regimens with all the others and with no treatment. 
Data were drawn from the literature, including some data on treatment effect 
(although from different studies for the different regimens). The findings are reported 
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in terms of net costs, taking into account further treatment costs, and in terms of cost 
per QALY. 
 
For our purposes the relevant comparisons are those of the DOT regimens with the 
SAT regimens and with no treatment. The study found that the 9H-DOT regimen cost 
US$475.10 per patient treated relative to no treatment, while the 3HP DOT regimen 
produced a net cost saving of $751.06. Incremental cost-effectiveness ratios in terms 
of net costs per QALY were: US$48,997 per QALY for 3HP (DOT) compared to 4R 
(SAT); $25,207 per QALY for 3HP (DOT) compared to 9H (SAT); and $7,879 per 
QALY for 9H-DOT compared to no treatment.  Sensitivity analyses showed that the 
4R (SAT) and 3HP (DOT) regimens generally dominated the others under a range of 
parameter values.  
 
Evidence statement 9: Cost-effectiveness of DOT for people with latent TB 
infection 
 
There is weak evidence from one (–) cost-effectiveness study1 that weekly isoniazid 
and rifapentine under DOT is cost saving compared to no intervention, while twice-
weekly isoniazid under DOT has an incremental cost-effectiveness ratio of $7,879 
per QALY compared to no intervention. 
 
1 Holland et al., 2009 (–) 
 
4.4.4 Migrants or new entrants (N=1) 
 
Porco and colleagues (2006 (++)) conducted a cost-effectiveness study of a 
programme for new immigrants to the USA. The basic intervention in this study was 
a programme of new entrant screening and self-administered therapy for LTBI (this 
alone would not meet the criteria for this review). Over and above this, the study then 
considered a range of potential interventions to promote uptake and adherence to 
treatment, including reminder letters and telephone calls, home visiting, and targeted 
DOPT. The model used was a continuous-time, discrete-event model, with an all-
payer perspective and a time horizon of 20 years. Data, including treatment effect 
data, were drawn from the literature. The presentation of the findings is somewhat 
different from the other studies in this review. The cost-effectiveness of the basic 
intervention is presented in terms of net costs and QALY gains. However, the 
interventions of interest for this review are presented in terms of a decision analysis 
which sequentially considered a range of interventions to increase uptake or 
adherence, with the incremental cost and benefit of each considered against the 
background of the previously implemented interventions. 
 
The main analysis shows the programme as a whole to have made net cost savings 
of $25,000, and yielded 7.7 net QALYs. (Detailed sensitivity analyses are reported in 
the study but are not reproduced here, as the intervention considered for this 
analysis is not strictly within the scope of this review.) The authors report their 
decision analysis in the form of the following table: 
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Table 7. Findings from Porco et al., 2006 (++) 
Beginning with … Choose between … Best choice 
1. Treat only active cases; 
detect them only passively 
(1) Offer LTBI treatment to 
TB2s or TB4s, or 
(2) send letters to improve 
evaluation 
Send letters (2.7 QALYs 
gained, $10 000 in net 
savings) 
2. Send letters; treat active 
cases 
(1) Offer LTBI treatment to 
TB2s, 
(2) Offer LTBI treatment to 
TB4s, or 
(3) make phone calls to 
improve evaluation rates 
Treat TB4s (3.2 QALYs 
gained, $11 000 in net 
savings) 
3. Treat active cases and 
TB4s; improve evaluation 
by letters 
(1) Offer LTBI treatment to 
TB2s, 
(2) make phone calls to 
improve evaluation rates 
further, 
(3) improve rates of 
starting therapy for TB4s, 
or 
(4) improve completion 
rates by DOPT 
Improve starting rates (1.3 
QALYs saved, $1 800 in 
net savings) 
4. Treat active cases and 
TB4s; improve evaluation 
rates by letters; improve 
starting rates 
(1) send letters to improve 
evaluation rates further, 
(2) treat TB2s, or 
(3) improve completion 
rates by DOPT 
Treat TB2s (0.7 QALYs 
saved, $3 000 in net cost) 
5. Treat active cases, 
TB2s, and TB4s; improve 
evaluation by letters; 
improve rates of starting 
therapy 
(1) Further improve 
evaluation rates by phone 
calls, or 
(2) improve rates of 
completing therapy (by 
targeted DOPT) 
Phone calls (0.5 QALYs 
saved, approximately 
$1 000 in net savings) 
6. Treat active cases, 
TB4s, and TB2s; improve 
evaluation by letters and 
phone calls 
(1) Further improve 
evaluation rates by home 
visits, or 
(2) improve rates of 
completing therapy by 
using targeted DOPT 
Home visits (0.3 QALYs 
saved, approximately 
$1 000 in net cost) 
7. Treat active cases, 
TB4s, and TB2s; improve 
evaluation by letters and 
phone calls 
(1) improve rates of 
completing therapy by 
using targeted DOPT 
> $100 000 per QALY 
saved; no further 
intervention 
 
Evidence statement 10: Cost-effectiveness of screening, LTBI treatment and 
DOPT for new entrants 
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There is good evidence from one (++) study1 that a screening and LTBI treatment 
programme for new entrants to the USA is cost saving compared to no intervention, 
and that reminders by phone, post or home visiting are also cost saving. However, 
this study finds the incremental cost of DOPT compared to the combination of all 
these interventions to be over US$100,000 per QALY.  
 
1 Porco et al., 2006 (++) 
 
4.4.5 Neonates (N=1) 
 
Berkowitz and colleagues (2006 (–)) present a decision-analytic model to assess the 
cost-effectiveness of directly observed prophylactic therapy in neonates who had 
been exposed to an adult with active TB in a hospital nursery, and of parent-
administered therapy, compared to no intervention. Very little information was 
presented on who delivered DOT or in what setting. The model used took into 
account infection rates, survival rates, and incidence of adverse effects from 
treatment (hepatotoxicity), with a horizon of 4 years. Many of the data sources were 
unclear for this study: most of the sources for cost data were not reported; the 
treatment effect for DOT appears to be assumed; and the treatment effect for parent-
administered therapy appears to be drawn from studies of self-administered therapy 
in adults. Adherence or compliance data were not considered in the model as such. 
Outcomes were presented in the form of cost per death prevented. 
 
This study found that DOPT had an incremental cost per death prevented of 
US$21,710,000 relative to no intervention, while parent-administered therapy had an 
incremental cost per death prevented of US$929,500. Sensitivity analysis indicated 
that DOPT would dominate no intervention if the probabilities of developing disease 
were substantially increased and adverse event rates reduced. 
 
Evidence statement 11: Cost-effectiveness of DOPT for neonates exposed to 
TB 
 
There is weak evidence from one (–) cost-effectiveness study1 that directly observed 
preventive therapy has an incremental cost-effectiveness of US$21,710,000 per 
death prevented compared to no intervention, substantially greater than parent-
administered therapy. 
 
1 Berkowitz et al., 2006 (–) 
 
4.5 Qualitative evidence  
 
Two studies presenting qualitative data about interventions were located. One (Wade 
et al., 2012 (+)) is from the same study as the economic evaluation discussed above. 
The characteristics of the studies are shown in Table 8. 
 
Table 8. Characteristics of the qualitative studies (N=2) 
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Ref. QA Country Population Intervention Methods 
Craig et 
al., 2008 
– UK Staff in agencies 
working with people 
with TB 
Social outreach case 






+ Australia Clinical and other 
staff delivering 
service; patients with 
TB 
Videophone DOT Interviews 
 
Craig and colleagues (2008 (–)) conducted a process evaluation of the 
implementation of a social outreach model of care for socially marginalized people 
with TB. The main innovation of the service was a case manager or ‘link worker’ role, 
focusing on supporting patients and facilitating linkages between distinct services. 
People were referred to the service because of homelessness or housing needs, 
asylum or immigration issues, substance use or imprisonment. Some had latent TB 
and others active disease.  
 
Qualitative data were collected from staff in a range of services who were in contact 
with link workers, such as agencies for refugees or homeless people. Themes 
included: greater understanding of clinical issues around TB on the part of staff in 
other agencies; the value of linking together different services; and the value of the 
emotional support provided by link workers, especially for asylum seekers who may 
be unable to access many other services. One participant also suggested that people 
may be more likely to access health services when this can also facilitate accessing 
other services at the same time. 
 
Wade and colleagues (2012 (+)) conducted a process evaluation of a videophone 
DOT service, in conjunction with the economic evaluation discussed above. The 
study included staff involved in delivering the service as well as patients who used 
the service. Patients’ perceptions were generally positive in ten of twelve cases, with 
two patients expressing more mixed views. They valued the personal relationship 
with the nurses who delivered DOT, and the improved privacy of the videophone 
service over the in-clinic DOT service. Staff participants found the videophone 
service convenient and easy to use, although there were some technical problems in 
its implementation. Some were concerned that patients found it easier to pretend to 
swallow pills using the videophone service, but generally had the impression that it 
improved adherence. The service was also seen to improve communication between 
staff in the community nursing service and the hospital chest clinic.  
 
Evidence statement 12: Qualitative evidence on interventions to promote 
adherence to treatment for TB or LTBI 
 
There is weak evidence from one (–) UK study1 that a link worker for marginalized 
people with TB or LTBI is viewed positively by staff in other agencies. Participants 
report that the link worker increases understanding of TB among workers in different 
services, facilitates service users’ access to different services and provides practical 
and emotional support.  
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There is medium evidence from one (+) Australian study2 that a videophone DOT 
service is viewed positively by staff and patients. The privacy and convenience of the 
videophone DOT service were especially valued.  
 
1 Craig et al., 2008 (–) 




5.1 Summary of findings 
 
The interventions discussed in this review can be divided into two types. On the one 
hand we have directly observed therapy alone, and on the other a range of 
interventions involving some type of enhanced case management, which include 
support for individuals undergoing treatment for TB or LTBI, or accessing services, 
beyond simply observing treatment or providing information or resources. 
 
The evidence on ECM is mixed. On the one hand, three studies show positive 
findings for some form of CM intervention (Goldberg et al., 2004 (–); Nyamathi et al., 
2006 (++); Rüütel et al., 2011 (++)). In addition, one qualitative study shows positive 
perceptions of a CM service (Craig et al., 2008 (–)), and one cost-effectiveness study 
finds an ICER of £4,100/QALY for enhanced CM, and £6,400/QALY for a service 
combining mobile screening and enhanced CM (Jit et al., 2011 (+)).  
 
However, of the CM approaches adopted in the effectiveness studies, two consist 
mainly of reminders and education or skills training (Nyamathi et al., 2006 (++); 
Rüütel et al., 2011 (++)). If we focus on ECM in the narrow sense, as an approach 
which combines interventions to increase adherence with more general social 
support and facilitating access to services, there are only two studies (Batki et al., 
2002 (++); Goldberg et al., 2004 (–)), and of these, the only one to receive a high 
quality rating (Batki et al., 2002 (++)) finds that this type of ECM is no more effective 
than DOT and methadone for IDUs.  
 
On DOT alone, the evidence suggests that it is not effective. Two high-quality trials 
find DOT to be no more effective than SAT (Chaisson et al., 2001 (++); MacIntyre et 
al., 2003 (++)), and another finds DOT alone to be much less effective than DOT with 
incentives (Malotte et al., 2001 (++)). These findings are in line with previous reviews 
of DOT (Volmink and Garner, 2007). Further, one study finds that requiring people to 
report to a clinic site to collect every dose may have adverse effects on completion 
(Matteelli et al., 2000 (–)). Those studies which do show a significant benefit for DOT 
over SAT are either methodologically questionable (Graham et al., 1996 (–)) or else 
involve different regimens in the DOT and SAT groups, making it impossible to 
isolate the effect of observation as such (Narita et al., 2002 (+); Sterling et al., 2011 
(+)).  
 
The economic evidence on DOT is prima facie more promising, with six studies 
finding DOT to be cost-saving compared to SAT once the medical costs of treatment 
for relapses and failures are taken into account (Burman et al., 1997 (+); Moore et 
al., 1996 (+); Perlman et al., 2001 (–); Snyder and Chin, 1999a (–); Weis et al., 1999 
(–); Wilton et al., 2001 (–)), and three showing more mixed findings (Berkowitz et al., 
2006 (–); Gourevitch et al., 1998 (–); Holland et al., 2009 (–)). The evidence suggests 
that DOT is more cost-effective if targeted at high-risk groups than if provided 
universally (Palmer et al., 1998 (+); Snyder et al., 1999b (+)). 
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However, on closer examination the economic evidence does not provide strong 
support for DOT. The finding that DOT is cost-effective generally rests on its being 
more effective than SAT at preventing treatment failure (i.e., DOT is cost-effective if it 
is effective). In many of the cost-effectiveness studies, the effectiveness of DOT is 
simply assumed; where empirical data are cited, they are often of highly questionable 
reliability and applicability (and none are based on a systematic review of prospective 
intervention studies). Our effectiveness findings thus cast considerable doubt on the 
basis of the finding that DOT is cost-effective, and suggest that it may largely be due 
to overly optimistic assumptions about effectiveness.  
 
It should also be noted that the one study to consider DOT in a broader context than 
simply the comparison with SAT, and compare it with reminders and other strategies 
for increasing uptake and adherence, finds that it is not cost-effective (Porco et al., 
2006 (++)). 
 
5.2 Limitations  
5.2.1 Limitations of the review 
 
This review was carried out using systematic methods, with extensive searching, a 
priori inclusion criteria, and full quality assessment and data extraction according to 
the NICE methods manual. However, there may be some limitations. 
 
It is challenging to define the idea of ‘case management’ and operationalize it in a 
precise way. CM might be considered a way of delivering interventions as much as 
an intervention in itself. Our search terms may not therefore have picked up all 
relevant studies, although a broad range of synonyms for elements of CM, as well as 
for the CM approach, were used. We were reasonably inclusive in defining CM at the 
screening stage, but we did exclude purely educational or informational interventions 
(which are covered in a separate review in this work programme) and incentives or 
enablers alone (which are not covered in either review). 
 
We excluded purely retrospective studies from the effectiveness review, due to their 
limited reliability in establishing effectiveness. However, we were otherwise inclusive 
with respect to study design. 
 
We excluded studies of views and barriers, such as qualitative research, which did 
not relate specifically to an actually implemented intervention programme. This 
criterion excluded the majority of qualitative research on TB. However, it did mean 
that the results were more clearly relevant to the effectiveness and cost-effectiveness 
findings. In addition, two robust (although not absolutely up-to-date) systematic 
reviews of this qualitative literature already exist (Munro et al., 2007; Noyes and 
Popay, 2007), and should be consulted for the broader literature on views and 
barriers.  
 
We were unable to carry out meta-analysis or other quantitative synthesis, and only 
conducted a narrative synthesis of the evidence. 
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5.2.2 Limitations of the evidence base 
 
As already noted, the evidence base largely consists of studies of directly observed 
therapy. As yet, few prospective evaluations or cost-effectiveness studies appear to 
have been conducted on CM or ECM approaches. Nonetheless, the evidence on 
DOT is inconclusive, with the economic evidence in particular vitiated by 
questionable assumptions about treatment effectiveness. Many of the studies also 
present limited information about who delivered DOT or in what setting. 
 
Most of the cost-effectiveness evidence is analysed in terms of net treatment costs, 
i.e. by comparing the costs of treatment to the costs of treatment failures and 
relapses averted, rather than to the impacts of TB on patients and others. Few cost-
effectiveness studies are analysed in terms of cost per QALY or other cost-utility 
measures (as usually recommended by NICE) and still fewer incorporate any 
measure of the broader social costs of TB. In addition, all the cost-effectiveness 
studies use static models; none attempt to model transmission dynamics and the 
likely impacts of this on cost-effectiveness.  
 
Those studies of broader CM approaches which do exist are heterogeneous in terms 
of the populations and interventions studied. Hence, while the evidence overall is 
promising, it is hard to draw any conclusions about what types or components of CM 
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7 Appendix A. Evidence tables 
 
7.1 Effectiveness studies 
 

































Aim of study: 
Source population/s: Drug 
users accessing methadone 
treatment in San Francisco 
 
Eligible population:  
Heroin-dependent IDUs that 
are tuberculin positive entering 
the 21-day methadone 
detoxification clinic at San 
Francisco with negative chest 
radiograph were recruited by 
clinic nurse. Percentage 
agreed to participate: NR. May 
have more complex needs than 
general population of IDUs. 
 
Selected population:  
Inclusion criteria: (1) latent TB 
infection as demonstrated by a 
positive PPD test (10 mm or 
greater in duration), a negative 
chest radiograph, and approval 
by a TB clinic physician; (2) a 
DSM-III-R diagnosis of opioid 
dependence; (3) age between 
21 and 59 years; (4) expressed 
willingness to receive 6 months 
of INH preventive therapy and 




description: Standard MT: 
received DOPT and daily 
methadone treatment (no 
information on context or 
delivery of DOPT), 7 days 
per week for 6 months, 
followed by a 6-week taper 
off methadone. Twice 
monthly counselling 
sessions, weekly random 
observed urine samples, 
medical services, 
psychiatric treatment as 
needed, and social work 
referrals. Participants could 
earn up to two take-home 
doses of methadone per 
week as a reward for 
negative urine drug and 
breath alcohol tests (but no 
participants did). 
 
Minimal MT: DOPT and 
methadone as per 
Outcomes:  
Treatment completion 





and by receipt of 
medication in usual-
care group) 
Duration of therapy 
(retention) 
Active TB cases 
Follow up periods: 7 
months for 
completion, 4 years 
for TB incidence 
 







Results for all relevant 
outcomes: Completion: 
Standard MT: N=22 (59.5%; CI 
43.6-75.3); Minimal MT: N=27 
(77.1%; CI 61.3-91.0); Routine 
care: N=5 (13.1%; CI 3-23.7)  
(Notes: Of the n=5 completers 
in routine care, 2 (40%) 
admitted to methadone 
maintenance treatment 
elsewhere and received daily 
observed INH outside of the 
study). Standard MT and 
Minimal MT significantly higher 
than routine care (p < 0.0001); 
no sig diff between Standard 
MT and Minimal MT.  
 
Duration of INH preventive 
therapy: Standard MT: 5.0 
months (CI: 4.5–5.5); Minimal 
MT: 5.7 months (CI: 5.4–6.0); 
Routine care 1.6 months (CI: 
0.9–2.25) (P< 0.0001).  
 
Active tuberculosis cases (4 
years after study entry): 
Non-completers: n=2 of 57 
Limitations identified by 
author: No arm including 
DOPT but not methadone, 
so cannot distinguish 
effects. Daily dosing 
regimen used, although 
less frequent may be 
possible. HIV+ IDUs 
excluded and findings may 
not be generalizable to 
them.  
 
Limitations identified by 
review team: Generally 
robust. Some minor 
reporting issues. 
Population may not be 
widely generalizable. 
 
Evidence gaps and/or 
recommendations for 
future research: Testing 
DOPT vs methadone, with 
and without incentives. 

































Excluded population: (1) 
pregnant; (2) HIV positive; (3) 
had evidence of active liver 
disease or aspartate 
transaminase (AST) greater 
than three times the upper limit 
of the normal range. 
 
Sample characteristics:  
Participant characteristics - % 
(n): 
Gender: Male: Standard 
MT=54% (20); Minimal MT= 
54% (19); Routine= 74% (29); 
p= 0.114  
Female: Standard MT=46% 
(17); Minimal MT= 46% (16); 
Routine= 26% (10) 
 
Ethnicity: African American: 
Standard MT=30% (11); 
Minimal MT= 34% (12); 
Routine= 27% (10); p= 0.896; 
X2=1.09 
White: Standard MT= 46% 
(17); Minimal MT= 37% (13); 
Routine= 40.5% (15) 
Other: Standard MT=24% (9); 
Minimal MT= 29% (10); 
Routine= 32.5% (12) 
 
Age (years): Standard 
MT=40.2 (4.8); Minimal MT= 
42.6 (6.2); Routine= 43 (4.8); 
p= 0.047 
Standard MT group, but no 
other services, except on 
an emergency basis or to 
enforce program rules. 
Counsellors met with 
patients approx once per 




description: Routine care: 
Standard referral with self-
administered preventive 
treatment. Methadone not 
provided, but participants 






Standard MT: N=37 
Minimal MT: N=35 
Routine care: N=39 
 
Baseline comparisons:  
Usual care group 
significantly older and 
worse mental health than 
either intervention group. 
Otherwise no significant 
differences w/r/t gender, 
ethnicity, marital status, 
education, income, 





(3.5%) (n=1 from the minimal 
MT arm; n=1 from routine 
care); Completers n=0 of 54. 
 
Results on inequalities: 
Alcohol abuse/dependence, 
cocaine abuse/dependence, 
level of commitment to 
abstinence, urine test results, 
ASI psychiatric severity, BDI 
score, diagnosis of antisocial 
personality disorder, 
homelessness, ethnicity, and 
gender not significantly related 
to treatment completion 
results.  
 
Attrition details: Unclear. 
Apparently 0 for TB incidence 
outcome (which was 
measured by clinic records) 
 
Source of funding:  







































Aim of study: 
To determine 




Source population/s: Injecting 
drug users in Baltimore 
 
Eligible population: IDUs 
seeking treatment for TB in the 
Baltimore City Health 
Department tuberculosis clinic 
Patients recruited in clinic. 
Limited information on 
recruitment and percentage 
agreed to participate NR 
 
Selected population: Patients 
who were at least 18 years old; 
used injection drugs (defined 
as the injection of illegal drugs 
within the previous 3 months or 
more remotely if the patient 
was enrolled in a methadone 
maintenance program); had a 
positive TST result; and were 




Patients who had active TB; a 
history of serious adverse 
reactions to INH; previous INH 
therapy for 6 months or longer; 
serum alanine aminotrans-
ferase level more than 5 times 









description: 1. Supervised 
group (DOPT): Patients 
were assigned to an 
outreach nurse who met 
with them twice weekly and 
administered INH 900 mg 
for 6 months per visit, and 
observed the patient 
swallow the medication 
(and assessed symptoms, 
provided counselling and 
encouraged adherence). 
Arrangements were made 
for treatment to be given at 




2. Peer group: patients 
received self-administered 
therapy in monthly supplies 
of 300mg/day of INH for 6 
months. They were 
required to return monthly 
for a refill and a nursing 
visit/ clinical assessment. 
Patients also received peer 
counselling twice during 
the first month of therapy 
and once a month 
Outcomes:  
Therapy completion  
Adherence at 80%, 




validated by pill 
count)  
Follow up periods: 6 
months 
 
Method of analysis:  
intention-to-treat. Chi-
square, Fisher’s 
exact, t-test, Wilcoxon 
rank sum. Log linear 
model for predictors. 
 
 
Results for all relevant 
outcomes:  
Completion: DOPT = 80%; 
Peer support =78%; Routine 
care = 79%.  DOPT vs. peer 
support: p = 0.73; DOPT vs. 
routine care: p = 0.86; Peer 
support vs. routine care sig NR  
 
Took at least 80% of doses: 
DOPT = 82%; Peer support = 
71%; Routine care = 90%. 
DOPT vs. peer support: p = 
0.08; DOPT vs. routine care: p 
= 0.10; Peer support vs. 
routine care sig NR 
 
Took at least 90% of doses: 
DOPT =80%; Peer support = 
51%; Routine care = 77%. 
DOPT vs. peer support: p  
<0.001;DOPT vs. routine care: 
p-value= 0.63; Peer support 
vs. routine care sig NR 
 
Took 100% of the doses:  
DOPT = 77%; Peer support = 
6%; Routine care =10%. 
DOPT vs. peer support: p  
<0.001; 
DOPT vs. routine care: p 
<0.001; Peer support vs. 
routine care sig NR 
 
Doses taken, as ascertained 
Limitations identified by 
author: NR 
 
Limitations identified by 
review team: Generally 
robust. Impact of incentives 
is somewhat unclear. 
Inconsistent findings with 
different measures of 
adherence not explored in 
depth. Limited information 
on recruitment; participants 
had good knowledge of TB 
and therapy at baseline, 
which may suggest 
selection bias. 
 
Evidence gaps and/or 
recommendations for 
future research:   
More research on 





Source of funding:  
National Institute on Drug 
Abuse; National Institute of 























Age (years, mean SD): 
Supervised= 41 +/- 7; Peer= 41 
+/- 9; Routine= 42 +/- 8 
Female sex: Supervised=27%; 
Peer= 26%; Routine= 27% 
Black race: Supervised=88%; 
Peer= 92%; Routine= 91% 
HIV seropositive: 
Supervised=18%; Peer= 24%; 
Routine= 17% 
Unemployed: 
Supervised=85%; Peer= 81%; 
Routine= 88% 
Less than high school 
education: Supervised=42%; 
Peer= 49%; Routine= 53%. 
thereafter. Patients were 
also asked to attend 
monthly support group 
meetings where lunch was 
provided. 
 
Peers were former IDUs 
who had completed INH 
preventive therapy and 
were trained in counselling 
patients with TB and HIV 
about health promotion, 
prevention, treatment 
adherence and life-coping 
strategies.  
 
Isoniazid was provided in 
bottles equipped with an 
electronic cap that 
recorded the time and date 
the bottle was opened. 
These patients were also 
asked to provide urine 
samples at each monthly 
visit. 
Note: all patients across 
groups received either an 
immediate or a deferred 
$10 stipend for each month 
they adhered to study 
procedures such as the 
routine assessments on 
adherence and drug 
toxicity. 
Control/comparison/s 
description: Routine care:  
Patients received a 
monthly supply of INH, 
300mg/day. Patients had 
by electronic monitoring of pill 
bottle caps:  
DOPT = not used; Peer 
support = 57%; Routine care = 
49%; Peer support vs. routine 
care: p <0.001.  
 
Urine testing: DOPT: not used; 
Peer support: 47% positive; 
Routine care: 55% positive. 
Peer support vs routine care: 
p=0.11 
 
Attrition details: 12.3% 
(37/300) 
 56 
an initial counselling 
session with the nurse, 
were encouraged to ask 
questions about their 
treatment, and were 
scheduled for a monthly 
assessment at the clinic 
where they were asked 
about adherence. 
 
Isoniazid was provided in 
bottles equipped with an 
electronic cap that 
recorded the time and date 
the bottle was opened. 
These patients were also 
asked to provide urine 
samples at each monthly 
visit. 
 
Sample sizes:  
Total: N=300 
Supervised (DOPT): N = 
99 
Peer: N = 101 
Routine: N = 100 
 
Baseline comparisons:  
There were no statistically 
significant baseline 
differences between 
groups w/r/t age, gender, 
ethnicity, HIV status, 






































Aim of study: 









Source population/s:  
Implicitly, people using TB 
services 
 
Eligible population:  
People with active TB under 
treatment in Pierce County, 
Washington, USA 
 
Selected population:  
Candidates for the 
telemedicine project were 
selected from active cases of 
TB treated within the county 
who had successfully 
completed at least 4 weeks of 




Patients who did not have a 
touch-tone phone, did not have 
a television, or had a previous 





Method of allocation:  
Unclear. All participants 
received some standard 
DOT and some 
videophone DOT, and 





units installed in patients’ 
homes. DOT carried out by 
videophone (approx 2-5 
mins visit, NR by whom).  
Control/comparison/s 
description: ‘Standard 
DOT’, not further described 
 










as completed visit) 
Personnel time 
Follow up periods: 









Results for all relevant 
outcomes: 
Standard DOT: 97.5% 
adherence 
Video DOT: 95% adherence 
 
Time for visit: 1h/visit for 
standard DOT, 3 min/visit for 
video DOT 
 
Total sample: 6 
 
Attrition details: 0% 
 
Limitations identified by 
author: NR 
 
Limitations identified by 
review team: Generally 
very limited reporting and 
methods are highly unclear 
throughout. Small sample. 
Limited data to support 
analysis of time saved. 
 
Evidence gaps and/or 
recommendations for 
future research: NR 
 


















































Aim of study:  




for LTBI in 
refugee 
populations 
Source population/s:  
Refugees in King County, WA, 
USA 
 
Eligible population:  
All refugees newly arriving in 
King County who presented to 
Public Health’s Refugee 
Screening Program, with LTBI 
 
Selected population:  
Recruitment focused on those 
from Somalia, former Soviet 
Union, and former Yugoslavia. 
Selection of individuals not 
defined – unclear if any from 
those groups were excluded; 
also some participants from 
other national origins were 
included 
 
Excluded population:  
Program had age cut-off of 35; 
nothing specific to study 
 
Sample characteristics: 
Approx 60% male; approx 70% 
15-34yo, 12% >34yo, 13%-
19% 5-14yo [Note: some 
inconsistency in age figures, 
and also don’t appear to line up 
with incl criteria] 
 
National origin: pre test former 
Soviet N=139, former 
Method of allocation:  
N/A. Pre-test data comes 
from historical comparison 





Cultural case management 
(CCM) delivered by case 
managers of same national 
origin as target population, 
known to local community. 
Case managers trained in 
CM including TB 
information, principles of 
management and 
information on referrals for 
social services and primary 
health care. CM included 
home readings of tests, 
tailored TB education, 
referrals, and general 
supportive and trusting 
relationships. Printed 





approach to treatment of 
LTBI.  Refugees reported 
to TB clinic for test 
readings and other 
Outcomes:  
Treatment start 
(delivery of initial 
supply of medication) 
Treatment completion 
Follow up periods:  
9 months 
 




Results for all relevant 
outcomes: 
Treatment start: pre 73%, post 
88% (p<0.001) 
(Subgroups. Former Soviet pre 
57%, post 73% (p=0.007); 
former Yugoslavia pre 39%, 
post 99% (p<0.001); Somalia 
pre 94%, post 92% (p=0.52); 
other pre 98%, post 91% 
(p=0.605).) 
 
Treatment completion: pre 
37%, post 82% (p<0.001) 
(Subgroups. Former Soviet pre 
45%, post 76% (p<0.001); 
former Yugoslavia pre 60%, 
post 94% (p<0.001); Somalia 
pre 34%, post 88% (p<0.001); 
other pre 31%, post 63% 
(p<0.001) 
 
Note: 80% of refugees actually 
received cultural case 
management (outcome figures 
include all participants that 
started treatment) 
 
Attrition details:  
NR 
Limitations identified by 
author:  
Effect might have resulted 
from broader diffusion in 
communities, behaviour of 
other patients and staff. 
Different individuals pre 
and post. 
 
Limitations identified by 
review team: 
Non-comparative design 
with retrospective pre-test. 
Recruitment not well 
defined.  
 
Evidence gaps and/or 
recommendations for 
future research:  
Qualitative research on 




Source of funding:  
Federal Refugee Program, 














Yugoslavia N=166, Somalia 
N=108, other N=349. Post test  
former Soviet N=128, former 
Yugoslavia N=109, Somalia 
N=118, other N=87 
 
 
treatment if needed. Some 
education carried out (with 
interpreter if needed). 
Persons on treatment 
either reported to the TB 
Clinic for a monthly 
symptom check and 
medication refill or received 
a phone call symptom 
check prior to a monthly 

























Galai N, Nelson 






















Aim of study:  
Describe trends 









Source population/s:  
Injecting drug users, Baltimore, 
MD, USA 
 
Eligible population:  
Unclear (recruitment from 
separate study, not described 
in detail in report of this study) 
 
Selected population:  
Recruitment via ‘street 
outreach and word of mouth’. 
Participants who had reported 
living in Baltimore City at 
enrolment and those whose 
residence was unknown at 
enrolment, but whose last 
known residence was 
Baltimore, were included. 
Percentage agreed to 
participate: NR. 
 




81% male, 89% Black, 72% 
injected drugs in month before 
enrolment, >84% not receiving 
treatment for drug dependency 
at enrolment, 24% HIV+ 





Unclear. First year of 
cohort received SAPT 
(isoniazid). At some point 
this changed, there was 
‘increased access’ to 
chemoprophylaxis, and 
DOT was implemented 
(isoniazid, for 6 months, 
extended to 12 if 
compliance maintained; no 
information on context or 
delivery of DOT). But 
outcomes relative to timing 















Incidence of TB and 
M. avium 
Follow up periods:  
Approx. 2 years at 
cohort level; unclear 
at individual level 
 
Method of analysis:  
Relative risks 
Results for all relevant 
outcomes: 
TB incidence. First year (pre) 
is reference; years 2-3 
(unclear if pre or post) RR 
2.5(0.5-13.2); years 4-5 
(presumably post) RR 
0.4(0.04-4.8) 
M. avium incidence. First year 
(pre) is reference; years 2-3 
(unclear if pre or post) RR 
2.7(0.7-10.3); years 4-5 
(presumably post) RR 7.3(2.2-
24.3) 
  
Attrition details:  
NR 
Limitations identified by 
author:  
Small sample  
 
Limitations identified by 
review team: 
Non-comparative design; 
main aim of study is to 
describe trends rather than 
evaluate intervention. 
Limited information on 
sampling. Very little 
information on intervention. 
No adherence/compliance 
outcome. Outcomes 
calculated as incidence 
rates per person-years of 
treatment, rather than at 
individual level, and full 
outcome data are not 
reported. 
 
Evidence gaps and/or 
recommendations for 
future research:  
NR 
 
Source of funding:  
National Institute on Drug 
Abuse; Centers for 
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Source population/s:  
Unclear – apparently general 
population 
 
Eligible population:  
A total of 7 health centre areas, 
3 urban and 4 rural, 
were selected as the project 
areas. 2 subcentres under 
each health centre were 
selected and each of them was 
randomly allocated to either the 
‘intensive’ or the ‘routine’ 
service group. 
 
Selected population:  
Patients newly registered at 
these health centers or 
subcentres during the year 
following April 1980 were taken 
into the study. The study aimed 
to recruit equal numbers of 
bacteriologically positive 
(including patients positive for 
both smear and culture and 
those positive only for culture) 
and negative patients in each 
treatment group. 
 




Initial positive bacteriology 46% 
Male 68.8% 
Age <29 years 31.7%, 30-39 
Method of allocation: 
Randomisation at level of 
the subcentres within 
health centres (methods of 
randomisation not  stated); 
only post test data reported 
 
Intervention/s 
description: In addition to 
comparator programme, a 
special type of supervision 
or motivation was given to 
the workers. This additional 
supervision included the 
closer checking of the 
workers’ tasks by the 
Health Centre director and 
the subsection chief, and 
periodic sessions for 
discussion of the 
achievements of each 
worker held at the Health 
Centre, sometimes 
attended by the 
supervisory medical officer. 
Note: the details of what 
the patients actually 
received is not described, 
only the process of 
providing the additional 
motivation to the staff 
Control/comparison/s 
description:  
Staff were instructed to 
follow the usual case 
Outcomes:  
Number of patient 
examinations 






Follow up periods:  
NR 
 
Method of analysis:  
Student’s t-test  
and chi-square test. 
The Mantel-Haenszel 
test was used when 
comparisons 
were made with 
stratification for each 
group. 
The basis of the 
analysis is not given. 
It appears to be 
completers rather 
than ITT 
Results for all relevant 
outcomes: 
 
Patient examinations: X-rays I 
98.0%, C 80.2%; sputum 
smear and culture I 97.6%, C 
70.2% (significance NR) 
 
Drug collection rates; I 87.9%, 
C 77.1% (p<0.01) 
 
Drug collection delayed by 7 
days or more: I 4.7%, C 12.2% 
(p<0.01) 
 
Treatment completion: I 
78.8%, C 65.2% (p<0.01) 
 
Treatment success 
(bacteriological conversion): I 
75.2%, C 45.8% (p<0.01) 
 
Inequalities: For patient 
examination, greater effect in 
rural than urban areas; for 
completion, greater in urban 
than rural. No significant 
difference by sex or age. 
 
Attrition details:  
N/A – only post test reported 
 




Limitations identified by 
review team: 
Details of the treatment the 
patients were receiving is 
not described. Details of 
the source population are 
not provided. Details of the 
methods of study 
allocation, randomisation 
and blinding are not 
described. Contamination 
may have occurred 
because randomisation 
was at the level of the sub 
centre within the health 
centre and so staff may 
have had contact with each 
other 
 
Evidence gaps and/or 
recommendations for 
future research:  
NR 
 
Source of funding:  
Partly funded by the World 
Health Organization. 














years 16.2%, 40-49 years 
16.8%, 50-59 years 14.5%, 60 
years or more 20.7% 
Prevous treatment 17.5% 
[Characteristics of health 
centre staff (who were the 
group initially targeted by the 
intervention) NR] 
motivation 
procedure as described in 
their service manual. Their 
performance was 
periodically supervised by 
the health centre director 
and the supervisory 
medical officer of the 
provincial government. 
 
Sample sizes: 1300 total = 
651 in the intervention 
group and 649 in the 
control group [patients] 
 
Baseline comparisons:  
There were slightly 
more cases with a past 
history of tuberculosis in 
‘intensive’ areas than in 
‘routine’ areas. Other 
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clinical trial of 





















Aim of study: 
To assess the 
Source population/s: People 
under treatment for TB in 
Victoria, Australia 
 
Eligible population: All new 
TB patients in two clinics in 
North-Western Health Care 
Network. Recruited by 
physicians, with information 
supplied by study nurse. 
Recruitment of sites NR (these 
clinics serve 30% of all TB 
patients in the city). 
 
Percentage agreed to 
participate: NR. 
 
Selected population: All 
consenting TB patients in two 
clinics in the North-Western 
Health Care Network, 
commencing treatment from 30 




Excluded population:  





Mean age: 41 years (median 
38 years, range 14–83); Sex: 
51% male (n=89/73); Countries 
of birth: Vietnam (29%), 







observed treatment): A 
suitable family member, 
nominated by the patient, 
was educated and trained 
to watch the patient 
swallow the anti-
tuberculosis drugs (daily 
treatment. Patients 
received normal monthly 
clinic follow-up and 





treatment:  Patients 
supervised at monthly 
clinic visits, but does not 
include DOT as standard. 
Patients received 
education and filled out 
their own pill sheets and 
handed their pill sheets to 













by (i) urine testing, 
with compliance 
defined as all six 
urinary INH levels 
greater than zero (ii) 
electronic pill bottles 
in random subsample 
(N=10) 
Follow up periods: 
Minimum of 6 months 
or until treatment was 
completed 
 




Results for all relevant 
outcomes:  
 
(58% of those allocated to 
FDOT actually received it 
(50/87), most due to not 
having a suitable family 
member.) 
 




treatment on urine testing 
ITT analysis: I 25.3%, C 22.1% 
(RR 1.04, 95%CI 0.88–1.23). 
Comparing those who actually 
received FDOT to all others 
(i.e. per-protocol analysis): RR 
0.96, 95%CI 0.75–1.23 
 
Trend analysis over 6 months 
on this outcome shows 
significantly better compliance 
in I than C (appears to be ITT, 
but not totally clear): chi-
square for trend 11.12, 
p<0.05). 
 
Non-compliance by electronic 
pill bottles: 13% of doses 
missed, not analysed by group 
 
Regression analysis shows 
that employment status or 
needing an interpreter did not 
Limitations identified by 
author: FDOT not suitable 
for many patients because 
no suitable family member; 
study not adequately 
powered; urine testing may 
not accurately measure 
compliance (because INH 
persists up to 24 hours in 
urine). 
 
Limitations identified by 
review team: Generally 
robust other than 
limitations noted by 
authors. Differences in 
baseline NR. Not true 
random allocation. 
 
Evidence gaps and/or 
recommendations for 
future research: Evaluate 
intervention in high-
incidence countries and in 
cultural settings where 
extended family units are 
the norm. 
 





























Somalia (10.4%), Australia 
(10.4%), China (5.2%), 
Ethiopia (3.5%); English as first 
language: 18.5% (32/173); 
Required interpreter: 36% 
(62/173).  
 
 At the time of diagnosis, 26% 
(45/173) in paid employment; 
24% (41/173) were home 
carers and 30% (52/173) were 
students.  
 
Pulmonary TB: 57% (98/173). 
Symptomatic TB: 81.5% 
(141/173). Over half (92/173, 
53%) had treatment initiated in 
hospital, with the remainder 
treated entirely on an out-
patient basis. No study patients 
were placed on nurse-







powered? Not sufficiently 
powered: A sample size of 
224 patients (112 in each 
arm) was required for 95% 
confidence and 80% power 
for detecting a difference in 
non-compliance, ranging 
from 25% in the ST arm to 








































Aim of study:  
To compare the  
independent  
and combined  





Source population/s:  
Active drug users (injecting or 
crack cocaine) with LTBI in 
Long Beach, California, USA 
 
Eligible population:  
Unclear - recruitment via 
another study. Setting was a 
‘storefront facility’ conducting 
research and risk-reduction 
programmes for drug users.  
 
Selected population: 
Participation rate 169/202 
(84%).  Included those with a 
positive tuberculin skin test 
(10mm indurations for HIB 
negative; 5 mm for HIV positive 
or unknown status) and no 
evidence of active disease or 
major contraindications to 
isonazid.  
 
Excluded population:  
Participants with active disease 
or medical contraindications.  
 
Sample characteristics: 
Mean age: 42 years (range 23 
to 69 years). 
Male: 82% 
African American: 71% 
Hispanic: 92.2% 
White: 13.5% 
Other race/ethnicity: 6.7% 
Method of allocation:  
Concealed random 




Condition 1: Twice weekly 
DOT by outreach worker at 
a location chosen by the 
participant (active 
outreach); and $5 
monetary incentive per 
visit. 
Condition 2: DOT as in 
condition 1, but no 
monetary incentive 
 
Condition 3: Twice weekly 
DOT at the study 
community site; and $5 
monetary incentive if they 
appeared for the 







Total: N=163; condition 1 
N=53, condition 2 N=55, 
condition 3 N=55 
 





completers if lost to 
follow-up) 
Percentage of 
medication taken on 
time 
Follow up periods:  
8-12 months 
 




Results for all relevant 
outcomes: 
Treatment completion c1 
52.8%; c2 3.6%; c3 60%. C1 
vs c2 p<0.0001; c3 vs c2 
p<0.0001 
 
ORs for completion w/r/t c2: c1 
29.7 (56.5–134.5), c3 
39.7(58.7–134.5) 
 
Medication taken on time c1 
72%, c2 12%, c3 69% [authors 
report p<0.001, but unclear 
what comparison this refers to] 
 
No binge drinking and earlier 
recruited participants 
associated with increased 
completion. 
 
Attrition details:  
Unclear; dropouts were 
counted as non-completers  




Limitations identified by 
review team: 
Generally robust study. 
Sampling not well-defined 
in this report. 
 
Evidence gaps and/or 
recommendations for 
future research:  
NR  
 
Source of funding:  




provision of  
DOT (for LTBI)  
treatment in a  
sample of  
active drug  
users. 
 












No statistically significant 
differences at baseline in 








































study: Italy  
  
Aim of study: 
To conduct a 
comparative 
prospective 





Recruitment sites: one health 
care unit for immigrants in 
Brescia and one clinic in Turin 
that serves as a TB screening 
site for contacts and people 
applying to enter 
dormitories/housing (Northern 
Italy--Brescia and Turin). 
 
Eligible population:  
Unclear. No details on 
recruitment or percentage 
agreed to participate 
 
Selected population:  
Eligible for the preventive 
therapy trial if subjects came 
from countries with an 
estimated tuberculosis 
incidence of 50/100,000 or 
more, history of immigration of 
less than 5 yr, and 
development of a skin 
induration >10 mm 72 h after 
intradermal injection of 5 
international units of PPD. 
 
Excluded population: 
Exclusion criteria included 
pregnancy, age older than 35 
yr, and liver enzymes (AST, 
ALT) five times or more than 
the upper normal values.. 
 
Sample characteristics: Male 
Method of allocation:  




description: Regimen A:  
Supervised isoniazid (900 
mg twice weekly) for 6 
months. Subjects were 
invited to report twice 
weekly to the clinical 
service sites (either the 
tuberculosis clinic or the 
clinic for migrants) to 
collect the drugs [NB it is 
unclear how this was 
‘supervised IPT’]. Drugs 




Regimen B: Unsupervised 
isoniazid 900 mg twice 
weekly for 6 months 
Regimen C: Unsupervised 
isoniazid regimen of 300 
mg daily for 6 months; 
standard treatment.  
 
Sample sizes:  
Total N=208 
Regimen A: n=82 patients 
Regimen B: n=73 patients 





treatment (defined as 
80% or more of the 
prescribed 
medications taken 
over 26 weeks; 
measured by 
reporting to sites and 
returned medication 
for group A, and by 
urine testing for 
groups B and C).  
 
Time to dropout 
 
Follow up periods: 
26 weeks 
 
Method of analysis:  
t-test; chi-square; for 





Results for all relevant 
outcomes:  
Treatment completion: 
Regimen A: 7.3%; Regimen B: 
26%; Regimen C: 41% (A vs B 
p=0.006; A vs C p=0.001; B vs 
C significance NR) 
 
Mean time to dropout: 
Regimen A 3.8 weeks, 
Regimen B 6 weeks, Regimen 
C 6.2 weeks (p=0.003, 
although unclear which 
comparison this refers to) 
 
Adherence was not associated 
with study site, patient’s sex or 
age, country of origin, 
alcohol/drug use, marital 
status, employment status or 
religion. 
 
Attrition details:  
N=127 lost to follow-up 
(61.1%) 
Limitations identified by 
author: Small sample size.  
 
Limitations identified by 
review team: Recruitment 
and sampling not well-
defined. Very little detail on 
intervention content, and 
unclear whether ‘super-
vised’ is an accurate 
description of intervention 
arm  
 
Evidence gaps and/or 
recommendations for 
future research: Efficacy 
of short-term multidrug 
regimens delivered through 
outreach DOPT to illegal 
immigrants  
 
Source of funding: Italian 
Tuberculosis Project of the 


















validity: –   
 
sex- Regimen A: 48 (58.5%); 
Regimen B: 48 (65.7%); 
Regimen C: 32 (60.3%) 
Age 15-24yr- Regimen A: 26 
(31.7%); Regimen B: 22 
(30.2%); Regimen C: 16 
(30.2%) Age 25-35yr- Regimen 
A: 56 (68.3%); Regimen B: 51 
(69.8%); Regimen C: 37 
(69.8%) Country of Origin – 
Africa- Regimen A: 60 (73.2%); 
Regimen B: 50 (68.5%); 
Regimen C: 37 (69.8%) 
Country of Origin – Other- 
Regimen A: 22 (26.8%); 
Regimen B: 23 (31.5%); 
Regimen C: 17 (32%) 
 
no statistically significant 
differences w/r/t gender, 
age, country of origin, 






Not sufficiently powered: 
411 evaluable subjects 
needed to show a 15% 
difference in adherence 
between arms A and C. 
However, the trial was 
terminated early because 
of a larger than expected 
difference in adherence 














































Source population/s:  
HIV infected patients in 
Broward County, Florida 
community HIV clinics  
 
Eligible population:  
All HIV-infected patients seen 
by healthcare providers from 
February 1, 1999, to March 31, 
2001. These patients were 
evaluated for LTBI and active 
tuberculosis disease. 
Percentage agreed to 
participate: NR. 
 
Selected population:  
TST-positive patients with the 
following characteristics: (1) 
the patient was a close contact 
to an infectious tuberculosis 
disease case, or (2) the patient 
had a current or previously 
documented positive TST 
result with no history of 
adequate treatment for LTBI. 
 




Mean age pre 38, post 42 
Male 57% pre, 67% post 
Black 90% pre, 83% post 
Method of allocation:  
N/A. Pre-test data come 





therapy (isoniazid). Post: 
twice-weekly DOT 



















(defined as drug 
collection for pre 
group) 
Follow up periods:  
24 months at 
individual level 
 
Method of analysis:  
t-test, Mann-Whitney 
rank sum test, Fisher 
exact test 
 
Results for all relevant 
outcomes: 
Treatment completion pre 
61%, post 93% (p<0.001) 
 
Attrition details:  
Pre 5%; post 17% at 12 
months, 53% at 24 months 
(individual level; N/A at cohort 
level) 
 
Limitations identified by 
author:  
Choice of specific regimen 
within DOT group not 
randomized. Historical 
comparison group. Pre 
group received longer 
treatment (and completion 
outcome measured at 
longer scale) than current 
guidelines indicate. 
 
Limitations identified by 
review team: 
Non-comparative design. 
Main focus of study is not 
on DOT and there is limited 
information on it.  
 
Evidence gaps and/or 
recommendations for 
future research:  
NR  
 
Source of funding: NR  
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homeless adults residing in the 
Skid Row region of Los 
Angeles, US from 1998 to 2003 
 
Eligible population:  
People attending homeless 
emergency and residential 
recovery shelters; recruited by 
flyers at intervention sites  
 
Selected population:  
participants were homeless 
adults aged 18–55, or those 
aged over 55 with reported risk 
activation factors for TB, who 
had slept in one of the study 
shelters the previous night and 
who reported no previous LTBI 
treatment, and who were TST-
positive 
 




Mean age 41.5 
Male 79.6% 
Black 81% 
High school graduate 72.5% 
No insurance 75.4% 
Median (range) of years 
homeless 1 (0.003–24) 
Lifetime intravenous drug use 
20% 
Recent intravenous drug use 
Method of allocation:  
Random allocation (details 
NR) by site, stratified by 





Nurse case-managed with 
incentives (NCMI) 
programme: The NCMI 
programme was based on 
the comprehensive health 
seeking and coping 
paradigm. Delivered by a 
research nurse and a 
trained outreach worker. 
Participants received eight 
one-hour TB education 
sessions, which included 
visual coping scenarios 
over the 24 weeks of 
treatment. The intervention 
components focused on 1) 
self esteem and attitudinal 
readiness for change; 2) 
TB and HIV risk reduction 
education; 3) coping, self 
management, and 
communication skills; 4) 
cognitive problem solving 
to implement behavior 
change; and 5) positive 
relationships and social 




(directly observed)  
TB knowledge 
Follow up periods: 6 
months 
 







Results for all relevant 
outcomes: 
 
Treatment completion: I 
61.5%, C 39.3% (p<0.01) 
TB knowledge improvement: I 
3.8±3.5, C 2.0±4.2 (p<0.01) 
 
Logistic regression model 
controlling for confounders 
shows odds ratio of 3.01 (2.15-
4.20) in favour of intervention 
group wrt treatment 
completion outcome (p<0.001) 
 
Compared to non-completers, 
completers were more likely to 
be Black, were older, were 
more often recruited from 
emergency rather than drug 
recovery shelters, and were 
more likely to be highly 
motivated to adhere 
 
Failure to complete treatment 
was positively associated with 
lifetime IDU, recent daily 
substance use and recent 
hospitalization 
 
Taken from Nyamathi 2008 
(write up of same study 
focusing on subgroups) 
 
Unadjusted results of 
treatment completion 
Limitations identified by 
author:  
Cannot identify precise 
contributions of different 
intervention components; 
may be bias in self-report 
outcomes 
 
Limitations identified by 
review team: 
Generally robust. Some 
minor limitations in 
methods; cluster 
randomisation not taken 
into account in analysis; 
some unclarity on 
recruitment of sites 
 
Evidence gaps and/or 
recommendations for 
future research:  
Additional studies are 
needed to assess cost 
effectiveness, program 
portability, and the 
feasibility of using lay 
personnel. 
 
Source of funding:  
The National Institute on 
Drug Abuse 
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Aim of study: 
































Prior drug treatment 23.9% 
Recent self help programme 
63.5% 
 
Over 80% indicated that they 
wanted to take INH and 
intended to adhere 
Intervention group 
participants were provided 
with community resources 
and were escorted to their 
medical and social service 
appointments. Unlike 
control group participants, 
NCMI participants were 
tracked when they missed 
a DOT dose. Tracking was 
performed by the outreach 
worker with a locator guide 
using contact data and pre-
approved photos collected 




Standard with incentives 
(SI) program: The SI 
control group was staffed 
by a separate team 
consisting of a trained 
nurse and outreach worker. 
This control group received 
a 20-minute basic lecture 
on TB and the importance 
of treatment adherence 
along with a local 
community resource guide. 
All participants had a 10-
minute period to discuss 
questions with their nurse 
when they presented for 
each INH dose over the 6-
month study period. 
 
All participants received $5 
US for each DOT dose. 
intervention completers n (%) / 
control completers n (%)  
Males  
I: 149 (61) C: 71 (37)  
RR 1.46 95% CI 1.21, 1.77 
Females  
I: 22 (65) C: 24 (33)  
RR 1.94 95% CI: 1.26, 2.98 
African Americans  
I: 148 (64) C: 84 (44)  
RR 1.45 95% CI: 1.22, 1.74 
Non-African Americans  
I: 24 (50)  C: 11(22)  
RR 2.32 95% CI 1.32, 4.06 
Homeless shelter recruits I: 
253 (91) C: 161 (66.5)  
RR 1.57  95% CI 1.29, 1.90 
Veteran  
I: 17 (68) C: 9 (43)  
RR 1.50 95% CI 0.93, 2.71 
Lifetime IDU  
I: 21 (55) C: 23 (35)   
RR 1.59 95% CI 1.01, 2.48 
 
Attrition details:  
11 in each group were lost to 
follow up. 57 in the 
intervention and 97 in the 
control group dropped out of 
intervention but completed the 
6 month questionnaire 
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Both treatment groups. 
 





Baseline comparisons:  
I more male; more from 
emergency shelters rather 
than recovery shelters; less 
lifetime IDU. No differences 
in age, ethnicity, education, 
alcohol/drug use, mental 
health, physical health 
 
Study sufficiently 
powered? Calculated for 
difference of 15% with 
power of 0.80 – but 
calculated wrt individual 
participants (as per 












Rüütel K, Loit 
























Aim of study: 









Source population/s:  




based methadone substitution 
treatment centre in Jõhvi (small 
town in north-eastern Estonia). 
All clients using centre on 
selected dates were 
approached by centre nurses. 
Participation rate 59%; refusals 
not different from participants 
w/r/t age or gender.  
 
Selected population: (1) 
participation in substitution 
treatment program; (2) age 18 
years or more; (3) able to read 
and write in Estonian or 
Russian; (3) able to provide 
informed consent. 
 
Excluded population: NR 
 
Sample characteristics: 
64.9% male, mean age 26.2 
(83.9% <30), 9.8% Estonian 
ethnicity 
 
Method of allocation:  
Randomization conducted 




Active case management. 
Study personnel scheduled 
the appointment and 
reminded to keep it, 
transportation was 
organized when needed. 
Participants were expected 
to attend TB services 
within the two months after 
the initial randomization. 
For those who returned to 
skin test reading on time 
an incentive was given 





referral. Instructed to 
schedule an appointment 
with TB services 
themselves. 
 






No sig differences w/r/t 
Outcomes: 
Attendance at TB 
services 
Follow up periods: 2 
months 
 
Method of analysis: 
Wilcoxon rank-sum 
test or Fisher exact 




Results for all relevant 
outcomes:  
Attendance: I 57.1%, C 30.4% 
(p = 0.004). 
 
None of the following were 
significantly associated with 
outcomes: age, gender, 
education, employment, drug 
injection history, prison, TB 
contacts, Mantoux results, HIV 
status 
 
Attrition details: NR 
 
Limitations identified by 
author:  
Small sample recruited 
from one centre, and low 
response rate, may limit 
generalizability 
 
Limitations identified by 
review team: None to add 
to authors’.  
 
Evidence gaps and/or 
recommendations for 
future research: Methods 
for screening among IDUs 
not in contact with harm 
reduction services. 
 
Source of funding: 
National Institute for Health 





Program; Estonian Ministry 
of Education and 
Research; New York State 
International Training and 
Research Program;  
National Institutes of 
Health; Fogarty 
International Center; 



















gender, age, ethnicity, 
education, employment, TB 
















Borisov AS, et 
al. 
 






























Source population/s: People 
at high risk of TB in USA, 
Canada, Brazil and Spain 
 
Eligible population: Limited 
information on sampling or 
recruitment (and likely that this 
differed between countries). 
Percentage agreed to 
participate: Unclear. Of 7,452 
assessed for eligibility in the 
later recruitment phase, 1,756 
(23.6%) declined to participate 
(and 1,469 (19.7%) did not 
meet criteria, and a further 359 
(4.8%) did not participate for 
‘other reasons’). But these data 
are unavailable for the 4,185 
who enrolled in the earlier 
recruitment phase. 
 
Selected population: 12 years 
or older (expanded to 2 years 
or older midway through 
study); contact of TB patient 




Confirmed or suspected 
tuberculosis, resistance to 
isoniazid or rifampin in the 
source case, treatment with 
rifamycin or isoniazid during 
the previous 2 years, previous 
completion of treatment for 
Method of allocation:  
Simple randomization (by 
household for those 
recruited and treated by 





DOT using combination 
therapy (rifapentine and 
isoniazid once weekly). No 
information on context or 













Significantly higher % 
American Indian and 
homeless in intervention 
group. Otherwise no sig 
differences by indication, 
age, ethnicity, HIV status, 
BMI or risk factors  
 
Study sufficiently 









Follow up periods: 
33 months  
 






Results for all relevant 
outcomes:  
Treatment completion: I 
82.1%, C 69.0% (p<0.001) 
 
Incidence of TB: ITT analysis: I 
0.19 cumulative rate per 
person-year aggregated over 
study period, C 0.43 (NS); per-
protocol: I 0.13, C 0.32 (NS) 
 
After adjustment for factors 
independently associated with 
TB risk (viz. smoking, HIV 
status and BMI), I patients 
were at significantly lower risk 
than C (adjusted hazard ratio, 
0.38; 95% CI, 0.15 to 0.99; 
p=0.05) 
 
Death: C 0.8%, I 1.0% 
(p=0.22) 
 
Attrition details: Somewhat 
unclear. Paper reports 33-
month follow-up rate as 88% 
for combination therapy and 
86% for isoniazid-only. But 
flow diagram in the appendix 
shows that 1065/3745 (28%) 
of the isoniazid group and 
623/3986 (16%) of the 
combination group did not 
complete regimen per 
protocol, most of which is 
dropouts. 
Limitations identified by 
author: Cannot distinguish 
effects of regimen from 
effects of observation. 
Control group had higher 
completion rates than 
usually observed in clinical 
practice. HIV+ rate lower in 
sample than in practice. 
 
Limitations identified by 
review team: Sampling 
and recruitment unclear. 
Study authors conceptual-
ize the comparison as 
between two drug 
regimens rather than 
between DOT and SAT. 
 
Evidence gaps and/or 
recommendations for 
future research: NR 
 
Source of funding: 
Centers for Disease 











tuberculosis or M. tuberculosis 
infection in HIV seronegative 
persons, sensitivity or 
intolerance to isoniazid or 
rifamycin, a serum aspartate 
aminotransferase level that 
was five times the upper limit of 
the normal range, pregnancy or 
lactation, HIV therapy within 90 
days after enrolment, or a 
weight of less than 10.0 kg 
 
Sample characteristics:  
Median age I 35, C 36. Male I 
53.5%, C 55.4%. White I 
57.5%, C 57.6%; Black I 
25.3%, C 24.5%; Asian or 
Pacific Islander I 13.1%, C 
12.4%; North American Indian: 
I 0.9%, C 2.1%; Multiracial (in 
Brazil) I 3.1%, C 3.4% 
 
size of 3200 subjects per 
study group would provide 
a power of more than 80% 
to show the noninferiority 
of combination therapy. To 
allow for 20% loss to 
follow-up and to account 
for clustering, 4000 
subjects were targeted for 





7.2 Cost-effectiveness studies 
 
Study Details Population and 
setting  













among newborns in a 
nursery: decision 
analysis for initiation 
of prophylaxis. 





Aim of study:  
“to use decision 





would be preferable 
to no administration 
of prophylaxis 
in a situation in which 





[NB this is a pure 
modelling study 
rather than an 
economic evaluation 
– the intervention, 







Data sources: All 







Isoniazid administered by 
directly observed therapy for 5 
days/week for 3 months, plus 
additional prophylaxis 
administered daily by parents 





administered by parents 7 
days/week 
 
No intervention (each arm is 
compared to no prophylaxis) 
 




Cost per death 
prevented 
 
Time horizon: 4 
years 
 








infection, of progress 
to disease, of death, 
of hepatotoxicity 




Modelling method:  




Probability of disease 
given infection 
Effect of DO and non-
DO prophylaxis 
Survival 
Primary analysis:  
Incremental cost-effectiveness 
of DOT wrt no prophylaxis: 




administered prophylaxis) wrt 
no prophylaxis: $929,500 per 
death prevented 
 
Secondary analysis:  
Sensitivity analysis compare 
DO prophylaxis to no 
prophylaxis. “One-way 
sensitivity analysis of the 
probability of survival showed 
that the DO prophylaxis 
strategy was dominant under 
the following circumstances: 
(1) the probability of 
developing infection was 
greater than 0.0002, (2) the 
probability of developing 
disease in the absence of 
prophylaxis was greater than 
0.12, (3) the probability of 
dying of tuberculosis was 
greater than 0.025, (4) the 
probability of hepatotoxicity 
was less than 0.004, and (5) 
the probability of dying of 
Limitations identified by 
author: Only survival and 
death taken into account, 
not e.g. impairment as a 
result of tuberculous 
meningitis, or costs of 
litigation [sic]. 
 
Limitations identified by 
review team: Static model; 
transmission not taken into 
account. Efficacy of DOT is 
simply assumed and not 
based on literature or 
evaluation data at all, and 
applicability of sources 
cited for efficacy of parent-
administered prophylaxis is 
questionable. Derivation of 
many parameters unclear. 
No QALY analysis. Short 
time horizon and high 
discount rate. Population 
may be of limited relevance 
to this review. 
 
Evidence gaps and/or 
recommendations for 
future research: Data on 























hepatotoxicity was less than 
0.04.” 
 
Also 2-way sensitivity analysis 
presented graphically for 
outcomes above (full data not 
extracted here) 
 






Study Details Population and 
setting  





Burman WJ, Dalton 
CB, Cohn DL, Butler 







analysis of directly 
observed therapy vs 
self-administered 
therapy for treatment 
of tuberculosis. Chest 
112(1):63-70. 
 
Aim of study:  
To compare 
the costs and 
effectiveness of 
directly observed 
therapy (DOT) vs 
self-administered 
therapy (SAT) for the 










A hypothetical cohort 






Data sources:  
Retrospective data 
from Denver Metro 
Tuberculosis Clinic, 
unpublished data 









The DOT treatment arm uses 
the "Denver regimen," a 62-
dose, largely intermittent 
regimen of isoniazid, rifampin, 
pyrazinamide, and 
streptomycin. DOT delivered 
by nurses, either on outpatient 





The SAT arm uses the 
currently recommended 
regimen for self-administered 
short-course therapy: daily 
isoniazid, rifampin, 
pyrazinamide, and ethambutol 
for 2 months followed by daily 
isoniazid and rifampin for 4 
months. SAT estimated to 
require 8 clinic visits over 6 
months. 
 







Average net cost 
 
Time horizon: 
None for model itself; 
6-24 months 















analysis of a number 
of parameters 
 
Modelling method:  
Decision tree 
Primary analysis:  
Programme perspective: 
DOT net costs US$1,405, SAT 
$2,314 per patient treated 
(=relative cost saving from 
DOT of $909) 
 
Healthcare perspective 
(excluding patient time cost but 
including hospitalisation costs 
for treatment failures): 
DOT net costs $2,785, SAT , 
$10,529 per patient treated 




(including patient time cost): 
DOT net cost $2,117, SAT 
$1,339 per patient treated 
(=relative cost of $778); 
including patient time costs of 
treatment failures DOT net 
cost $3,999, SAT $12,167, per 
patient treated (=relative cost 
saving of $8,168). 
 
Secondary analysis:  
Threshold analysis calculate 
values required for SAT to 
overturn DOT’s advantage. 
 
Cost of medications used for 
Limitations identified by 
author:  
Did not include other 
outcomes of treatment that 
are likely to make DOT 
more cost-effective than 
SAT. Did not include an 
analysis of the costs of a 
fatal relapse of TB. Did not 
include any costs that 
result from transmission.  
 
Limitations identified by 
review team:  
Model is very simplified. 
Effect and baseline data 
from programme only.  
 
Evidence gaps and/or 
recommendations for 
future research:  
Effectiveness and cost-
effectiveness of DOT in 
developing countries 
 













initial treatment using DOT ($): 




Cost of medications used for 
initial treatment using SAT ($): 
model value=584, TB 
program=not found, 
healthcare=not found (DOT 
advantage remains) 
 
Nursing time to administer one 
DOT dose (h): model=0.25, 
TBp=1.25, hc=8.75 
 
Cost of hospitalization for a 
drug-susceptible treatment 
failure ($): model=7662, 
TBp=n/a, hc=not found 
Cost of hospitalization for a 




Failure rate of initial therapy 
using DOT: model=0.55, 
TBp=0.306, hc=0.325 
 
Proportion of DOT treatment 
failures acquiring MDR: 
model=0.16, TBp=not found, 
hc=not found  
 
Failure rate of initial therapy 




Proportion of SAT treatment 
failures acquiring MDR: 
model=0.29, TBp=not found, 
hc=not found 
 
Hourly cost of a patient’s time 









Study Details Population and 
setting  
















drug users at high 
risk for tuberculosis. 
International Journal 




Aim of study:  
To define whether 





justified by cases and 
costs of tuberculosis 
prevented among 
persons at high risk 





Drug users enrolled in 
a methadone 
maintenance 
treatment program in 
















(n=159): Male 58%; 
Hispanic 69%, Black 
16%, White 14%, 
Other race 1%; 
PPD+ve 16%; anergic 
37%; PPD-ve (non-
anergic) 47%.  
 
HIV-seronegative 
(n=348): Male 59%; 
Hispanic 66%, Black 
Intervention/s description: 
Screening by X-ray and smear 
and sputum culture. 
Chemoprophylaxis for eligible 
patients given on-site and 
observed by clinical staff when 
patients receive dose of 
methadone (or given for off-
site consumption when 
patients do not receive 
methadone at clinic). 
Programme of DOPT is 
voluntary and can be refused 
(but rarely is). Regimen is INH 
300mg and pyroxidine 50mg 
daily for 6 months (HIV-) or 12 








Total N=507 (screening); 
N=151 (chemoprophylaxis) 

























HIV prevalence, TB 
cases in HIV-
seropositive anergics, 
inclusion of outpatient 




Modelling method:  
Not explicitly 
reported, seems like 
a discrete-time 
Primary analysis:  
Net cost savings of 
programme per patient 
receiving chemoprophylaxis: 
under SAT range from 
US$1,289 to $3,418 
depending on INH efficacy, 
and under DOT from $1,380 to 
$3,590 depending on INH 
efficacy and DOT 
effectiveness. (Note: authors 
interpret this as showing that 
DOT is cost-effective, even 
though in some cases the cost 
savings from DOT are less 
than those from SAT.) 
 
Secondary analysis:  
Figures are calculated, 





Lower TB prevalence (PPD 
prevalence drop from 16% and 
29%, to 10% and 15% 
respectively for HIV sero+ve 
and –ve patients): 
$333645/9=$37072 
TB hazard in HIV-seropositive 
PPD+ve halved: 
$283012/8=$35376.5 (lower 
Limitations identified by 
author:  
Did not model the impact of 
chemoprophylaxis beyond 
5 years of follow-up. Model 
did not take into account of 
multi-drug resistance, 
multiple hospitalizations 
per case of TB, out-patient 
costs of TB care, and the 
costs of treating secondary 
infections and cases that 
could have been averted 
by chemoprophylaxis. 
Model is based on analysis 
of the population attending 
a single methadone 
maintenance treatment 
program in the Bronx.  
 
Limitations identified by 
review team:  
Appears to be some biased 
reporting of outcomes and 
discrepancies between 
figures and write-up of 
findings. Treatment effect 
of DOT appears to be pure 
assumption, not based on 
any data. Data sources 
elsewhere are also unclear.  
 














15%, White 19%, 
Other race 1%; 
PPD+ve 29%; anergic 
6%; PPD-ve (non-
anergic) 66%. 
compartmental model than baseline) 
Lower prevalence of HIV 
infection (drop from 31% to 
5%): $117096/4=$29274 
(lower than baseline) 
No TB in HIV-seropositive 
anergic: $244584/7=$34941 
(lower than baseline) 
Include out-patient costs 
($3009.90): 
$431395/11=$39218 
Include multi-drug resistance 
costs (13 cases at a cost of 




Applicability of model to 
other settings; effect of 
diminishing TB incidence 
on outcomes; cost-
effectiveness of prevention 
compared with case finding 
and treatment 
 
Source of funding:  
National Institute of Drug 
Abuse, NY State AIDS 
Institute, and New York 





Study Details Population and 
setting  





Holland DP, Sanders 



















Aim of study:  
To evaluate the costs 
and cost-
effectiveness of 
regimens for the 
















Data sources:  
Most from literature, 





Recent contacts of 
infectious TB cases; 
average age 39 
years. 
Intervention/s description: 
(1) Isoniazid 300 mg given as 
daily self-administered therapy 
for 9 months (9H);  
 
(2) Isoniazid 900 mg given 
twice weekly by DOT for 9 
months (9H-DOT);  
 
(3) Isoniazid 900 mg 1 
rifapentine 900 mg given once 
weekly by DOT for 12 weeks 
(3HP);  
 
(4) Rifampin 600 mg given as 
daily self-administered therapy 
for 4 months (4R). 
 
I.e. (2) and (3) = DOT, (1) and 
(4) = SAT. DOT administered 
by outreach worker, 














None for model itself; 
some outcomes 







Not explicitly stated, 







analyses on Risk of 
TB, Adherence, 
Efficacy, Toxicity and 
Costs 
 
Modelling method:  
Markov 
Primary analysis:  
9H-DOT net cost of 
US$475.10 relative to no 
treatment (NT) per patient. 
Others all net cost saving: 9H 
(SAT) -$847.81, 4R 
(SAT) -$1,032.12, 3HP 
(DOT) -$751.06  
 
ICERs: 3HP (DOT) vs 4R 
(SAT): US$48,997/QALY; 3HP 
(DOT) vs 9H (SAT): 
$25,207/QALY. 9H-DOT vs no 
treatment [calculated, not 
given in study report]: 
$7,879/QALY 
 
Secondary analysis:  
[Detailed quantitative data not 
provided for sensitivity 
analyses, mostly reported 
verbally] 
 
Risk of TB. 2x risk: 4R (SAT) 
and 3HP (DOT) dominate; 
3HP more CE thean 4R at 
$20,099 per QALY. 5.2x risk: 
3HP (DOT) dominates. 10x 
risk: 3HP (DOT) cost-saving 
wrt 9H (SAT) 
  
Adherence: 4R (SAT) 
dominates all except 3HR 
Limitations identified by 
author:  
Limited data on efficacy 
and adherence for 3HP.  
 
Limitations identified by 
review team:  
Model does not consider 
transmission. Presentation 
of findings is rather 
unclear, particularly for 
sensitivity analyses. Effect 
of direct observation not 
clearly distinguished from 
drug efficacy. DOT and 
SAT treatment effect 
estimates come from 
different studies with 
different populations. Data 
source for 9H-DOT 
effectiveness unclear 
(study quotes ref (24), but 
this appears to be an 
error).   
 
Evidence gaps and/or 
recommendations for 
future research:  
NR 
 





Not explicitly stated, 








(DOT) if completion >54% for 
4R; 3HP (DOT) if both SAT 
regimens have low compliance 
(<34% for 9H, <37% for 4R) 
 
Efficacy: [only SAT regimens 
considered] 
  
Toxicity: not sensitive to 
changes in toxicity rates 
 
Costs: if DOT <$1.00/dose, 
3HP (DOT) dominates 4R 
(SAT). [Analysis on drug costs 





Study Details Population and 
setting  




Authors: Jit M, 
Stagg HR, Aldridge 
RW, White PJ, 
Abubakar I, for the 
Find and Treat 





outreach service for 









Aim of study:  
To evaluate the cost-
effectiveness of the 
Find and Treat 
service from 
September 2007 to 









Individuals with active 
pulmonary 
tuberculosis screened 
or managed by the 
service with record 
dates between 






Data sources:  
Retrospective data 







services pay and 










Find and Treat service 
including (1) mobile 
radiography unit which visits 
drug treatment centres, 
homeless shelters etc., and 
provides voluntary screening 
(2) enhanced case 
management service to 
support treatment completion 
(including home visits and 
accompanying clients to 
services, and links with other 
services e.g. drug support, 
criminal justice), and 




Usual care, i.e. patients who 
presented to usual TB 





(including N=48 identified by 
mobile screening unit, N=188 
referred to Find and Treat for 
case management support, 
N=180 referred to Find and 
Treat for loss to follow-up) 
Control: N=252 
Outcomes: 














analyses on a range 
of conditions that are 
unfavourable to Find 
and Treat, including 
increased costs for 
mobile screening unit 
(£530024 to 
£600000); increased 
cost of TB treatment 
(drug sensitive and 
MDR-TB rise from 
from £5522 and 
£31329, to £8300 and 
£75000 respectively); 
improved quality of 
life for untreated TB 
(0.68 to 0.76), and 
poor quality of life for 
Primary analysis:  
£6,400 per QALY (net cost of £1.4 
million and gains 220 QALYs).  
 
Mobile screening unit 
£18,000/QALY; case management 
component £4,100/QALY  
 
Secondary analysis:  
Increased mobile screening unit 
costs: F&T=£6,700/QALY, mobile 
screening=£20,000, case 
management=£4,100; 




Improved QoL for untreated TB 




Asymptomatic mobile screening 
unit cases do not always progress 




Cases referred to F&T for 
enhanced cases management 
have lower rate of loss to follow-up 
than those not referred: 
F&T=£7,100, mobile 
Limitations identified by 
author:  
Absence of a trial 
randomising TB cases to be 
either managed or not 
managed by the F&T 
service. Methods used for 
modelling do not fully 
capture the benefits of the 
F&T service (because 
transmission not taken into 
account). Did not measure 
the effect of the F&T service 
on reducing the likelihood of 
patients developing and 
transmitting acquired drug 
resistance (as a result of 
poor treatment adherence) 
 
Limitations identified by 
review team:  
None to add to authors’. (NB 
unlike other cost-
effectiveness studies in this 
review, averted treatment 
costs are not taken into 
account in assessing 
benefits.) 
 
Evidence gaps and/or 
recommendations for 
future research:  














hence unlikely to 
have active 
tuberculosis); cases 
for which the 
diagnostic delay 
could not be 
calculated; and cases 
younger than 16 
years. Other than that 
no info.  
TB cases on 
treatment (0.79 to 
0.76); asymptomatic 
cases detected by 
mobile screening unit 
do not always 
progress to 
symptomatic disease 
(50% of original); 
cases referred to Find 
and Treat service for 
enhanced case 
management have a 
reduced loss to 
follow-up rate in the 
absence of the 
service (34.7% to 
17.2%); cases 
referred to Find and 
Treat service for loss 
to follow-up could still 
passively re-engage 
with treatment (51%) 
 
Modelling method:  





Case referred to F&T service for 
loss to follow-up could passively 





Combination of all most 
unfavourable components: F&T 
£10,000/QALY, mobile screening 




delivery of treatment; 
randomised trial of F&T 
service 
 
Source of funding:  
English Department of 






Study Details Population and 
setting  





GB, Ambrosetti M, 







ment for tuberculosis 
patients in Italy. 




Aim of study: To 
perform an economic 
analysis of changes 
to TB management 
















reporting units in Italy; 
no further information 
 
Setting: 17 outpatient 
units, 10 inpatient 










described. 15 centres 
were in the North, 13 
in the Centre and 13 




Scenario 1: Current policy of 
managing TB patients in Italy. 
Smear-positive patients 
admitted for 2 months, smear-
negative and extrapulmonary 
patients admitted for 1.5 
months, total treatment 
duration 6.5 months, 
standardised treatment 
regimen for 88% of patients. 





Scenario 2: Hypothetical 
policy orientated to outpatient 
care. 50% smear positive, 
10% smear negative and 
extrapulmonary cases 
admitted for 1 month, 
treatment duration 6 months. 
Standardised regimens for all 
patients. 
 
To each of these scenarios 
different provision of DOT was 
assumed (1) No DOT, (2) DOT 
no additional staff (3) DOT + 
additional staff + no incentives 
(4) DOT no additional staff + 
incentives (5) DOT additional 
Outcomes: Cost per 
case cured  
 










exhaustive list of 
parameters tested is 
given. ‘Sensitivity 
analysis was 
conducted on the 
variable when a result 
was uncertain to test 
the robustness of the 
student results. In 
particular all fixed and 
variable costs in 
determining the costs 
per case treated 
successfully in 
scenario 2 were 
progressively 
increased until a 
similar cost-
effectiveness was 
obtained at different 
Primary analysis:  
Assuming a success rate of 
77.3% (smear positive) and 
86.3% (smear negative) as 




1 (no DOT). US$16,494 / 
11,230 
2 (DOT). $16,703 / 11438 
3. (DOT + addnl staff) $17,105 
/ 11,838 
4. (DOT + incentives) $17,576 
/ 12,308 
5. (DOT + addnl staff + 
incentives) $17,978 / 12,708 
Scenario 2: 
1  (no DOT). $5690 / 2202 
2. (DOT) $5946 / 2448 
3. (DOT + addnl staff) $6437 / 
2920 
4. (DOT + incentives) $7014 / 
3474 
5. (DOT + addnl staff + 
incentives) $7505 / 3946 
[These are apparently health 
perspective results, but this is 
unclear.] 
 
Secondary analysis:  
Test Positive, scenario 1: 
For no DOT the range was 
Limitations identified by 
author:  
Methodology to estimate 
indirect costs, as they 
aggregated possible 
individual losses of income 
into a lost production for 
the society as a whole. The 
treatment effectiveness for 
the scenario 2 is not 
known. 
 
Limitations identified by 
review team:  
Source data for effects not 
clearly described. 
Modelling method not 
described. The results from 
the broader perspective are 
only reported in a summary 
form and the assumptions 
not clearly described. 
 
Evidence gaps and/or 
recommendations for 
future research:  
NR 
 
Source of funding: Istituto 
Superiore di Sanità, Rome 
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staff and incentives. Incentives 
were the provision of a meal 
and 5 US dollars. 
 
Smear positive and smear 
negative were also analysed 
seperately. And different % of 
success rate 50%, 70%, 
77.3% 80% and 90% 
assumed. 
 
Sample sizes: N=682 for 
treatment effect data, N=992 
for cost data (although appear 
to be the same sample) 
 
 






25,503 (50%) to 14,181 (90%) 
For DOT the range was 
25,827 (50%) to 14,362 (90%) 
For DOT + staff  
26,448 (50%) to 14707 (90%) 
For DOT + incentives 
27,177 (50%) to 15,112 (90%) 
For DOT + staff + incentives 
27,798 (50%) to 15,458 (90%) 
 
Test positive scenario 2: 
For no DOT the range was 
8799 (50%) to 4893 (90%) 
For DOT the range was 
9195 (50%) to 5113 (90%) 
For DOT + staff  
9954 (50%) to 5535 (90%) 
For DOT + incentives 
10,845 (50%) to 6030 (90%) 
For DOT + staff + incentives 
11,604 (50%) to 6452 (90%) 
 
Test negative, scenario 1: 
For no DOT the range was 
19,374 (50%) to 10,752 (90%) 
For DOT the range was 
19,734 (50%) to 10,952 (90%) 
For DOT + staff  
20,424 (50%) to 11,335 (90%) 
For DOT + incentives 
21,234 (50%) to 11,785 (90%) 
For DOT + staff + incentives 
21,924 (50%) to 12,168 (90%) 
 
Test negative scenario 2: 
For no DOT the range was 
3799 (50%) to 2108 (90%) 
For DOT the range was 
 93 
4224 (50%) to 2344 (90%) 
For DOT + staff  
5038 (50%) to 2796 (90%) 
For DOT + incentives 
5994 (50%) to 3327 (90%) 
For DOT + staff + incentives 
6809 (50%) to 3779 (90%)[ 
[Note: these are understood to 
be health perspective results; 
the costs from a broader 
perspective are summarised 
only and it is unclear what the 
assumed success rate is: 
“$4159 for smear positive and 
$2792.20 for smear negative in 
scenario 1 … $2079.90 for 
smear positive and $1864.10 






Study Details Population and 
setting  




Authors: Moore RD, 












American Journal of 
Respiratory and 
Critical Care 
Medicine 154(4 Part 
1):1013-9 
 
Aim of study: To 
compare 3 alternative 
strategies for a 6 














No information on 
population; cost data 
taken from population 
under TB treatment in 
Baltimore 
 
Setting: NR; costs 
include an 
assumption of one 
on-site TB clinic visit 




Resource use is from 
a time and motion 




taken from State 
data. Effects are 








Intervention/s description:  
DOT included one on-site visit 
and 50 subsequent patient 
outreach visits (drug regimen 
was rifampin, ethambutol, 
pyrazinamide). Observed by 




Self administered individual 
conventional = isoniazid, 
rifampin, ethambutol, 
pyrazinamide – 6 months 
Self administed fixed dose 
combination = rifater, rifamate, 
ethambutol, isoniazid – 6 
months 
 





Outcomes: Cost per 
relapse averted and 




rates assume 2-year 
window) 
 
Discount rates: 4% 
 
Perspective: ‘urban 






completion rates for 
fixed dose 
combination therapy, 
the drug-resistant TB 
rate for fixed dose 
combination therapy, 
and cure rate for DOT 
when therapy is not 
completed. Costs of 
relapse with resistant 
TB, relapse with non 
resistant TB, the 




Cost per relapse averted 
$17,305 for conventional 
$15,446 for fixed dose 
$14,378 for DOT 
 
Cost per life saved 
$15,200 for conventional 
$14,068 for fixed dose 
$13,966 for DOT 
 
Secondary analysis:  
Cost effectiveness of the 3 
regimens was not found to be 
sensitive to variability in cost of 
managing resistant or non 
resistant TB in patients who 
relapsed 
Per relapse averted DOT is 
more cost effective than fixed 
dose combination therapy until 
the direct cost of DOT exceeds 
$14,500 an increase in of 
$1000 over the baseline direct 
cost. An increase in the cost of 
DOT of only $100 would result 
in comparable cost-
effectiveness per life saved for 
DOT and fixed dose 
combination therapy. Results 
were also sensitivity to 
estimates of the effectiveness 
of the interventions DOT and 
Limitations identified by 
author:  
Rate of completion of fixed 
dose combination therapy 
not well known, but 
analysis described as not 
sensitive to this parameter. 
Relapse rates for DOT 
abstracted from foreign 
treatment studies. Lack of 
trial data to inform rate of 
relapse rate for drug 




Limitations identified by 
review team:  
Description of the model is 
limited. Description of the 
population and estimates of 
effect are limited. The 
effects are not taken from 
the same sources as the 
costs drawing instead on 
the literature. The methods 
of identifying these effects 
are not described. 
 
Evidence gaps and/or 
recommendations for 


















Modelling method:  
Decision tree 
fixed dose intervention 
 
Sensitivity analyses 
(abstracted from figures and 
not fully reported in text, so all 
numbers approximate):   
Cost of DOT: marginal cost per 
life saved of DOT $0 to 
$1,350, and marginal cost per 
relapse averted $0 to $450, as 
cost of DOT ranges from 
$13,600 to $15,000 
Probability that incomplete 
DOT leads to relapse: 
marginal cost per life saved of 
DOT $0 to $43 as probablility 
ranges 0.27-0.30 
Probability of relapse with 
resistant TB for fixed-dose 
combination therapy: marginal 
cost per life saved of DOT 




Source of funding: 
Supported in part by 






Study Details Population and 
setting  




Authors: Palmer CS, 





Citation: A model of 
the cost effectiveness 
of directly observed 
therapy for treatment 
of tuberculosis. 




Aim of study: To 
compare universal 
DOT with partial DOT 

















Hypothetical cohort of 
25,000 TB patients 
using data taken from 




Data sources: TB 
clinical records from 4 
outpatient TB control 
programmes (11 





authors’ estimates in 





Outpatient data from 
Newark (n=35), San 
Fransisco (N=86), 
Los Angeles (n=36), 
Mississippi (n=21). 
Males = 73%, White = 
32%, US born 58%, 
mean age 44. Noted 
to be somewhat 
Intervention/s description: 
DOT observed either in clinic 





Partial DOT (15%) 




Details of DOT or patient 
responsible therapy not 
described. The following is 
noted about the sources of the 
patient records: 
In Newark patient began on 
patient responsible therapy 
and switched to DOT if 
treatment failed, in San 
Francisco certain patients 
were selected for DOT a priori 
based on clinical 
characteristics (not described), 
in Los Angeles patients 
received DOT depending on 
the clinic they attended, in 
Mississippi all patients 
received DOT. 
 
Sample sizes:  
Total: 178 
Outcomes: Cost per 
TB case cured  
 
Time horizon: 10 
years 
 






1. Discount rates 3% 
vs 6% 
2. Default rate 
3. infection rate 
following default 
4. rate of 
development of drug 
resistant TB following 
default 
5. death rate for drug 
resistant TB 
6. Rate of 
immunosuppression 
among patients 




9. outpatient costs 
 
Modelling method: 
Primary analysis:  
Direct cost per TB case cured: 
US$16,846 for partial DOT 
$20,106 for No DOT 
$17,323 for 100% DOT 
 
Incremental cost of 100% DOT 
vs partial DOT = $24,064 per 
cure 
 
Secondary analysis:  
Sensitivity analyses only 
presented for incremental cost 
of 100% DOT vs partial DOT 
not against not DOT. 
Discount rate 6% = $24,441 
5% increase in default rate = 
$24,092 
15% increase in infection rate 
following default $23,453 
5% increase in development of 
drug resistant TB following 
default = $22,810 
Increase in drug resistant TB 




patient with drug resistant TB 
to 50% = $24,735 
Mean hospital stay increased 
to 30 days = $23,735 
60% hospitalised = $22,519 
Limitations identified by 
author:  
Mortality rate was held 
constant at 9% across 
treatment delivery 
strategies, but in the data 
patients who received DOT 
had a higher mortality rate. 
Data were in some cases 
from a comparatively small 
number of patient records 
from a small number of 
clinics. The model did not 
include direct costs of all 
TB activities relate to 
treatment failure. The 
model did not include 
indirect costs associated 
with decreased productivity 
or intangible costs 
associated with impaired 
quality of life. It was 
assumed that all lost 
patients returned to 
treatment within 2 years 
and that lost patients 
placed on patient 
responsible therapy 
switched to DOT. All 
patients in the model 









younger than US 
national estimates (49 
years) 
 
Intervention: 70 patients 
received DOT 
Control: 91 patients received 
patient responsible therapy 
only, 17 switched from patient 
responsible therapy to DOT. 
 
 
Decision tree  
 
20% hospitalised = $24,991 
outpatient costs decreased by 
20% = $18,184 




patients with drug resistant 
TB died within the year 
they begain treatment 
 
Limitations identified by 
review team:  
The authors’ list of 
limitations appears 
comprehensive. The data 
is for a cost year 1992 and 
therefore may not be 
accurate for the current 
context. 
 
Evidence gaps and/or 
recommendations for 
future research: NR 
 
Source of funding:  







Study Details Population and 
setting  





DC, Gourevitch MN, 
Trihn C, Salomon N, 











for active drug 
injectors at a syringe-
exchange 
programme. Journal 
of Urban Health 
78(3): 550-67 
 
Aim of study: To 
examine the cost-
effectiveness of a 
screening and DOPT 
programme, and of 









hypothetical cohort of 
1000 patients, based 
on the characteristics 
of people visiting a 
needle exchange 
programme in New 





Data sources: Most 
from records 
collected at the 
needle exchange. 
Treatment effect of 
DOPT taken from 
Gourevitch 1998, 
which itself appears 
to be assumption. 





These are the 
characteristics of the 
974 people at the 
needle exchange 
agreeing to TB 
screening. Male 67%, 
Intervention/s description: 
TB screening offered to all 
needle exchange clients (cash 
and transport token incentive 
offered, total $15)  
DOPT: Twice weekly visits to 
received INH 900mg and 
pyridoxine 50mg for 6 months 
(HIV+ 9 months). Patients 
could be dosed on any two 
non consecutive days of the 
week. Four transportation 
tokens were provided for 
transportation to and from 
DOPT visits. Patients were 







Sample sizes: 1000 (offered 
screening); 175 (receive 
DOPT) [hypothetical cohort] 
 
 
Outcomes: Cost per 
case of TB averted; 
net cost savings 
 
Time horizon: 3 











varying the decrees 
of INH effectiveness 
and CXR referral 
adherence and as a 
function of the role of 
anergy in TB 
incidence. Further, 
one scenario ignored 
anergy, the second 
included testing for 
anergy and assumed 
that HIV infected 
anergic patients had 
a moderately 
increased risk of 
developing TB (but 
no DOPT), the third 
Primary analysis: Baseline 
model (31% CXR completion 
rate and no monetary 
incentives). INH effectiveness 
is assumed (from the 
literature) across a range of 
65% to 90%. 
 
3 year follow up, INH 65% 
effective: 
3 TB cases prevented, 
US$103,078 TB costs 
prevented 
Costs of programme per case 
of TB averted $18,951 
Net savings $46,226 
5 year follow up INH 65% 
effective: same results as for 3 
years 
 
3 year follow up INH 90% 
effective: 
3 TB cases prevented, 
$141,506 TB costs prevented, 
cost of programme per case of 
TB averted $14,213, Net 
savings $84,654 
5 year follow up, INH 90% 
effective: 
4 TB cases prevented, 
$179,934 TB costs prevented, 
cost of programme per case of 
TB averted $14,213, Net 
Limitations identified by 
author:  
Uncertainties in input data; 
otherwise NR 
 
Limitations identified by 
review team: 
Limited description of 
model (although some of 
this is reported in 
Gourevitch et al. 1998). 
Data sources for inputs 
unclear (some assumed, 
some from literature and 
some from programme 
evaluation data). Unclear 
how patient characteristics 
incorporated into modelling 
process. Difficult to reach 
conclusions on different 




Evidence gaps and/or 
recommendations for 
future research: NR 
 
Source of funding: 
National Institute on Drug 
Abuse. New York City 












Median age 33, White 
(not hispanic) 47%, 
US Born 88%, ever in 
drug treatment 72%, 
drug use in past 6 
months any heroin 
65%, any cocaine 
58%, HIV+ 18%, 
previously known 
PPD result negative 
67%.  
 
Note: how these 
characteristics relate 
to the baseline 
characteristics of the 
cohort in the model is 
unclear, only 175 of 
the patients are 
suitable to receive 
DOPT 
 
scenario ascribed to 
HIV infected anergic 
patients had a 
moderate risk of 




Updated version of 
the model in 
Gourevitch 1998 
(also included in this 
review, see the DE 
for that study). 
Described in this 
paper only as a 






Secondary analysis:  
The cost per TB case averted 
is reported in the data 
extraction. The authoris report 
than all these scenarios 
resulted in cost savings 




If the CXR adherence rate was 
increased to 50% with a $25 
incentive the cost of 
programme per case of TB 
averted for 3 year follow up 
was $21,684 (65% effective) 
and $17,347 (90% effective). 
For 5 year follow up the results 
were $17,347 and $12,391 
respectively  
 
If the $25 incentive increased 
adherence to 100% the cost of 
programme per case of TB 
averted was $23,339 (65% 
effective) and $14,852 (90% 
effective). For 5 year follow up 
the results were $13,614 and 
$10,211 respectively 
 
Scenario 1 with no anergy 
The cost of programme per 
case of TB averted was 
$16,661 (65% effective) and 
$12,496 (90% effective). For 5 
year follow up the results were 
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$16,661 and $9,997 
respectively 
Scenario 2 with anergy no 
DOPT 
The cost of programme per 
case of TB averted was 
$17,914 (65% effective) and 
$13,435 (90% effective). For 5 
year follow up the results were 
$17,914 and $10,748 
respectively 
 
Scenario 3 with anergy and 
DOPT: 
The cost of programme per 
case of TB averted was 
$18,951 (65% effective) and 
$14,213 (90% effective). For 5 
year follow up the results were 










Study Details Population and 
setting  




Authors: Porco TC, 
Lewis B, Marseille E, 
Grinsdale J, Flood 










BMC Public Health 
6:157  
 
Aim of study:  
To evaluate the cost-
effectiveness of 
domestic follow-up of 
suspected LTBI 















cohort rather than 
evaluation data.] 
Immigrants to 
California with LTBI 






Data sources: Most 
from the literature; 






No info, other than 
clinical characteristics 
Intervention/s description: 
First analysis considers 
screening programme in 
general; further analysis 
incorporates active 
recruitment of immigrants 
using letters, phone calls and 
home visits; screening; directly 
observed preventive therapy 
for those eligible (setting and 
intervention delivery unclear) 
 
Comparator/control/s 
Description: None as such, 
but a range of different 
programme components 
considered – see Table 9 
 
Sample sizes N/A; 






Time horizon: 20 
years 
 
Discount rates: 3% 









on a range of 
combinations of 
screening rate, 
starting (uptake) rate, 
and completion rate; 
also on treatment 
delay, screening 
delay, % active 





cost multipliers, DOT 
costs, TST specificity, 
% INH resistance, 
risk multiplier for 
Primary analysis:  
Screening programme yields 
net cost saving of US$25,000, 
and yielded 7.7 net QALYs 
 
The results regarding 
programmes to improve the 
efficiency of the programme 
(Table 9) show that most CE 
intervention component is 
sending letter reminders (2.7 
QALYs, save $10,000); next is 
to treat people with inactive TB 
(3.2 QALYs, save $11,000); 
next is to improve starting 
rates for preventive therapy 
(although unclear what this 
means in practice) (1.3 
QALYs, save $1,800); next is 
to treat people with inactive TB 
(0.7 QALYs, cost $3,000); next 
is to improve evaluation rates 
by phone calls (0.5 QALYs, 
save $1,000); next is to 
improve evaluation rates by 
home visiting (0.3 QALYs, cost 
$1,000); and only then to use 
targeted DOT to improve 
completion rates (>$100,000 
per QALY saved). 
 
Secondary analysis:  
Full three-way analysis on 
Limitations identified by 
author: Accurate cost data 
hard to find. Life years not 
adjusted for quality in some 
cases. HIV+ people not 
included in model (because 
generally barred from 
immigration). Findings not 
disaggregated by age. 
Considerable uncertainty 
on many parameters.  
 
Limitations identified by 
review team: Generally 
highly robust study. Most 
inputs based on single 
studies, not systematic 
reviews. Unclear how 
reliable reimbursement 
standards are as guides to 
costs. Presentation of cost-
effectiveness findings not 
the most perspicuous for 
this review 
 
Evidence gaps and/or 
recommendations for 
future research: NR 
 
Source of funding: 
Centers for Disease 
Control and Prevention 
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(i.e. societal but 
without lost 
productivity / wage 
costs) 
 







disutility of hepatitis, 
disutility of INH side-
effects, QALY loss 




and discount rate 
 
Modelling method:  
Continuous time, 
discrete event model 
evaluation rate, starting rate 
and completion rate presented 
in Table 4 – not extracted 
completely here. Evaluation 
rate sensitivity analysis: 45% 
1.9 QALYs, saving $11,000; 
65% 2.9 QALYs, saving 
$16,000; 85% 3.9 QALYs, 
saving $22,000 
Passive treatment delay 100 
days (reference 74): 10 
QALYs, save $22,000 
Screening delay 14 days 
(reference 0): 8.1 QALYs, save 
$25,000 
% active cases 6% (reference 
3%): 12 QALYs, save 
$290,000 
Transmission rate 16 
(reference 8): 8.3 QALYs, save 
$33,000 
Hospitalisation rates: not fully 
extracted here 
Reactivation rates of people 
with inactive TB 430 (reference 
600): 7.1 QALYs, save 
$12,000 
Hospitalisation cost multiplier 
20% more: 7.8 QALYs, save 
$83,000 
Other cost multiplier 20% 
more: 7.7 QALYs, cost 
$14,000 
Nurse refill visit cost $8.40 
(reference $16.80): 7.5 
QALYs, save $43,000 
DOT visit cost $25.00 
(reference $19.23): 7.8 
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QALYs, save $24,000 
TST specificity 0.875 
(reference 0.99): 7.6 QALYs, 
save $21,000 
Fraction INH resistant 0.2 
(reference (0.13): 6.7 QALYs, 
save $16,000  
Risk multiplier for severe 
hepatitis 3x more: 7.6 QALYs, 
save $17,000 
Disutility for hepatitis 
hospitalization 0.9 (reference 
0.4): 8.0 QALYs, save $23,000 
Disutility for outpatient 
hepatitis 0.5 (reference 0.265): 
8.0 QALYs, save $24,000 
Disutility for other INH side-
effects 0.2 (reference 0.1): 7.4 
QALYs, save $22,000 
Disutility for untreated TB 0.2 
(reference 0.1): 9.0 QALYs, 
save $22,000 
QALY loss from one month 
INH 0.01 (reference 0): lose 16 
QALYs, save $22,000 
Disutility multiplier for TB 
hospitalization 0.5 (reference 
1): 7.9 QALYs, save $24,000 
Disutility multiplier for 
outpatient TB 0.5 (reference 
1): 8.3 QALYs, save $21,000 
Discount rate 5% (reference 
3%): 5.9 QALYs, save $16,000  
 
Threshold analysis: net cost 
saving when fraction of active 
cases >2.7%; cost effective at 
WTP threshold of $50k/QALY 
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Study Details Population and 
setting  











analysis of directly 
observed 
therapy for patients 
with tuberculosis at 





Medicine 160: 582-6 
 
Aim of study:  
To determine the 
cost-effectiveness of 
DOT for people at 
low risk of default, to 
inform the decision to 
extend DOT to this 
group (i.e. to change 









Patients in California 
defined as at low risk 
for default, i.e. at 
least 15 yr of age; no 























study for population 
data; previous cost-
effectiveness analysis 
for treatment effect 
Intervention/s description: 
Directly observed therapy 
daily for 2wk followed by 
twice-weekly for 22wk, 
including incentives to the 
value of US$25/week. No 













Cost per patient 




Effects estimated with 
reference to 2-year 
horizon (time horizon 
of model itself 
unclear) 
 









according to: default 
rate on SAT; DOT 
effectiveness wrt 
default rates; relapse 
rate on SAT; contacts 
with active disease; 
hospitalization rate; 
cost of hospitalization 
 
Modelling method:  
Decision tree, 1 time 
cycle 
Primary analysis:  
DOT has total incremental cost 
wrt SAT of US$1,332 per 
patient treated; net incremental 
cost of US$919 per patient 
treated; net incremental cost of 
US$40,620 per patient cured 
(or $51.656 from programme 
perspective, i.e. not counting 
hospitalisation costs) 
 
Secondary analysis:  
SAT probability of default 0%, 
incremental net cost $51,234 
per cure; 40%, net cost saving 
of $2,160 per cure 
DOT effectiveness in 
preventing default 50%, 
incremental net cost $42,406 
per cure; 100%, $39,165 
Relapse rate on SAT 6.0%, 
incremental net cost $11,182; 
1.5%, $307,862 
Contacts with active disease 
0%, $42,158; 1.5%, $39,851 
Patients with TB hospitalized 
10%, $44,833; 100%, $30,790 
Cost of hospitalization for 
MDR-TB, $20,000, incremental 
net cost $42,786 per cure; 
$200,000, $17,371 
Limitations identified by 
author: Benefits of DOT 
not fully measured 
 
Limitations identified by 
review team:  
Only includes healthcare 
costs. Model is simple. 
Cost data are from 
reimbursement regulations, 
not estimates of actual 
cost. Only outcome 
reported is cost per cure; 
implications of this are 
unclear  
 
Evidence gaps and/or 
recommendations for 
future research: Further 
analyses with more 
complete measurement of 
benefits of DOT; 
comparison of DOT with 
other TB control activities 
 












and other transition 
probabilities; cost 













Study Details Population and 
setting  




Authors: Snyder DC, 
Paz EA, Mohle-
Boetani JC, Fallstad 

















Aim of study:  
To evaluate the 
effectiveness of a 
DOT programme 





















data from project 
evaluation; data from 
literature for 
treatment effect and 
transition 
probabilities; cost 
data from California 
Dept of Health and 
unpublished 




59% M; 58% non-





lander, 1% other; 
median age 40 (range 
Intervention/s description: 
All clients of methadone clinic 
tested for TB. Those 
recommended for preventive 
therapy received 6/12 mo 
(depending on HIV status) of 
isoniazid and pyridoxine, 
observed by nurse; education 
by methadone clinic staff; 
clients accompanied by 
community health worker who 
facilitated registration; 
transport and food provided; 
reminders; clients encouraged 












Outcomes: Net cost 
saving (i.e. cost of 
DOT programme 
minus costs of 
treatment and contact 
tracing averted) 
 
Time horizon: 10 
years 
 








on: rates of 
hospitalization; 
completion rates; 
rates of return for test 
reading; rates of 
uptake of preventive 




Markov model; 1-year 
cycles; 4 states 
(remain well, develop 
TB and survive, 
develop TB and die, 
Primary analysis:  
Net savings US$104,660 
(programme cost US$771,569 
and averted costs of 
US$876,229); mean cost 
saving per case averted 
US$3,724 
 
Secondary analysis:  
60% of patients have TB-
related hospitalization 
(reference 81%): net cost per 
case $2,702.  
Completion rate 95% 
(reference 75.4%): net cost 
saving $6,674. Completion 
rate 30%: net cost $12,677 
75% return for test result 
(reference unclear): net cost 
saving $6,674 
75% begin preventive therapy 
(reference 91%): net cost $822 
75% receive medical 
evaluation (reference 96%): 
net cost $1,776 
Limitations identified by 
author: Data for model 
inputs derived from other 
(i.e. non-IDU) populations 
 
Limitations identified by 
review team: Health states 
not valued in model. No 
comparison group. Model 
structure is simple 
 
Evidence gaps and/or 
recommendations for 
future research: NR 
 










18-77); 63% HIV–, 
18% HIV+, 19% 
unknown HIV status 
 






Study Details Population and 
setting  




Authors: Wade VA, 
Karnon J, Eliott JA, 






direct observation in 
tuberculosis 
treatment: a mixed 
methods evaluation. 
PLoS ONE 7(11): 
e50155 
 
Aim of study:  
“to compare the 
effectiveness of in-
person versus home 
videophone direct 
observation as 
measured by the 
proportion 
of missed 
observations in each 




observations under a 





















Video group: 55% M, 
45% F; 41% <30 
years; 12% African 
origin, 2% Australian, 
3% European, 16% E 
Asian, 31% SE Asian, 
36% S Asian; 69% 
proficient in English 
In-person group: 66% 
M, 34% F; 34% <30 
years; 17% African 
origin, 16% 
Australian, 9% 
European, 7% E 
Asian, 31% SE Asian, 
Intervention/s description: 
Telehealth system for 
medication management. 
Desktop videophones and 
broadband connections 
installed in patients’ homes. 
Daily video calls made by 
nurses to patients at agreed 
times. (This arm includes 
patients who were deemed 
unsuitable for videophone 
treatment and continue to 






directly observed therapy 
service delivered by nurses 



























respect to: Number of 
patients; Type of 
patients (% 
noncompliant); 
Driving time; Cost of 
technology; Staff 
salaries; Weekend 
service; Length of 
service 
 
Modelling method:  
Decision tree analysis 
Primary analysis:  
Videophone service: cost per 
complete care episode 
A$2,654 
In-person service: cost per 
complete care episode 
A$2,589 
ICER A$1.32 (95% CI 0.51–
2.26) per additional successful 
day of observation 
 
Secondary analysis: Only 
reported qualitatively. Number 
of patients: reduced number 
makes video service more 
costly but still favours video; 
increased number favours 
video 
Type of patients: if 
noncompliance reduced from 
25% to 10%, ICER 
unchanged; if increased to 
40%, favours in-person 
Driving time: 5 mins driving 
time assumed; any increase 
favours video 
Cost of technology: 
Decreasing cost favours video 
Staff salaries: Reducing 
salaries slightly favours in-
person 
Weekend service: Reducing 
weekend service favours in-
Limitations identified by 
author:  
Retrospective cohort data 
cannot rule out 
confounding; referral 
service changed criteria, 
leading to demographic 
difference between groups; 
client record search may 
not have been complete; 
clinical outcomes not 
measured (study not 
powered to measure them); 
no group who received 
therapy at clinic; no access 
to confidential financial 
data to establish cost 
figures; model may be a 
simplification wrt practice. 
 
Limitations identified by 
review team:  
Lack of health status 
outcomes limits usefulness 
for this review.  
 
Evidence gaps and/or 
recommendations for 
future research: Large-
scale RCT of video 
observation; research on 

























20% S Asian; 56% 
proficient in English 
person, increasing favours 
video 
Length of service: If in-person 
service increased to same 
length of time as video service, 
video becomes dominant 
 
Source of funding:  
Royal District Nursing 







Study Details Population and 
setting  




Authors: Weis SE, 
Foresman B, Matty 













of Tuberculosis and 
Lung Disease 3(11): 
978-984 
 
Aim of study:  
To compare costs of 














All TB cases reported 






Setting: TB care 
services 
 
Data sources: All 
based on a 
retrospective cohort 
study; data drawn 
from patient charts 




Non-DOT group: 24% 
aged <30; 38% white, 
30% black, 24% 
Hispanic, 8% Asian; 
70% male; 23% 
foreign-born; 24% 
history of alcohol 
abuse; 4% history of 
drug abuse; 0% HIV+ 
DOT group: 23% 
aged <30; 30% white, 
41% black, 19% 
Intervention/s description: 
Directly observed therapy with 
isoniazid and rifampin, carried 
out in the clinic, the patient’s 
home or workplace or some 
other location. Duration of 
treatment 6-9 months at 
minimum, extended for 
































Modelling method:  
None – analysis is 
based purely on 
descriptive data 
about service use in 
the two periods 
Primary analysis:  
Total net cost per patient 
US$11,260 in DOT group, 
US$27,630 in ‘traditional’ 
group 
 
Secondary analysis: None 
 
 
Limitations identified by 
author: Comparison is 
between two time periods 
and may be confounded by 
other factors. Short-course 
therapy was more widely 
used in the later (DOT) 
period.  
 
Limitations identified by 
review team:  
Purely descriptive analysis; 
health states are not 
valued, or projected into 
the future using modelling 
 
Evidence gaps and/or 
recommendations for 
future research:  
NR 
 








Hispanic, 10% Asian; 
64% male; 22% 
foreign-born; 22% 
history of alcohol 
abuse; 29% history of 






Study Details Population and 
setting  




Authors: Wilton P, 
Smith RD, Coast J, 










in the United States 




Lung Disease 5(12): 
1137-42 
 
Aim of study:  
To develop an 
economic model of 













and intervention.] Not 
clearly defined; USA 
and South Africa 




Not clearly defined 
 











‘Conventional therapy’, not 
further defined 
 




Cost savings based 
on costs of 














line drug costs 
 
Modelling method:  
Monte Carlo model 
incorporating cure 
rates, death rates and 
probability of 
progressing to more 
severe forms of drug-
resistance 
Primary analysis:  
DOT total mean cost 
US$18,932 (SD $2,329) 
‘Conventional therapy’ total 
mean cost US$20,720 (SD 
$2,070) 
 
Secondary analysis: DOT 
remains more cost-effective 
when protocol regarding 
resistance to second-line 
drugs is altered 
 
 
Limitations identified by 
author: Model is simplistic 
and does not take account 
of all factors affecting 
spread of resistance, or of 
‘feedback loops’ regarding 
defaulters. Original data 
could not be located, so 




Limitations identified by 
review team: Some 
concerns regarding 
reliability and applicability 
of input data. Very little 
information on intervention 
content, esp. comparator.  
 
Evidence gaps and/or 
recommendations for 
future research: Use of 
Markov modelling to 
encompass more complex 
impacts; application of 
model to other countries 
 
Source of funding: Global 














7.3 Views studies 
 
Study details Research parameters Population and sample 
selection 
Outcomes and methods of analysis 
Results 
Notes by review team 
Authors: 
Craig GM, Booth 















Quality score: – 
Report the research questions: 
Process evaluation of a social 
outreach model of care including a 
link worker to develop collabor-
ative care pathways. 
 
Report theoretical approach: 
NR 
 
State how the data were 
collected: 
What method(s): Group 
discussions and interviews, face-
to-face or by telephone (for 
stakeholders; NB patient data is 
quantitative, so not considered 
here). 
By whom: NR 
What setting(s): NR 
When: NR 
Report population were the 
sample recruited from: 
Stakeholders with experi-
ence of collaborative working 
from agencies “represent-
ative of the type of referrals 
made by the [link worker] 
and patients’ presenting 
problems” (p415) 
 
Report how were they 
recruited: Written invitation 
 
Report how many 
participants were 
recruited: N=8 individual i/vs 
(44% response rate), N=1 
group i/v (exact total N NR) 
 
State specific inclusion 
criteria: NR 
 
State specific exclusion 
criteria: NR 
Brief description of methods and process of 
analysis: Analysed “in relation to the questions 
in the interview schedule” using N*Vivo 
 
Key themes relevant to this review:  
Other workers have better understanding of TB 
patients’ needs: “Once the client was diagnosed 
with TB he was quite unmotivated, missing 
appointments, and we worked jointly to help him 
re-motivate himself with the understanding he 
would feel weak, have a temperature and he 
wasn’t just being lazy. Now we understand the 
symptoms and can be flexible around that.” 
(homeless hostel worker) “It’s been good for 
frontline staff to understand where TB links in, 
and get support accessing services.” (homeless 
organisation)  
Link workers help to link together services: “The 
TBLW’s done what the job implies: Link the 
community, person and health service with a 
consistency of service you wouldn’t otherwise 
get. With limited resources it’s helped us to make 
appropriate criteria links, by accessing the 
medical to those most in need.” (social worker) 
Link workers offered emotional and practical 
support, and a trusting relationship with patients, 
and could communicate patients’ needs to other 
agencies. This was especially important for 
asylum seekers who may be excluded from other 
services. 
Referral documents helped to reassure other 
agencies, e.g. housing, about potential health 
risks. 
Limitations identified by 
author: NR for qualitative 
aspect of the study 
 
Limitations identified by 
review team: Qualitative 
component is only one aspect of 
total evaluation. Limited 
information on methods or 
sample. Unclear if negative 
findings would be adequately 
represented in analysis. 
 
Evidence gaps and/or 
recommendations for future 
research: NR 
 
Source of funding:  King’s 
Fund, The Henry Smith’s 
Charity, The Sir Halley Stewart 
Trust, The Kirby Laing 
Foundation, The Adint 
Charitable Trust. 
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Improved communication with hospital clinicians 
was important, especially in relation to service 
discharge. 
Provision of other services acts as an incentive 
for patients to access services: “They will have 
loads of other issues apart from their health and 
are more likely to turn up to the services if other 
issues can be addressed. It’s like a day centre – 
get tea, see nurses, get help with housing and 






Study details Research parameters Population and sample 
selection 
Outcomes and methods of analysis 
Results 
Notes by review team 
Authors: Wade 
VA, Karnon J, 
















Quality score: + 
Report the research questions: 
To investigate the implementation 
of a videophone DOT intervention, 
and identify reasons for 
successful uptake 
 
Report theoretical approach: 
NR 
 
State how the data were 
collected: 
What method(s): Semi-structured 
interviews; some information also 
from case notes 
By whom: Lead researcher 
What setting(s): NR 
When: NR (quantitative 
component of study runs 2003-
2010) 
Report population were the 
sample recruited from: 
Clinicians and other staff 
involved in delivering the 
service; patients  
 
Report how were they 
recruited: Patients recruited 
by service staff and then 
contacted by researcher; 
staff recruited by email or 
direct contact 
 
Report how many 
participants were 
recruited: N=44 staff; N=11 
patients 
 
State specific inclusion 
criteria: Staff: any delivering 
or associated with the 
service. Patients: had been 
receiving service at least 1 
month 
 
State specific exclusion 
criteria: NR 
Brief description of methods and process of 
analysis: Used NVivo for analysis. “Realist” 
thematic analysis method. Staff reviewed 
transcripts. 
 
Key themes relevant to this review: 
Staff see services as more convenient for 
patients, especially those who are working long 
hours and short of time. Patients can request call 
at specific times which are convenient for them, 
and change time at the last minute, so service is 
more flexible. 
10/12 patients [sic – elsewhere N=11 total] 
wholly positive about service, 2/12 express more 
mixed feelings.  
Patients value relationship with nurses: “you sort 
of develop this friendship with the nurses … 
there are two nurses that I was first introduced to 
when I was taking my medication, ‘cause when I 
started mine I was isolated at home, so I was 
always there for a solid three weeks … they are 
very caring people.” 
Patients say videophone improves privacy, 
although some would prefer to go to clinic so 
their families did not know they had TB. 
Technology seen as easy to use. 
Staff find videophone service more efficient than 
in-person DOT. Easier to finish visits as patients 
do not try to prolong interactions out of 
politeness. 
Technical difficulties with service created 
considerable problems, particularly for patients 
who did not speak fluent English. 
Video service may make it easier for patients 
who struggle to physically swallow pills. 
Limitations identified by 
author: Only patients receiving 
intervention included, not 
comparison group (in-person 
DOT). Interpreters not used for 
patients who did not speak 
fluent English.  
 
Limitations identified by 
review team: Reporting of 
qualitative component is fairly 
brief, both methods and data. 
Limited information on sampling. 
Unclear if negative perceptions 
would have been reflected in 
analysis. 
 
Evidence gaps and/or 
recommendations for future 
research: Larger RCT of 
intervention; investigate this 
approach in low-income 
countries 
 
Source of funding: Royal 





Patients may find it easier to ‘cheat’ by 
pretending to take tablets with videophone. 
Service improved communication between staff 
in community nursing service and Chest Clinic. 
Chest Clinic encouraged other hospitals to refer 
to the service. 








MEDLINE In Process 173 
EMBASE 2886 
ASSIA 124 
BL Ethos 7 
British Nursing Index 191 
CINAHL 396 






Social Policy and Practice 2 
Sociological Abstracts 27 
Web of Science 1654 
Cochrane CIDG Specialized register 88 
Total 8079 
De-duplication  -4283 






Data Parameters: 1946 to October Week 1 2013 




# Searches Results 
1 (Tuberculosis or TB).ti,ab,kw. 146098 
2 exp Tuberculosis/ 157772 
3 1 or 2 195113 
4 *Directly Observed Therapy/ 700 
5 (DOT$ or (directly observ$ adj3 (therap$ or treat$))).ti,ab,kw. 33781 
6 (short$ course$ adj3 (therap$ or treat$)).ti,ab,kw. 2162 
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7 
((observ$ or supervis$ or watch$ or witness$ or see$ or monitor$ or check$) 
adj3 (therap$ or treat$)).ti,ab,kw. 
109079 
8 ((record$ or report$) adj3 (therap$ or treat$)).ti,ab,kw. 44221 
9 or/4-8 185231 
10 Case Management/ 8381 
11 ((case or care or treatment) adj3 manage$).ti,ab,kw. 55577 
12 ((manag$ or support$ or plan$) adj3 care).ti,ab,kw. 60941 
13 Managed Care Programs/ 23650 
14 ("patient centered" or "patient centred").ti,ab,kw. or Patient-Centered Care/ 14718 
15 
((Tuberculosis or TB) adj5 (nurs$ or staff or team$ or multidisciplinary or 
outreach or centre$1 or center$1 or clinic$1)).ti,ab,kw. 
2900 
16 ((case or link) adj3 worker$1).ti,ab,kw. 647 
17 ("treatment partner" or "treatment supporter").ti,ab,kw. 37 
18 "Continuity of Patient Care"/ 14553 
19 or/10-18 128394 
20 9 or 19 311034 
21 (uptake or up-take or (up adj1 tak$) or takeup or take-up).ti,ab,kw. 264424 
22 
(Adher$ or nonadheren$ or (non adj1 adheren$) or access or refus$ or 
compliance or comply$ or compli$ or concordan$ or default$ or dropout$1 or 
drop out$1 or interrupt$ or complet$ or finish$ or (follow$ adj1 up$1) or (miss$ 
adj2 appointment$1)).ti,ab,kw. 
2447803 
23 *Medication Adherence/ 4269 
24 *Patient Compliance/ 19401 
25 *PATIENT DROPOUTS/ 2374 
26 *TREATMENT REFUSAL/ 5293 
27 or/21-26 2689187 
28 3 and 20 and 27 2759 
29 limit 28 to yr="1993 -Current" 2559 
30 limit 29 to english language 2205 
31 exp animals/ not humans.sh. 4050082 
32 30 not 31 2196 
33 
(cow or cows or cattle or bovine or calves or badger or badgers or hedgehog or 
hedgehogs or mice or mouse or rat or rats).mp. 
3037295 
34 32 not 33 2189 
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Notes: this search was run whilst the American government was in partial shut-down. The 
NLM (PubMed) records might be out of date. 
File Name: Medline2189.txt  
 
Database: MEDLINE In Process 
Host: OVID 
Data Parameters: October 01, 2013 




# Searches Results 
1 (Tuberculosis or TB).ti,ab,kw. 9499 
2 exp Tuberculosis/ 0 
3 1 or 2 9499 
4 *Directly Observed Therapy/ 0 
5 (DOT$ or (directly observ$ adj3 (therap$ or treat$))).ti,ab,kw. 6461 
6 (short$ course$ adj3 (therap$ or treat$)).ti,ab,kw. 128 
7 
((observ$ or supervis$ or watch$ or witness$ or see$ or monitor$ or check$) 
adj3 (therap$ or treat$)).ti,ab,kw. 
6621 
8 ((record$ or report$) adj3 (therap$ or treat$)).ti,ab,kw. 3317 
9 or/4-8 16206 
10 Case Management/ 0 
11 ((case or care or treatment) adj3 manage$).ti,ab,kw. 3532 
12 ((manag$ or support$ or plan$) adj3 care).ti,ab,kw. 3595 
13 Managed Care Programs/ 0 
14 ("patient centered" or "patient centred").ti,ab,kw. or Patient-Centered Care/ 814 
15 
((Tuberculosis or TB) adj5 (nurs$ or staff or team$ or multidisciplinary or 
outreach or centre$1 or center$1 or clinic$1)).ti,ab,kw. 
169 
16 ((case or link) adj3 worker$1).ti,ab,kw. 45 
17 ("treatment partner" or "treatment supporter").ti,ab,kw. 4 
18 "Continuity of Patient Care"/ 0 
19 or/10-18 6516 
20 9 or 19 22501 
21 (uptake or up-take or (up adj1 tak$) or takeup or take-up).ti,ab,kw. 14072 
22 
(Adher$ or nonadheren$ or (non adj1 adheren$) or access or refus$ or 
compliance or comply$ or compli$ or concordan$ or default$ or dropout$1 or 
164094 
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drop out$1 or interrupt$ or complet$ or finish$ or (follow$ adj1 up$1) or (miss$ 
adj2 appointment$1)).ti,ab,kw. 
23 *Medication Adherence/ 0 
24 *Patient Compliance/ 0 
25 *PATIENT DROPOUTS/ 0 
26 *TREATMENT REFUSAL/ 0 
27 or/21-26 176314 
28 3 and 20 and 27 185 
29 limit 28 to yr="1993 -Current" 184 
30 limit 29 to english language 173 
31 
(cow or cows or cattle or bovine or calves or badger or badgers or hedgehog or 
hedgehogs or mice or mouse or rat or rats).mp. 
71030 
32 30 not 31 173 
 
Notes: this search was run whilst the American government was in partial shut-down. The 
NLM (PubMed) records might be out of date. 




Data Parameters: 1974 to 2013 Week 41 




# Searches Results 
1 (Tuberculosis or TB).ti,ab,kw. 171381 
2 exp tuberculosis/ 192490 
3 1 or 2 236380 
4 *directly observed therapy/ 364 
5 (DOT$ or (directly observ$ adj3 (therap$ or treat$))).ti,ab,kw. 43277 
6 (short$ course$ adj3 (therap$ or treat$)).ti,ab,kw. 2814 
7 
((observ$ or supervis$ or watch$ or witness$ or see$ or monitor$ or check$) 
adj3 (therap$ or treat$)).ti,ab,kw. 
149954 
8 ((record$ or report$) adj3 (therap$ or treat$)).ti,ab,kw. 63236 
9 or/4-8 253687 
10 case management/ 7291 
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11 ((case or care or treatment) adj3 manage$).ti,ab,kw. 73646 
12 ((manag$ or support$ or plan$) adj3 care).ti,ab,kw. 80309 
13 *patient care/ 45104 
14 ("patient centered" or "patient centred").ti,ab,kw. 9953 
15 
((Tuberculosis or TB) adj5 (nurs$ or staff or team$ or multidisciplinary or 
outreach or centre$1 or center$1 or clinic$1)).ti,ab,kw. 
3445 
16 ((case or link) adj3 worker$1).ti,ab,kw. 853 
17 ("treatment partner" or "treatment supporter").ti,ab,kw. 52 
18 or/10-17 168254 
19 9 or 18 418219 
20 (uptake or up-take or (up adj1 tak$) or takeup or take-up).ti,ab,kw. 328356 
21 
(Adher$ or nonadheren$ or (non adj1 adheren$) or access or refus$ or 
compliance or comply$ or compli$ or concordan$ or default$ or dropout$1 or 
drop out$1 or interrupt$ or complet$ or finish$ or (follow$ adj1 up$1) or (miss$ 
adj2 appointment$1)).ti,ab,kw. 
3253976 
22 *medication compliance/ 360 
23 *patient compliance/ 18476 
24 *treatment refusal/ 3566 
25 or/20-24 3546960 
26 3 and 19 and 25 3697 
27 limit 26 to yr="1993 -Current" 3414 
28 limit 27 to english language 2922 
29 exp animals/ not exp humans/ 4345750 
30 28 not 29 2900 
31 
(cow or cows or cattle or bovine or calves or badger or badgers or hedgehog or 
hedgehogs or mice or mouse or rat or rats).mp. 
3348026 
32 30 not 31 2886 
 
Notes: Some MeSH did not map to Emtree. Accordingly lines such as managed care 
programmes were not used here. 




Data Parameters: 1987 - current 






Searched for: (Tuberculosis or TB) 




Searched for: SU.EXACT("Tuberculosis") 




Searched for: s1 or s2 




Searched for: (DOT* or (directly observ* NEAR/3 (therap* or treat*))) 




Searched for: SU.EXACT("Directly observed therapy") 




Searched for: (short* course* NEAR/3 (therap* or treat*)) 




Searched for: ((observ* or supervis* or watch* or witness* or see* or monitor* or check*) 
NEAR/3 (therap* or treat*)) 




Searched for: ((record* or report*) NEAR/3 (therap* or treat*)) 





Searched for: s4 or s5 or s6 or s7 or s8 




Searched for: SU.EXACT("Case management") 




Searched for: ((case or care or treatment) NEAR/3 manage*) 




Searched for: ((manag* or support* or plan*) NEAR/3 care) 




Searched for: ("patient centered" or "patient centred") 




Searched for: ((Tuberculosis or TB) NEAR/5 (nurs* or staff or team* or multidisciplinary or 
outreach or centre*1 or center*1 or clinic*1)) 




Searched for:  ((case or link) NEAR/3 worker*1) 




Searched for: ("treatment partner" or "treatment supporter") 




Searched for: s10 or s11 or s12 or s13 or s14 or s15 or s16 





Searched for: s9 or s17 




Searched for: (uptake or up-take or (up NEAR/1 tak*) or takeup or take-up) 




Searched for: (Adher* or nonadheren* or (non NEAR/1 adheren*) or access or refus* or 
compliance or comply* or compli* or concordan* or default* or dropout*1 or drop out*1 or 
interrupt* or complet* or finish* or (follow* NEAR/1 up*1) or (miss* NEAR/2 appointment*1)) 




Searched for: SU.EXACT("Adherence") 




Searched for: s19 or s20 or s21 




Searched for: s3 and s18 and s22 




Searched for: (s3 and s18 and s22) AND yr(1994-2013) 
Databases: Applied Social Sciences Index and Abstracts (ASSIA) 
Results: 124° 
 
* Duplicates are removed from your search, but included in your result count. 
° Duplicates are removed from your search and from your result count. 
 
Notes: The year limit 1993-Current was applied by the earliest record returned by the search 
was from 1994. Hence the application of the date limit at line 24. 
File Name: ASSIA124.txt 
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Database: BL Ethos 
Host: http://ethos.bl.uk/Home.do  
Data Parameters: Not Specified  




((Tuberculosis or TB) and (DOT)) n=4 
((Tuberculosis or TB) and (directly observed therapy)) n=2 
((Tuberculosis or TB) and (case management)) n=2 
 
Notes: 1 hit was a duplicate. This was manually removed.  
File Name: BLETHOS7.txt 
 
Database: British Nursing Index (BNI) 
Host: ProQuest 
Data Parameters: 1994-Current 





Searched for: ti((Tuberculosis or TB)) OR ab((Tuberculosis or TB)) 




Searched for: SU.EXACT("Tuberculosis") 




Searched for: s1 or s2 




Searched for: ti((DOT* or (directly observ* NEAR/3 (therap* or treat*)))) OR ab((DOT* or 
(directly observ* NEAR/3 (therap* or treat*)))) 





Searched for: ti((short* course* NEAR/3 (therap* or treat*))) OR ab((short* course* NEAR/3 
(therap* or treat*))) 




Searched for: ti(((observ* or supervis* or watch* or witness* or see* or monitor* or check*) 
NEAR/3 (therap* or treat*))) OR ab(((observ* or supervis* or watch* or witness* or see* or 
monitor* or check*) NEAR/3 (therap* or treat*))) 




Searched for: ti(((record* or report*) NEAR/3 (therap* or treat*))) OR ab(((record* or report*) 
NEAR/3 (therap* or treat*))) 




Searched for: S4 or S5 or S6 or S7 




Searched for: SU.EXACT("Care Plans and Planning") 




Searched for: ti(((case or care or treatment) NEAR/3 manage*)) OR ab(((case or care or 
treatment) NEAR/3 manage*)) 




Searched for: ti(((manag* or support* or plan*) NEAR/3 care)) OR ab(((manag* or support* or 
plan*) NEAR/3 care)) 




Searched for: ti(("patient centered" or "patient centred")) OR ab(("patient centered" or "patient 
centred")) 





Searched for: ti(((Tuberculosis or TB) NEAR/5 (nurs* or staff or team* or multidisciplinary or 
outreach or centre*1 or center*1 or clinic*1))) OR ab(((Tuberculosis or TB) NEAR/5 (nurs* or 
staff or team* or multidisciplinary or outreach or centre*1 or center*1 or clinic*1))) 




Searched for: ti(((case or link) NEAR/3 worker*1)) OR ab(((case or link) NEAR/3 worker*1)) 




Searched for: ti(("treatment partner" or "treatment supporter")) OR ab(("treatment partner" or 
"treatment supporter")) 




Searched for: s9 or s10 or s11 or s12 or s13 or s14 or s15 




Searched for: s8 or s16 




Searched for: ti((uptake or up-take or (up NEAR/1 tak*) or takeup or take-up)) OR ab((uptake 
or up-take or (up NEAR/1 tak*) or takeup or take-up)) 




Searched for: ti((Adher* or nonadheren* or (non NEAR/1 adheren*) or access or refus* or 
compliance or comply* or compli* or concordan* or default* or dropout*1 or drop out*1 or 
interrupt* or complet* or finish* or (follow* NEAR/1 up*1) or (miss* NEAR/2 appointment*1))) 
OR ab((Adher* or nonadheren* or (non NEAR/1 adheren*) or access or refus* or compliance or 
comply* or compli* or concordan* or default* or dropout*1 or drop out*1 or interrupt* or 
complet* or finish* or (follow* NEAR/1 up*1) or (miss* NEAR/2 appointment*1))) 





Searched for: s18 or s19 




Searched for: s3 and s17 and s20 




Searched for: (s3 and s17 and s20) AND pd(19930101-20131015) 
Databases: British Nursing Index with Full Text 
Results: 191° 
 
* Duplicates are removed from your search, but included in your result count. 




File Name: BNI191.txt 
 
Database: CINAHL 
Host: Ebsco HOST 
Data Parameters: 1937-Current 




S1. (Tuberculosis or TB)  
S2. (MH "Tuberculosis+") 
S3. S1 or S2 
S4. (MM "Directly Observed Therapy")  
S5. (DOT* or (directly observ* N3 (therap* or treat*))) 
S6. (short* course* N3 (therap* or treat*)) 
S7. ((observ* or supervis* or watch* or witness* or see* or monitor* or check*) N3 
(therap* or treat*)) 
S8. ((record* or report*) N3 (therap* or treat*)) 
S9. S4 or S5 or S6 or S7 or S8 
S10. (MM "Case Management")   
S11. ((case or care or treatment) N3 manage*) 
S12. ((manag* or support* or plan*) N3 care) 
S13. (MM "Managed Care Programs")  
S14. ("patient centered" or "patient centred") 
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S15. ((Tuberculosis or TB) N5 (nurs* or staff or team* or multidisciplinary or 
outreach or centre*1 or center*1 or clinic*1)) 
S16. ((case or link) N3 worker*1) 
S17. ("treatment partner" or "treatment supporter") 
S18. (MH "Continuity of Patient Care") 
S19. S10 or s11 or s12 or s13 or s14 or s15 or s16 or s17 or s18 
S20. S9 or s19 
S21. (uptake or up-take or (up NEAR/1 tak*) or takeup or take-up) 
S22. (Adher* or nonadheren* or (non NEAR/1 adheren*) or access or refus* or 
compliance or comply* or compli* or concordan* or default* or dropout*1 or drop 
out*1 or interrupt* or complet* or finish* or (follow* NEAR/1 up*1) or (miss* 
NEAR/2 appointment*1)) 
S23. (MH "Medication Compliance")  
S24. (MH "Patient Compliance") 
S25. (MH "Patient Dropouts") 
S26. (MH "Treatment Refusal") 
S27. S21 or s22 or s23 or s24 or s25 or s26  
S28. S3 and S20 or S27 
S29. Limit to English Language 
S30. Limit 1993-2013 
 
Notes: N/A 
File Name: CINAHL396.txt 
 
Database: Cochrane Library 
Host: The Cochrane Library via http://www.thecochranelibrary.com/view/0/index.html  
Data Parameters: CENTRAL: Issue 9 of 12, Sept 2013; CDSR: Issue 10 of 12, October 
2013; DARE:  Issue 3 of 4, Jul 2013; NHS EEDS: Issue 3 of 4 Jul 2013; HTA: Issue 3 of 4 
Jul 2013; Cochrane Groups: Issue 9 of 12, Sept 2013. 
Date Searched: 15/10/2013 
Hits: (CDSR: 45; DARE 11; CENTRAL 112; Methods 3; NHS EEDS 33) 204 hits 
Search Strategy: 
 
#1 Tuberculosis or TB:ti,ab,kw  (Word variations have been searched) 2869 
#2 MeSH descriptor: [Tuberculosis] explode all trees 1539 
#3 #1 or #2  2877 
#4 MeSH descriptor: [Directly Observed Therapy] this term only 117 
#5 (DOT* or (directly observ* near/3 (therap* or treat*)))  2525 
#6 (short* course* near/3 (therap* or treat*))  1674 
#7 ((observ* or supervis* or watch* or witness* or see* or monitor* or check*) near/3 
(therap* or treat*))  16831 
#8 ((record* or report*) near/3 (therap* or treat*))  10468 
#9 #4 or #5 or #6 or #7 or #8  28359 
#10 MeSH descriptor: [Case Management] explode all trees 591 
#11 ((case or care or treatment) near/3 manage*)  6082 
#12 ((manag* or support* or plan*) near/3 care)  7052 
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#13 MeSH descriptor: [Managed Care Programs] this term only 290 
#14 ("patient centered" or "patient centred")  826 
#15 MeSH descriptor: [Patient-Centered Care] this term only 248 
#16 ((Tuberculosis or TB) near/5 (nurs* or staff or team* or multidisciplinary or outreach or 
centre*1 or center*1 or clinic*1))  48 
#17 ((case or link) near/3 worker*1)  0 
#18 ("treatment partner" or "treatment supporter")  15 
#19 MeSH descriptor: [Continuity of Patient Care] this term only 469 
#20 ((manag* or support* or plan*) near/3 care)  7052 
#21 #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 
 10760 
#22 #9 or #21  37559 
#23 (uptake or up-take or (up near/1 tak*) or takeup or take-up)  10368 
#24 (Adher* or nonadheren* or (non near/1 adheren*) or access or refus* or compliance or 
comply* or compli* or concordan* or default* or dropout*1 or drop out*1 or interrupt* or 
complet* or finish* or (follow* near/1 up*1) or (miss* near/2 appointment*1))  178971 
#25 MeSH descriptor: [Medication Adherence] this term only 655 
#26 MeSH descriptor: [Patient Compliance] this term only 7224 
#27 MeSH descriptor: [Patient Dropouts] this term only 1418 
#28 MeSH descriptor: [Treatment Refusal] this term only 251 
#29 #23 or #24 or #25 or #26 or #27 or #28  186430 
#30 #3 and #22 and #29 from 1993 to 2013 204  
 
Notes: N/A 
File Name: Cochrane204.txt 
 
Database: TRoPHI 
Host: http://eppi.ioe.ac.uk/webdatabases/Intro.aspx?ID=5  
Data Parameters: not specified  




Select Search #        Search No 
of hits  
 1 Freetext: "((Tuberculosis or TB) and (DOT)) "    0
  
 2 Freetext: "((Tuberculosis or TB) and (directly observed therapy)) "  0
  









Data Parameters: 1966 - current 










Searched for: ti((DOT* or (directly observ* NEAR/3 (therap* or treat*)))) OR ab((DOT* or 





Searched for: ti((short* course* NEAR/3 (therap* or treat*))) OR ab((short* course* NEAR/3 





Searched for: ti(((observ* or supervis* or watch* or witness* or see* or monitor* or check*) 
NEAR/3 (therap* or treat*))) OR ab(((observ* or supervis* or watch* or witness* or see* or 





Searched for: ti(((record* or report*) NEAR/3 (therap* or treat*))) OR ab(((record* or report*) 











Searched for: ti(((case or care or treatment) NEAR/3 manage*)) OR ab(((case or care or 





Searched for: ti(((manag* or support* or plan*) NEAR/3 care)) OR ab(((manag* or support* or 











Searched for: ti(((Tuberculosis or TB) NEAR/5 (nurs* or staff or team* or multidisciplinary or 
outreach or centre*1 or center*1 or clinic*1))) OR ab(((Tuberculosis or TB) NEAR/5 (nurs* or 



























Searched for: ti((uptake or up-take or (up NEAR/1 tak*) or takeup or take-up)) OR ab((uptake 





Searched for: ti((Adher* or nonadheren* or (non NEAR/1 adheren*) or access or refus* or 
compliance or comply* or compli* or concordan* or default* or dropout*1 or drop out*1 or 
interrupt* or complet* or finish* or (follow* NEAR/1 up*1) or (miss* NEAR/2 appointment*1))) 
OR ab((Adher* or nonadheren* or (non NEAR/1 adheren*) or access or refus* or compliance or 
comply* or compli* or concordan* or default* or dropout*1 or drop out*1 or interrupt* or 



















* Duplicates are removed from your search, but included in your result count. 




File Name: ERIC6.txt 
 
Database: HMIC Health Management Information Consortium 
Host: OVID 
Data Parameters: 1979 to March 2013 





# Searches Results 
1 (Tuberculosis or TB).ti,ab. 776 
2 Tuberculosis.mp. 886 
3 1 or 2 905 
4 Directly Observed Therap*.mp. 20 
5 (DOT$ or (directly observ$ adj3 (therap$ or treat$))).ti,ab. 84 
6 (short$ course$ adj3 (therap$ or treat$)).ti,ab. 16 
7 
((observ$ or supervis$ or watch$ or witness$ or see$ or monitor$ or check$) adj3 
(therap$ or treat$)).ti,ab. 
817 
8 ((record$ or report$) adj3 (therap$ or treat$)).ti,ab. 524 
9 4 or 5 or 6 or 7 or 8 1375 
10 Case Management.mp. 842 
11 ((case or care or treatment) adj3 manage$).ti,ab. 5194 
12 ((manag$ or support$ or plan$) adj3 care).ti,ab. 8534 
13 Managed Care Programs.mp. 3 
14 ("patient centered" or "patient centred").ti,ab. or Patient-Centered Care.mp. 1037 
15 
((Tuberculosis or TB) adj5 (nurs$ or staff or team$ or multidisciplinary or outreach or 
centre$1 or center$1 or clinic$1)).ti,ab. 
38 
16 ((case or link) adj3 worker$1).ti,ab. 138 
17 ("treatment partner" or "treatment supporter").ti,ab. 1 
18 Continuity of Patient Care.mp. 333 
19 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 11045 
20 9 or 19 12336 
21 (uptake or up-take or (up adj1 tak$) or takeup or take-up).ti,ab. 2587 
22 
(Adher$ or nonadheren$ or (non adj1 adheren$) or access or refus$ or compliance or 
comply$ or compli$ or concordan$ or default$ or dropout$1 or drop out$1 or interrupt$ 
or complet$ or finish$ or (follow$ adj1 up$1) or (miss$ adj2 appointment$1)).ti,ab. 
34162 
23 Medication Adherence.mp. 80 
24 Patient Compliance.mp. 476 
25 PATIENT DROPOUTS.mp. 1 
26 TREATMENT REFUSAL.mp. 9 
27 21 or 22 or 23 or 24 or 25 or 26 36130 
28 3 and 20 and 27 50 
 137 
29 limit 28 to yr="1993 -Current" 47 
30 limit 29 to english 47 
31 
(cow or cows or cattle or bovine or calves or badger or badgers or hedgehog or 
hedgehogs or mice or mouse or rat or rats).mp. 
1015 
32 30 not 31 47 
 
Notes: N/A 
File Name: HMIC47.txt 
 
Database: OpenGrey 
Host: http://ethos.bl.uk/Home.do  
Data Parameters: not specified  




((Tuberculosis or TB) and (DOT)) n=0 
((Tuberculosis or TB) and (directly observed therapy)) n=0 
((Tuberculosis or TB) and (case management)) n=1 
 
Notes: N/A 
File Name: OG1.txt 
 
Database: Social Policy and Practice (SPP) 
Host: OVID 
Data Parameters: 201307 




# Searches Results 
1 (Tuberculosis or TB).ti,ab. 139 
2 Tuberculosis.mp. 169 
3 1 or 2 180 
4 Directly Observed Therap*.mp. 4 
5 (DOT$ or (directly observ$ adj3 (therap$ or treat$))).ti,ab. 76 
6 (short$ course$ adj3 (therap$ or treat$)).ti,ab. 2 
7 
((observ$ or supervis$ or watch$ or witness$ or see$ or monitor$ or check$) adj3 
(therap$ or treat$)).ti,ab. 
728 
8 ((record$ or report$) adj3 (therap$ or treat$)).ti,ab. 580 
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9 4 or 5 or 6 or 7 or 8 1354 
10 Case Management.mp. 1390 
11 ((case or care or treatment) adj3 manage$).ti,ab. 4541 
12 ((manag$ or support$ or plan$) adj3 care).ti,ab. 9413 
13 Managed Care Programs.mp. 1 
14 ("patient centered" or "patient centred").ti,ab. or Patient-Centered Care.mp. 179 
15 
((Tuberculosis or TB) adj5 (nurs$ or staff or team$ or multidisciplinary or outreach or 
centre$1 or center$1 or clinic$1)).ti,ab. 
4 
16 ((case or link) adj3 worker$1).ti,ab. 266 
17 ("treatment partner" or "treatment supporter").ti,ab. 0 
18 Continuity of Patient Care.mp. 2 
19 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 11418 
20 9 or 19 12728 
21 (uptake or up-take or (up adj1 tak$) or takeup or take-up).ti,ab. 2343 
22 
(Adher$ or nonadheren$ or (non adj1 adheren$) or access or refus$ or compliance or 
comply$ or compli$ or concordan$ or default$ or dropout$1 or drop out$1 or interrupt$ 
or complet$ or finish$ or (follow$ adj1 up$1) or (miss$ adj2 appointment$1)).ti,ab. 
41154 
23 Medication Adherence.mp. 84 
24 Patient Compliance.mp. 10 
25 PATIENT DROPOUTS.mp. 0 
26 TREATMENT REFUSAL.mp. 8 
27 21 or 22 or 23 or 24 or 25 or 26 43046 
28 3 and 20 and 27 2 
 
Notes: N/A 
File Name: spp2 
 
Database: Sociological Abstracts 
Host: ProQuest 
Data Parameters: 1952 - current 





Searched for: (Tuberculosis or TB) 





Searched for: SU.EXACT("Tuberculosis") 




Searched for: s1 or s2 




Searched for: (DOT* or (directly observ* NEAR/3 (therap* or treat*))) 




Searched for: (short* course* NEAR/3 (therap* or treat*)) 




Searched for: ((observ* or supervis* or watch* or witness* or see* or monitor* or check*) 
NEAR/3 (therap* or treat*)) 




Searched for: ((record* or report*) NEAR/3 (therap* or treat*)) 




Searched for: s4 or s5 or s6 or s7 




Searched for: SU.EXACT("Case Management") 




Searched for: ((case or care or treatment) NEAR/3 manage*) 
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Searched for: ((manag* or support* or plan*) NEAR/3 care) 




Searched for: ("patient centered" or "patient centred") 




Searched for: ((Tuberculosis or TB) NEAR/5 (nurs* or staff or team* or multidisciplinary or 
outreach or centre*1 or center*1 or clinic*1)) 




Searched for: ((case or link) NEAR/3 worker*1) 




Searched for: ("treatment partner" or "treatment supporter") 




Searched for: s9 or s10 or s11 or s12 or s13 or s14 or s15 




Searched for: s8 or s16 




Searched for: (uptake or up-take or (up NEAR/1 tak*) or takeup or take-up) 





Searched for: (Adher* or nonadheren* or (non NEAR/1 adheren*) or access or refus* or 
compliance or comply* or compli* or concordan* or default* or dropout*1 or drop out*1 or 
interrupt* or complet* or finish* or (follow* NEAR/1 up*1) or (miss* NEAR/2 appointment*1)) 




Searched for: s18 or s19 




Searched for: s3 and s17 and s20 
Databases: Sociological Abstracts 
Results: 27° 
 
* Duplicates are removed from your search, but included in your result count. 




File Name: SOCABS27.txt 
 
Database: Web of Science (SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH) 
Host: ISI 
Data Parameters: ((SCI-EXPANDED) --1900-present; (SSCI) --1956-present; (CPCI-S) --
1990-present; (CPCI-SSH) --1990-present) 






Topic=(Tuberculosis or TB) 










Topic=((("directly observ*" NEAR/3 (therap* or treat*)))) 




Topic=((("short* course*" near/3 (therap* or treat*)))) 




Topic=(((observ* or supervis* or watch* or witness* or see* or monitor* or check*) near/3 
(therap*))) 




Topic=(((observ* or supervis* or watch* or witness* or see* or monitor* or check*) near/3 
(treat*))) 




Topic=(((record* or report*) near/3 (therap*))) 




Topic=(((record* or report*) near/3 (treat*))) 




#8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 




Topic=(((case or care or treatment) near/3 manage*)) 




Topic=(((manag* or support* or plan*) near/3 care)) 





Topic=(("patient centered" or "patient centred")) 




Topic=(((Tuberculosis or TB) near/5 (nurs* or staff or team* or multidisciplinary or outreach or 
centre*1 or center*1 or clinic*1))) 




Topic=(((case or link) near/3 worker*1)) 




Topic=(("treatment partner" or "treatment supporter")) 




#15 OR #14 OR #13 OR #12 OR #11 OR #10 




#16 OR #9 




Topic=((uptake or up-take or (up near/1 tak*) or takeup or take-up)) 




Topic=((Adher* or nonadheren* or (non near/1 adheren*) or access or refus* or compliance or 
comply* or compli* or concordan* or default* or dropout*1 or drop out*1 or interrupt* or 
complet* or finish* or (follow* near/1 up*1) or (miss* near/2 appointment*1))) 





#19 OR #18 




#20 AND #17 AND #1 




#20 AND #17 AND #1 
Refined by: Languages=( ENGLISH ) 
Databases=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH Timespan=1993-2013 
 
Notes: N/A 
File Name: WOS1654.txt 
 
Database: Health Economics Evaluation Database (HEED) 
Host: via Wiley (through The Cochrane Library) 
Data Parameters: Unspecified  





(Tuberculosis or TB) AND (directly observed)   n=51 
 
2. 
(Tuberculosis or TB) AND (DOT)   n=26 
 
3. 
(Tuberculosis or TB) AND (case management) n=7 
 
Notes: the search terms used here reflect the core terms used for the interventions as 
represented by the key Cochrane reviews identified in scoping.  
File Name: HEED.txt 
 
Database: Cochrane CIDG Specialized register 
Host: Cochrane CIDG 
Data Parameters: 18/10/2013 





This resource is held by the Cochrane CIDG group. The search was conducted by Dr Vittoria 
Lutje, Information Specialist, Cochrane Infectious Diseases Group, Liverpool School of Tropical 
Medicine, www.liv.ac.uk/evidence  
 
Notes: N/A  
File Name: CIDG.txt 
 
